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Have you ever felt depressed? The answer to this question is usually “YES” and this is not 
unreasonable since most of us have felt depressed once or more in our life-time. Typically, 
“feeling depressed” or “feeling BLUE” is not more than the well-accepted low mood or just 
being temporarily unhappy. On the contrary, clinical depression is a serious neuropsychiatric 
mood disorder that has a leading role in the global burden of diseases causing much of the 
disability world-wide.1,2 Individuals suffering from depression have feelings of guilt, helplessness, 
hopelessness, are occupationally impaired, often have desire for social withdrawal, suffer from 
sleep and concentration disturbances, have a loss of interest in life-pleasures and almost all 
other activities, and suffer from a loss of appetite and sex drive.3 This extensive list of depressive 
symptoms can also include daily experience of suicidal thoughts that can result in a suicidal act.3 
As a matter of fact, depression is a complete contrast to the beauty of the colour BLUE; a colour 
that awakens feelings of tranquillity, stability and inspiration (Yves Klein dedicated a life-time of 
work to the colour blue: “Blue Revolution”).
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In the last 15 years a number of successful campaigns took place around the world to raise the 
awareness for depression.4,5 One of the main goals of such campaigns was to reduce the stigma 
of depression and to clarify the differences between being sad and suffering from depressive 
disorders. These goals were mostly achieved and the knowledge over depressive illness among 
the public has increased. More persons have some understanding of the physical and mental 
exhaustion caused by this medical illness. However, the reality is: “We still do not completely 
understand all aspects of depression”! Even though depression may not be an enigma anymore, 
there are many core questions asked by lay people, medical doctors, and academic experts that 
remain unclear. One such question is “What actually causes depression?”! Briefly, this thesis is an 
attempt to unravel some aspects of the aetiology of depression.
IS DEPRESSION the DIABETES OF the BRAIN or a DEMONIC POSSESSION? A brief historical 
aspect
I would first like to quote the famous Chinese philosopher Confucius who said “Study the past 
if you would define the future”. Indeed, if we try to obtain new insights into the aetiology of 
depression and draw conclusions on this illness; and finally define some future perspectives for a 
better understanding of depression, we should certainly understand the history of this disorder. 
Throughout history, depression transformed from the old concept of melancholia to the current 
concept of depression which is mainly viewed as a multifactorial behavioural mental disorder. This 
transition did not occur all of a sudden, but throughout the centuries, many philosophers and 
scientists struggled explaining depression while facing a lot of controversies. This explains why 
studying depression and its aetiology is a great challenge even today.6
It was in the ancient times that the first theories were postulated to define and explain depression: 
Melancholia, a condition characterized by fear, loss-of appetite, and sleeplessness. The humoral 
theory proposed by Hippocrates (370-460 B.C), the father of medicine; explained melancholia.7 
According to the humoral concept melancholia was a condition caused by disequilibrium between 
the four humors and more specifically by an increase in the black bile.7 The core of this theory 
was slightly modified and edited during the centuries to come. It took almost 2,500 years to 
move from Hippocrates melancholia to Emil Kraepelin’s concept of depression (1856 –1926). He 
was the first scientist to propose the use of the term depression, but what made it so difficult to 
progress to defining depression as a disorder?8
In order to define this medical condition as a disorder, depression must be associated with specific 
symptoms and signs that are caused by external factors and internal dysfunctions. Scientists, 
doctors and people described and classified the symptoms of depression to a moderate extent. 
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Depression was mainly viewed as a mental insanity characterized by personality changes and 
altered/disturbing emotions that did not have a clear cause. This limited understanding in what 
causes depression restrained the process of defining depression as a mental disorder.
In the golden scientific ages of the 19th and the 20th century, mental diseases for the first time, 
were proposed as diseases of the brain by Wilhelm Griesinger (1817-1869).10 Krapelin’s “unitary 
concept of depression” was the first theory to define depression as a unitary endogenous 
disorder.11 Based on clinical observations, this concept emphasized depression as a specific 
psychiatric illness characterized by a combination of several symptoms with a specific organic 
aetiology and pathology. Krapelin’s categorization of mental diseases established the basic tool 
for the widely-used classifications of mental disorders by the American Psychiatric Association 
(DSM-Classification)3 and the World Health Organization (International classification of Disease)12. 
However, these classifications do not account for the aetiology of the disease. A group of 
scientists, e.g. Meyer, refused to regard depression as a biological disease only and proposed to 
view depression as a psychobiological reaction of the human body to stress.13 Whether depression 
is a reactive answer to stress, a systemic disease, or both remains the object of discussion until 
today. Solving the aetiological puzzles would help to disentangle the true causes of depression 
and improve diagnosis.
Over the past 60 years, a large number of scientists spent literally hundreds of thousands of 
research hours, producing and publishing a substantial number of scientific articles on depression. 
This enormous work helped in better understanding the disease. One of the most remarkable 
scientific discovery of the last century (1952) was detecting the presence of serotonin in the 
brain and this discovery started the so-called antidepressant revolution.14 Betty Twarog was 
the first scientist to confirm that indeed depression is the diabetes of the brain and supported 
the biological theory defining depression as a mental disorder caused by an imbalance in brain 
neurotransmitters.15 This start of the era of antidepressant drugs, inspired many researchers to 
reconcile different aetiologic orientations of depression, from social-psychodynamic to biological 
aspects. Due to this work, many questions related to the causes of depression have been 
answered. However, the knowledge over the aetiology of depression remains patchy. Important 
elements in the aetiology of depression are still missing.
What do we really know about the AETIOLOGY OF DEPRESSION? – Epidemiological 
aspects
Depression is generally seen as a bio-psychosocial disease. Thus, there is no single explanation 
of what causes depression, and no minimalist aetiology could capture the complexity of this 
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develops as a result of interaction and accumulation of various different psychosocial, biological 
and environmental risk factors. Psychosocial factors such as traumatic early-childhood events16 
such as abuse, socio-economic status17, marital status18, and loss of a partner19 are all established 
aetiologic risk factors involved in the pathogenesis of depression. These factors were observed by 
clinicians and are also related to depression in population-based studies. But these associations 
do not necessarily imply causality between two entities and the typically cross-sectional study 
design may only answer questions such as “Are older persons more likely to be depressed?” On 
the contrary, longitudinal study designs, such as those included in this thesis are more informative 
when we try to infer causality. Specifically, these designs help answer temporal questions: “Do 
events such as abuse precede depression?”. For a factor to be considered causal to depression, 
the time between that factor and the consequence is important and that factor has to precede the 
depressive event. Indeed, this conceptualizes the well-known criterion for temporality by Bradford 
Hill that perhaps is the only criterion which epidemiologists universally agree on and is essential 
to infer causality.20 Longitudinal studies are still relatively rare when studying aetiologic factors 
of depression and therefore most studies presented in this thesis are focused on investigations 
performed within a longitudinal framework.
Various biological factors such as neuroendocrine, neuro-immunological, and genetic, have been 
related to depression and have an important role in the complex aetiology of this disease.21-23 
However, whether these factors are in the causal path to development of depression or they 
appear as a consequence of depression it is still unclear. In this thesis we carefully study few blood 
extracted neuro-inflammatory markers such as interleukin (IL)-6, alpha-1-antichymotrypsin (ACT) 
and C reactive protein (CRP) as well as serum vitamin D levels (a neuroendocrine factor) and their 
impact on the development of depression. These potential biomarkers could reflect a disease 
cause, biological signals of a pathophysiological processes related to extraneous factors, or 
response to a therapeutic intervention specific to depression, or a related condition.21 Determining 
such biomarkers for depression could one day have an influential role in clinical practice and may 
increase the possibility for early detection, treatment and successful management of depression.24
Moreover, psychiatric epidemiology traditionally showed more interest in studying risk factors for 
depression than studying the consequences of depression for health in the general population. 
Taking into account that depression threatens to become the leading global cause of disability2, 
the interest to study the long-term consequences of depression rises. Therefore, one of the studies 
described in this thesis studies the cognitive decline that appears as a long-term consequence in 
persons suffering from depression.
In order to completely understand the biology and the pathophysiology of depression, we need 
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involvement of those genes in the pathology of depression. The technical development in the last 
years has allowed easy and cheap DNA sequencing, thus studying the genetics of depression on 
a large epidemiologic scale became easily accessible. Many studies aimed to identify common 
genetic variation involved in depression using large scale genome-wide association studies (GWAS) 
were performed.25 Only recently, one study showed that 44 different common genetic variants 
are associated with depression (study under review). Compared to other outcomes studied with 
GWAS medical studies, those studying depression are challenging and with moderate success 
only. Genetic epidemiological research using genotyping arrays approach has detected common 
variants with small effect sizes which may not be appropriate when studying heterogenetic traits 
such as depressive disorder.26 In addition to the common genetic variants, rare variants with 
substantial effect sizes may also be involved in the development of depression. Therefore, exome-
sequencing and exome-chip genotyping methods were proposed as a good solution in order to 
identify rare genetic variants associated with depression.27 This thesis presents two studies that 
employ such methods in discovering rare variants with possible large effects on depression in the 
general population.
Depression is a mental disorder with an estimated heritability from 30 to 40%, and most of 
the risk for depression is explained by environmental factors.22 A complex interplay between 
environment and genetics is conceptualized to increase neurodevelopmental processes involved 
in depression.28 The basis of this hypothesis, as well as the moderate success in determining the 
genetic risk for depression, increased the interest in studying the epigenetics of depression. A few 
investigations in post-mortem depression patients have performed epigenome wide association 
studies (EWAS)29, however a population-based study has not yet been conducted. Such an 
approach is essential in detecting epigenetic associations for psychiatric conditions given the lack 
of prior knowledge.22 Therefore, in Chapter 4 we present the first and the largest population-
based EWAS of depression.
AIMS
This thesis includes several population-based studies that explore the aetiology of depression, 
with a specific interest on biological factors, genetics and epigenetics, and physical health factors 
for depression.
Unravelling the aetiology of depression could potentially answer some remaining questions about 
depression, and finally may explain why we consistently fail to develop effective management 
and treatment tools for depression. Therefore, this thesis aims to apply advanced epidemiological 
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based data, the studies described in this thesis examine several risk factors and predictors that 
may enlighten the pathophysiological mechanism that underlie the development of depression. 
Specifically, Chapter 2 of this thesis presents longitudinal studies that examine the impact of 
potential biomarkers, such as vitamin D (Chapter 2.1), and inflammatory markers (Chapter 2.2) 
on the occurrence of depression. Chapter 3 of this thesis presents two studies which apply 
advanced genetic epidemiological methods to study the genetics of depression. Chapter 4 
focuses on the epigenetics of depression and presents the largest epigenome wide association 
population-based study so far. Moreover, we dedicated a chapter to the impact of physical health 
conditions such as myocardial infarct on depression (Chapter 5.1) as well as one to the physical 
consequences of depression such as cognitive decline (Chapter 5.2). Finally, Chapter 6 provides 
a more general discussion of the main findings in this thesis and addresses several methodological 
considerations of the studies. Clinical implications of the results in this thesis, and future directions 
are also presented.
SETTING
The studies described in this thesis are large population-based studies of older adults screened 
for depressive symptoms and continuously followed for the occurrence of depressive disorders. 
Data presented in Chapter 4 includes eleven large, population-based cohorts that contributed 
to an epigenome-wide meta-analysis and a replication analysis within the Cohorts for Heart 
and Aging Research in Genomic Epidemiology (CHARGE) Consortium. The remaining chapters 
present studies embedded in the Rotterdam Study, a population-based cohort that enrolled 
14 926 adults aged 45 and older in Rotterdam, the Netherlands.30 Participants underwent cycles 
of extensive home interviews and research examinations every 3 to 4 years. During the home 
interview participants were asked to self-report on the presence of depressive symptoms (using 
the Center for Epidemiologic Studies Depression Scale - CES-D). Those with clinically relevant 
depressive symptoms underwent a semi-structured psychiatric interview (Schedules for Clinical 
assessment in Neuropsychiatry - SCAN) during the research centre visit to diagnose depressive 
disorders. Moreover, participants were continuously monitored for various disorders, among 
which depression, via computerized linkage of data retrieved from pharmacists and general 
practitioner’s reports. Detailed depression assessment was conducted since 1993 onwards.31 A 
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Figure 1. Diagram of measurements of depression in the Rotterdam Study used in the current thesis.
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ABSTRACT
Objective: The evidence for a prospective association of vitamin D deficiency with the occurrence 
of late-life depression is limited. We aimed to study the long-term association between vitamin D 
serum levels and depression in a large population-based study of older adults.
Method: We included 3 251 participants from the Rotterdam Study, aged 55 and older with 32 
400 person-years follow-up for depression. Baseline 25-Hydroxivitamin D (25(OH)D) serum levels 
were analyzed continuously and categorically. Repeated depressive symptoms questionnaire 
assessments were used to assess the change of depressive symptoms. Semi-structured psychiatric 
interviews, and GP-records were used to assess incident major depressive disorder according to 
DSM-IV criteria.
Results: Low serum vitamin D levels were cross-sectionally associated with more depressive 
symptoms. However, low 25(OH)D serum levels were not prospectively associated with change of 
depressive symptoms (unstandardized beta β = 0.02, 95%CI = -0.23; p = 0.26) or incident MDD 
(hazard ratio HR = 0.95, 95%CI = 0.86; p = 1.05).
Conclusion: We observed a cross-sectional but no prospective association between serum 
vitamin D levels and depression. A cross-sectional association in the absence of the longitudinal 
association can mostly be attributed to reverse causality or residual confounding. Probably, 
vitamin D deficiency is not an independent risk factor for depression but co-occurs with late-life 
depression.
Significant outcomes: 1. Serum vitamin D deficiency and late-life depression are not prospectively 
associated. 2. Only in the cross-sectional analysis we observed that older persons with lower 
vitamin D serum levels were more likely to have more depressive symptoms. 3. This study provides 
further evidence that vitamin D deficiency accompanies late-life depression, but does not suggest 
a causal role of vitamin D deficiency in the development of depression.
Limitations: 1. This study reports analysis of single intra-individual assessment of vitamin D serum 
levels thus variability of vitamin D serum levels over time cannot be observed. 2. This observational 
study design limits the possibility to address reverse causality and draw conclusion about the 
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INTRODUCTION
Chronic/long-standing vitamin D deficiency is a common health risk factor that affects as many 
as one third to half of all elderly people world-wide.1-3 The main sources of this neuro-steroid 
hormone are the synthesis in the skin in response to sunlight exposure and dietary intake. In the 
elderly, the skin capacity to synthesize vitamin D is reduced up to 25%.4 Often the frequency of 
outdoor physical activity and the sunlight exposure are also low, making older people prone to 
vitamin D deficiency.5
Vitamin D deficiency and depression can coexist during late-life. It has been reported that one 
in every five geriatric patients with vitamin D deficiency suffer from depression.6 A growing 
body of epidemiological evidence reports a relationship between low 25(OH)D serum levels and 
depression.7-9 Several studies showed a consistent cross-sectional relationship between low serum 
levels of 25(OH)D and more depressive symptoms in older adults.6,8,10 Yet, few epidemiological 
studies addressed the longitudinal relationship between vitamin D deficiency and late-life 
depression, and yielded inconclusive results, or failed to confirm the possible relationship.7,8,10-13 
Two recently published reviews concluded that the available prospective data is scarce, the 
analysis are not comprehensive, and the reported estimates were not precise.8,14 In order to clarify 
the uncertainty about a prospective association between vitamin D and depression well-designed 
longitudinal studies are needed.8,14
Further, the few available longitudinal studies had limited precision for defining vitamin D 
deficiency and used different cut-offs. Second, their results were mostly based on self-reported 
depressive symptoms, thus the association with well-defined cases of major depression remains 
understudied in prospective research.8,11 Third, three of the previous reports were focused on men 
and one of these was conducted in cardiovascular patients. These studies cannot necessarily be 
considered representative of the general population.7,13,15
Forth, potential confounding bias is a main challenge of all vitamin D studies.8 Serum 25(OH)D 
levels depend on UVB-induced synthesis; thus sunlight exposure, season, and outside activity, are 
all relevant determinants of a person’s serum 25(OH)D levels. Sunlight exposure is correlated with 
both vitamin D serum deficiency and depression and its confounding effect on this relationship 
was previously acknowledged.8 Still, whether sunlight exposure and health-related problems 
influence the prospective association between 25(OH)D serum levels and depression is not well 
understood.8
Importantly, it is uncertain whether vitamin D deficiency is an independent risk factor for 
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or other chronic diseases.8,10 Earlier studies indicate that vitamin D deficiency may contribute to 
the development of many systemic diseases like cardiovascular diseases, diabetes, and cancer; all 
highly prevalent in elderly population.2,3,16,17
Aims of the study
In conclusion, the cross-sectional association between vitamin D and depression is observed 
consistently. In contrast, the more recently published prospective studies reported inconsistent 
results and failed to establish a longitudinal association. Given the inconclusive evidence of a 
longitudinal association between vitamin D deficiency and depression, additional prospective 
studies are needed. In the current study we sought to clarify whether vitamin D serum levels are 
prospectively associated with depression, using data with a well-defined change of depressive 
symptoms as well as major depression during follow-up. The first aim was to replicate the cross-
sectional relation between vitamin D and depressive symptoms. The second aim was to explore 
whether there is any long-term relationship of the vitamin D serum levels with the change of 
depressive symptoms or with incident major depression. We hypothesized that 25(OH)D serum 
levels are not only cross-sectionally associated with depression but also affect the risk of incident 
depression after carefully controlling for confounders.
METHODS
Study population
The present study was embedded in the Rotterdam Study, a population-based cohort designed to 
investigate diseases and their determinants among people aged 55 years and older. All residents of 
a district in Rotterdam, The Netherlands, were invited to participate.18 Trained research assistants 
collected data on health, medication use, medical and family history, and lifestyle factors in 
extensive home interviews. From March 1997 till December 1999 (baseline of this study), 4 214 
participants visited the research center for clinical examination and blood sampling. Blood serum 
sample of 25(OH)D was available for 3 828 participants. Out of these, 562 participants with 
an Mini-Mental State Examination (MMSE) score < 26 or missing, were excluded.19 Another 15 
participants, with no assessment of baseline depressive symptoms (CES-D - the Dutch version of 
the Centre for Epidemiologic Studies Depression scale) were excluded; leaving 3 251 participants 
in the study population. Women (57% versus 61%, p = 0.03), younger persons (mean age 72 
versus 75 years, p < 0.05); and those with less depressive symptoms (mean CES-D score 4 versus 
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The medical ethics committee approved the study (Wet Bevolkingsonderzoek-Population Study 
Act executed by the Ministry of Health, the Netherlands).18 Written informed consent was 
obtained for all participants.
Vitamin D
Vitamin D was measured at baseline only, by assessing serum levels of 25(OH)D. This is the product 
of cutaneous synthesis from sun exposure and dietary sources, and after 25 hydroxylation in the 
liver; it represents the major storage form of vitamin D in the human body.20 In 1997 - 1999, 
fasting blood samples were collected and centrifuged for 20 min. The serum was separated, 
dispensed and frozen within 3 hours at -80° C. Serum total 25(OH)D was quantitatively 
determined using Elecsys vitamin D total assay (COBAS, Roche Diagnostics GmbH, Germany). The 
electrochemiluminescence immunoassay is intended for use on Elecsys and cobas-e immunoassay 
analyzers. The test functional sensitivity was determined to be 10 nmol/L. Limit of quantitation 
was 22.5 nmol/L and intra-and inter-assay coefficients of variation were < 8% and < 11% for 
concentration between 7.5 and 175 nmol/L.21 We analyzed different cut-off points of vitamin D, 
rather than using a single definition of deficiency to reduce the likelihood of chance findings.8
Depressive symptoms
Depressive symptoms were assessed with the Dutch version of the Centre for Epidemiologic 
Studies Depression scale (CES-D).22 The CES-D scale was designed to assess presence and severity 
of self-reported depressive symptoms.23 We asked participants 20 questions that correspond with 
criterion based-symptoms associated with depression, and participants could score from 0 up-to 
60. The screening for depressive symptoms was performed at baseline 1997 - 1999. To assess 
for change of depressive symptoms the screening was reassessed twice; first during examination 
round 2002 until 2004 and second during examination round 2009 until 2011.24
Major depressive disorder
We continuously followed participants for the occurrence of incident major depression from 
baseline 1997 - 1999 until 1 January 2012. The participants were followed for on average 10.0 
years (± 3.5 SD, between 1997 - 2012; for 32 400 person-years) for the occurrence of depression. 
If no depression was identified, participants were censored at the end of follow-up, if they moved 
or at death. Incident events of major depressive disorder (MDD) were identified from two sources 
of information, as reported in detail previously.25 At first, all screen-positive participants identified 
by a CES-D score of 16 or above in each follow-up examination, were interviewed by a clinician 
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(Dutch version of the Schedules for Clinical Assessment in Neuropsychiatry - SCAN)26 to diagnose 
depressive disorders. Major depressive disorders were classified according to the Statistical Manual 
of Mental Disorders, 4th revised edition (DSM-IV) criteria.
Second, information on occurrence of episodes of MDD were continuously collected from general 
practitioners medical records. The CES-D screening and SCAN interview provided information on 
depressive episodes that are present during a follow-up examination. The medical records data 
identified depressive episodes that occurred and remitted in the intervals between follow-up 
examinations. The Netherlands has a primary physician health-care system, thus all medical records 
(hospital discharge letters, specialists reports, and GP notes) could be extracted and copied by a 
research-assistants looking for potential depressive symptoms. These data were rated/categorized 
by two medical doctors.25 Consensus decisions were made for disagreeing categorizations. Finally, 
incident episodes of MDD were defined as the first event that chronologically occurred in one of 
the two data sources described above.25 In order to control for prevalent baseline depression (both 
clinical and subclinical) we adjusted the longitudinal analysis for baseline depressive symptoms.
Covariates
The following socio-demographic variables, were assessed during the baseline home interview 
and included in the analysis: age, gender, partner status, living independently or in a nursing 
home, and level of education. Partner status was classified as never married or divorced, married, 
and widowed. Education was classified as low, intermediate, or high. Alcohol consumption and 
smoking habits were both assessed at baseline and classified as never, past, or current smoker/
consumer. Self-reported vitamin dietary supplementation was assessed at baseline.27 Everyday 
functional competence was assessed by using the Activities of daily living scale ADL.28 In order to 
assess cognitive performance the MMSE was measured.19 Body mass index BMI (kg/m2), systolic 
blood pressure (mmHg), creatinine and estimated glomerular filtration rate were assessed with 
standard medical and laboratory procedures. Presence of chronic conditions/diseases (stroke, 
diabetes mellitus, cardiovascular disease, liver conditions (based to elevated liver enzymes), and 
Parkinson’s disease) was based on self-report, examination, medical record information, and drug 
utilization. A past diagnosis of cancer was based on self-report only. Latitude, season and sunlight 
exposure are widely accepted as determinants of serum vitamin D.7,29 Therefore, season was 
categorized as blood intake in winter, spring, summer and autumn. Moreover, we used the data 
of the Dutch Royal Meteorological Center KNMI to calculate the individual hours of sunlight in 
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DATA ANALYSIS
Serum 25(OH)D level (nmol/L) was analyzed continuously as a Z-transformed square root variable, 
in order to normalize the distribution and for better interpretation of results. Additionally, we 
analyzed 25(OH)D using two pre-defined cut-offs; a ≤ 37.5 nmol/L, a ≤ 50 nmol/L, and ≤ 75 
nmol/L to define vitamin D serum level deficiency. Also vitamin D was categorized into quartiles, 
within our study sample to explore effects across the range of the continuum. These alternative 
categorizations used in previous research8, facilitate comparison and tests consistency of results 
across cut-off.8
We studied the association between serum 25(OH)D levels and depression both cross-sectionally 
and longitudinally. First, we addressed the cross-sectional association between serum 25(OH)D and 
depressive symptoms (CES-D score) with linear regression. Second, we studied the longitudinal 
association between serum 25(OH)D and change of depressive symptoms (CES-D score) with 
linear regression and generalized estimating equation analysis (GEE). Moreover, we studied the 
longitudinal association between serum 25(OH)D and incident MDD by Cox proportional hazard 
survival analysis. The proportional hazards assumption was assessed by visual inspection of log-
survival curves and by performing an interaction test with time. For all approaches we built two 
models: first, age and sex adjusted (in the longitudinal approach we additionally adjusted for 
baseline depressive symptoms) and second, a fully adjusted model. We included a covariate in 
the model if it changed the estimate of the main determinant by more than 10%, predicted 
depression (p < 0.05) or was an important priory confounder.31 Sex differences in serum 25(OH)
D levels and depression have been described.6,32 Gender interaction-term and possibility of non-
linear relationship were tested. 
Multiple imputations were used in order to account for missing data on potential confounding 
variables (missing values: systolic blood pressure 0.4%, BMI 0.9%, ADL 0.1%, EGRF 0.2%, 
creatinine 0.2% and calcium serum levels 0.1%, education 1.4%, sunlight exposure 0.1%, 
chronic conditions 0.1%, and vitamin dietary supplements 6.7%). All analyses were rerun in the 
complete case and five imputed data sets. In this manuscript we present results from the imputed 
data. All statistical tests were two-sided and p < 0.05 was considered statistically significant. 
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RESULTS
Baseline characteristics of the cohort are presented in Table 1. The mean age was 71.6 (± 6.6 
SD) years and 57.4% of participants were women. The 3 251 participants had a mean 25(OH)D 
serum level of 49.68 nmol/l. In total, 1 843 (56.7%) individuals had a deficient 25(OH)D serum 
levels (≤ 50 nmol/L), and 1 408 (43.3%) individuals had a sufficient 25(OH)D serum levels (> 50 
nmol/L).
Cross-sectional analysis
The cross-sectional analysis of the relationship between 25(OH)D level serum level and depressive 
symptoms are presented in Table 2. In both continuous and categorical analyses of vitamin D 
we found strong inverse relationship between 25(OH)D serum levels and depressive symptoms. 
After adjustment for age, sex, BMI, baseline CES-D score, ADL score, chronic conditions, sunlight, 
and other lifestyle factors, participants with a lower serum 25(OH)D levels had more depressive 
symptoms unstandardized beta (β) = -0.27, 95% CI = -0.51;-0.04, p = 0.023).
Additionally, we analyzed low 25(OH)D serum levels as a categorical exposure using two different 
cut-off points and quartiles. A serum 25(OH)D level ≤ 37.5 nmol/l was associated with depressive 
symptoms (β = 0.48, 95% CI = -0.01;0.95, p = 0.046) compared to serum 25(OH)D levels > 37.5 
nmol/l. Similarly, when we analyzed the exposure using the cut-off ≤ 75 nmol/L serum 25(OH)
D levels, these were associated with depressive symptoms (β = 0.61, 95% CI = -0.02;1.20, p = 
0.045) compared to levels > 75 nmol/l. When analyzing 25(OH)D serum level quartiles, persons 
in each of the lower quartile groups had more depressive symptoms than those in the reference 
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Age (years) 71.6 (6.6) 73 (6.8) 69.7 (5.8)
Female gender, N(%) 1866 (57.4) 1206 (64.6) 660 (35.4)
Systolic blood pressure (mmHg) 143.2 (21) 144.7 (21.4) 141.1 (20.3)
Body mass index (kg/m2) 26.8 (4) 27.3 (4.3) 26.3 (3.4)
Mini mental state examination (score) 28.2 (1.3) 28.1 (1.3) 28.2 (1.2)
Smoking status 
Non smoker, N(%) 1032 (31.7) 653 (63.3) 379 (36.7)
Past smoker, N(%) 1627 (50.0) 830 (51.0) 797 (49.0)
Current smoker, N(%) 592 (18.2) 360 (60.8) 232 (39.2)
Alcohol consumption 
Non consumer, N(%) 319 (9.8) 233 (73.0) 86 (27.0)
Past consumer, N(%) 215 (6.6) 138 (64.2) 77 (35.8)
Current consumer, N(%) 2717 (83.6) 1472 (54.2) 1245 (45.8)
Activities of Daily Living (ADL score) 1.39 (0.5) 1.5 (0.6) 1.3 (0.4)
Creatinine serum levels (nmol/L) 80.5 (27.2) 78.4 (21.2) 83.2 (33.2)
Calcium serum levels (mmol/L) 2.4 (0.1) 2.4 (0.1) 2.4 (0.1)
Estimated glomerular filtration rate 74.6 (15.5) 74.4 (15.8) 74.8 (15.1)
Education 
Low education, N(%) 1788 (55.0) 1079 (60.3) 709 (39.7)
Middle education, N(%) 1055 (32.5) 550 (52.1) 505 (47.9)
High education, N(%) 363 (11.2) 179 (49.3) 184 (50.7)
Marital status
Never married or divorced, N(%) 357 (11.0) 222 (62.2) 135 (37.8)
Married or living with partner, N(%) 2182 (67.1) 1120 (51.3) 1062 (48.7)
Widowed, N(%) 712 (21.9) 501 (70.4) 211 (29.6)
Season of blood intake
Winter, N(%) 1089 (33.5) 548 (50.3) 541 (49.7)
Spring, N(%) 668 (20.5) 420 (62.9) 248 (37.1)
Summer, N(%) 1049 (32.3) 669 (63.8) 380 (36.2)
Autumn, N(%) 442 (13.6) 203 (45.9) 239 (54.1)
Sunlight exposure, (hours)ᵇ 305.6 (120.5) 292.5 (114.6) 322.8 (125.8)
Chronic conditions, N(%)ͨ 1049 (32.3) 671 (64.0) 378 (36.0)
Cancer status, N(%) 235 (7.2) 136 (57.9) 99 (42.1)
Vitamin dietary supplements, N(%) 303 (9.3) 135 (44.6) 168 (55.4)
Baseline CES-D score ͩ
CES-D < 16, N(%) 3047 (93.7) 1714 (56.3) 1333 (43.7)
CES-D ≥ 16, N(%) 204 (6.3) 129 (63.2) 75 (36.8)
Abbreviations: SD, standard deviation; CES-D, Dutch version of the Centre for Epidemiologic Studies 
Depression scale.
ᵃ Unless otherwise is indicated;
ᵇ Sunlight hours during 10 week period preceding the blood drawing;
d Chronic conditions: History of stroke, history of diabetes mellitus, history of Parkinson disease, history of 
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Table 2. Cross-sectional association between serum vitamin D levels and depressive symptoms 
(CES-D) with linear regression (N = 3 251)
Vitamin D 
serum levels
Depressive symptoms (CES-D score)
N Model 1 Model 2
β (95 % CI) p β (95 % CI) p
Continuously
Vitamin D √SD nmol/La 3251 -0.54 (-0.77;-0.30) <0.001 -0.27 (-0.51;-0.04) 0.023
Cut-off
<37.5 nmol/L 1226 0.95 (0.48;1.43) <0.001 0.48 (0.01;0.95) 0.046
>37.5 nmol/L 2025 Reference Reference
<50 nmol/L 1843 0.62 (0.17;1.08) 0.008 0.28 (-0.18;0.73) 0.23
>50 nmol/L 1408 Reference Reference
<75 nmol/L 2748 0.85 (0.24;1.46) 0.006 0.61 (0.02;1.20) 0.045
>75 nmol/L 503 Reference Reference
Quartiles
 <28.57 nmol/L 732 1.48 (0.82;2.15) <0.001 0.74 (0.07;1.41) 0.030
28.58-43.81 nmol/L 819 1.11 (0.49;1.72) <0.001 0.83 (0.22;1.43) 0.008
43.82-63.21 nmol/L 848 0.83 (0.23;1.43) 0.007 0.75 (0.19;1.31) 0.012
>63.21 nmol/L 852 Reference Reference
Abbreviations: SD, standard deviation; CES-D, Dutch version of the Centre for Epidemiologic Studies 
Depression scale; β, unstandardized beta; CI, confidence interval.
Interaction term vitamin D serum levels*gender was tested and showed no statistical significance (p = 0.936).
a Standard Deviation of the square root of the Vitamin D serum levels (nmol/L)
Model 1. Adjusted for gender and age
Model 2. Additionally adjusted for: body mass index, systolic blood pressure, chronic conditions, cancer 
status, smoking habits, alcohol consumption, marital status, level of education, 10 week sunlight exposure 
prior to the blood intake, calcium serum levels, and activity of daily leaving score.
Longitudinal analysis
Next, we studied the longitudinal relationship between 25(OH)D serum levels and change of 
depressive symptoms as well as incident major depressive disorder.
First, (see Table 3.) in contrast to the cross-sectional analysis, low levels of 25(OH)D did not predict 
higher depressive symptoms at the first follow-up (β = 0.01, 95%CI = -0.28;0.29, p = 0.95) or 
second follow-up assessment (β = 0.05, 95%CI = -0.31;0.40, p = 0.80). Moreover, we did not 
found an association between 25(OH)D serum levels and change of depressive symptoms in the 
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Second, we assessed the long-term relationship of 25(OH)D serum level and incident MDD. (see 
Table 4.) 32 400 person-years (mean 10.0 ± 3.5 SD, interquartile range 4.1 - 13.8), during which 
150 incident MDD occurred. The serum level of 25(OH)D did not predict long-term risk of incident 
MDD (hazard ratio (HR) = 0.95, 95%CI = 0.86;1.05, p = 0.61).
Table 4. Longitudinal analysis of the association between serum vitamin D levels and incident 
major depressive disorder with Cox regression analysis (N = 2 466)
Vitamin D serum 
levels
Major depressieve disorder
events Model 1 Model 2
HR (95%CI) p HR (95%CI) p
Continuously
Vitamin D √SD nmol/La 150 0.98 (0.81 to 1.18) 0.79 0.95 (0.86 to 1.05) 0.61
Cut-off
<37.5 nmol/L 70 0.96 (0.68 to 1.36) 0.84 1.04 (0.87 to 1.25) 0.81
>37.5 nmol/L 80 Reference Reference
<50 nmol/L 92 0.82 (0.58 to 1.17) 0.27 0.84 (0.70 to 1.01) 0.34
>50 nmol/L 58 Reference Reference
<75 nmol/L 137 1.32 (0.74 to 2.36) 0.35 1.28 (0.95 to 1.73) 0.41
>75 nmol/L 13 Reference Reference
Quartiles
<28,57 nmol/L 38 0.77 (0.52 to 1.14) 0.19 0.82 (0.67 to 1.02) 0.36
28,58-43,81 nmol/L 45 1.13 (0.79 to 1.61) 0.49 1.13 (0.79 to 1.61) 0.51
43,82-63,21 nmol/L 43 1.36 (0.95 to 1.95) 0.10 1.24 (0.87 to 1.78) 0.24
>63.21 nmol/L 24 Reference Reference
Abbreviations: SD, standard deviation; HR, hazard ratio; CI, confidence interval.
Interaction term Vitamin D serum levels*gender was tested and showed no statistical significance (p = 0.160)
aStandard Deviation of the square root of the Vitamin D serum levels (nmol/L)
Model 1. Adjusted for gender, age and baseline depressive symptoms
Model 2. Additionally adjusted for: body mass index, alcohol consumption, smoking status, marital status and 
activity of daily living score.
Sensitivity analysis
Several sensitivity analyses were performed. First, we repeated the analysis of the association 
of 25(OH)D serum levels and incident MDD restricting the analysis to 2 and 5 years follow-up 
(Supplementary material 1). Again we found no indication of a prospective association between 
vitamin D serum levels and incident depression.
Second, sex interaction-term with 25(OH)D serum levels was tested and showed no statistical 
significance (p = 0.94). A quadratic terms of serum 25(OH)D was examined to test for non-linear 
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DISCUSSION
In this large population-based cohort of older people, we observed a cross-sectional association 
of both continuously modeled vitamin D serum levels and vitamin D deficiency with depressive 
symptoms, consistent with previous studies.7,8 However low levels of serum vitamin D were not 
prospectively associated with either change of depressive symptoms or incident MDD. Further, 
analyzing vitamin D as a continuous measure did not reveal any prospective association between 
vitamin D serum levels and depression.
Several epidemiological studies explored the cross-sectional relation between vitamin D serum 
levels and depression.6,8 In line with previous investigations6,7,12,33, we found a consistent cross-
sectional relation regardless of whether we analyzed vitamin D serum levels categorically or 
continuously. Older adults with vitamin D deficiency are clearly more likely to have depressive 
symptoms.8 Importantly, the presence of a cross-sectional relationship between vitamin D serum 
levels and depression is not discredited by the absence of long-term risk between them. Yet, 
our findings suggest that if there is a true relationship between low vitamin D serum levels and 
depression this would reflect on a short-term rather than a long-term effect on the development 
of depression.
Our study extends the results of the few earlier studies exploring the prospective relationship with 
conflicting results.10,12,34,35 The three studies showing a prospective association between vitamin 
D and depression13,34,36 were based on selected study populations, i.e. cardiovascular patients or 
men only. In contrast to these findings, Toffanello, et al. and Chan, et al. reported no prospective 
association in men and during relatively short period of 4 years follow-up, respectively.10,12 Our 
results were consistent, none of the analysis provided any statistical evidence for longitudinal 
relationship between vitamin D serum levels and depression, regardless of vitamin D serum level 
cut-offs or severity of depression (depressive symptoms and incident depression). Unlike previous 
studies, we assessed depression using different information sources, and did not rely on self-
report only. Depression was continuously monitored in GP-records over a mean time period of 10 
years. Combining multiple sources of depression reduces ascertainment bias often seen in other 
studies.8
The observed effect estimates present depression rates over 10 years follow-up with respect 
to the vitamin D serum levels measured at baseline. Vitamin D serum levels are highly variable, 
depend on sunlight exposure and diet that changes over time.3 Our report is limited by the single 
intra-individual assessment of vitamin D serum levels. The time-dependent variation of vitamin D 
serum levels may explain why we did not capture an association with depression during follow-
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serum level is probably diluted when the follow-up period is longer than 5 years.37 Thus, we 
tested different follow-up times of shorter duration. Yet, the findings remained negative. Also, 
studies with other outcomes showed that the variability of vitamin D does not preclude the 
observation of long-term effects. An independent association of vitamin D deficiency with both 
the development of cardiovascular disease and mortality has been reported.16,38
Many authors have speculated that vitamin D activates vitamin D receptors in brain regions related 
to depression, stimulates neurotrophic release, and protects the brain by buffering antioxidant 
and anti-inflammatory defense against vascular injury.3,29 Current pathophysiological theories 
postulate an etiological link between vitamin D and depression. However, whether the cross-
sectional findings reflect such a causal mechanism is questionable. Cherniack, et al. suggested 
that cross-sectional studies may miss sensitive period underlying any plausible association because 
mental illness typically take many months or years to develop.3
We speculate that, if there is any relationship, then vitamin D deficiency rather has a short-term 
than a long-term effect on the development of depression. However, it is very probable that there 
is no causal association between vitamin D deficiency and depression. There are several alternative 
explanations why we observed a cross-sectional association between vitamin D deficiency and 
depression, in the absence of a longitudinal association, in particular residual confounding and 
reverse causality.
The association between vitamin D and depression is complex and likely to be subject of 
residual confounding. This study was embedded in a population-based study, allowing us to use 
prospective measures of outcome and assess a large number of confounding factors. Yet, vitamin 
D deficiency and depression coexist during late-life33 and it is possible that the cross-sectional 
association is due to the higher prevalence of both conditions in the elderly. Chronic diseases 
are common among elderly and convey a high risk of depression. These largely affect the mental 
health by lowering the quality of life, restricting activities, social isolation, and interfering with 
the quality of sleep but also via biological mechanisms such as immune and vascular factors.39 
Hence, we cannot reject the possibility of residual confounding that might bias our results, e.g. 
by physical activity or unmeasured health problems. Indeed Anglin, et al. pointed out that the 
risk of bias due to unmeasured confounding remains high.8 Arguably, vitamin D deficiency is 
partly a marker of chronic nonspecific disease rather than a determinant or a direct contributor 
to the pathogenesis of depression. Sunlight exposure was already acknowledged as an important 
factor that can confound the relationship between vitamin D and depression.8 Assessment of 
sunlight exposure prior to the vitamin D serum level measurement remains a challenge in previous 
studies.7,8 We have tested for confounding by both sunlight exposure 10 week preceding the 
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small part of cross-sectional association. Further, sunlight exposure did not affect the longitudinal 
association. We did not account for parathyroid hormone (PTH) which has been acknowledged 
as a covariate and an intermediate factor with a role in the association between vitamin D and 
depression.34 However, May et al. showed that PTH cannot explain the relation between vitamin 
D and depression.34
Other limitation is the possibility of reverse causality. Depression may precede the vitamin D 
deficiency and reverse causality may explain the observed cross-sectional association between 
depression and vitamin D deficiency. In particular, depressed individuals don not easily go outside 
thus are typically less exposed to sunlight. In this longitudinal study we did not repeatedly assess 
vitamin D and we cannot demonstrate the directionality of the association or rule out that 
depressive symptoms occur prior to any vitamin D deficiency.
Also, we should point out that even though many elderly persons had low levels of vitamin D, the 
analysis of more severe vitamin D insufficiency (≤ 37.5 nmol/L) may not have had optimal power 
to detect an increased risk of incident depression (in contrast to that of continuous depressive 
symptoms) as new onset MDD is not very common in elderly populations.
This study provides further evidence for the cross-sectional association between serum vitamin D 
levels and depression. Clearly, older persons with lower vitamin D serum levels are more likely to 
have more depressive symptoms. However, we observed that vitamin D deficiency and late-life 
depression are not prospectively associated. In conclusion, vitamin D deficiency co-occurs with 
late-life depression, but has no causal role in the development of depression. Although, this is 
an observational study and defining causal mechanisms is not possible, the co-occurrence of 
vitamin D deficiency and late-life depression is a fact that may have clinical implication. Screening 
for vitamin D deficiency in elderly with chronic conditions such as depression remains important 
even if the conditions are not causally related. Vitamin D deficiency is associated with bone 
health, osteoporosis, and increased risk of falls and subsequent fractures.40 Detection of vitamin 
D serum deficiency is easy and treatable. Even if treatment of vitamin D deficiency has no effect 
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ABSTRACT
Rationale: Evidence suggests that depression is cross-sectionally and longitudinally associated 
with activation of inflammatory response system. Few studies, however, have investigated the 
longitudinal relationship between raised inflammatory biomarkers and persistence of depressive 
symptoms. We examined the temporal relationship between serum levels of inflammatory 
biomarkers and persistence of depressive symptoms among older participants.
Methods: Center for Epidemiologic Studies Depression Scale (CES-D) was used to assess 
depressive symptoms at baseline and at 5 year follow up in 656 participants (233 men, 423 
women) aged > 60 years of the Rotterdam Study. Markers of inflammation interleukin (IL)-6, 
alpha-1-antichymotrypsin (ACT) and C reactive protein (CRP) were assessed at baseline, and all 
participants taking antidepressant medications were excluded from the analysis.
Results: No cross-sectional association was found between IL-6, ACT and CRP with depressive 
symptoms at baseline. However, higher levels of IL-6 and CRP predicted depressive symptoms 
at 5 year follow-up. Adjustment for confounding variables had no impact on the observed 
associations. Similarly, a positive association was found between baseline levels of IL-6 (odds ratio 
[OR], 2.44; p = 0.030) and CRP (OR, 1.81; p = 0.052) and persistence of depressive symptoms 
over 5 years. 
Conclusion: Our data suggest that dysregulation of the inflammatory response system is associated 
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INTRODUCTION
There is evidence implicating inflammation as a potential etiologic factor for mood disorders. 
Meta-analysis studies have reported higher levels of inflammatory cytokines (such as Interleukin-6, 
(IL)-6) and acute phase proteins (such as C-reactive protein; (CRP)) in the peripheral blood and 
cerebrospinal fluid of patients with major depression.1,2 In addition, inflammation and depressive 
symptoms seem to be associated in large epidemiological cross-sectional studies.3-5
Further evidence stems from prospective studies showing that acute or chronic administration 
of cytokines leads to development of depressive symptoms. Chronic administration of the 
pro-inflammatory cytokine IFN-α for treatment of hepatitis C induced clinically significant 
depression in 30 - 50% of persons with no psychiatric disorders previous to interferon-alpha 
(IFN-α) treatment.6,7 Additional evidence to support an association between elevated immune-
inflammatory cytokines and depressive-like behavioural systems is provided in animal models. 
Elevated immune-inflammatory cytokines induce and exacerbate depressive-like symptoms, 
whereas tumour necrosis factor-alpha (TNF)-α and IL-6 receptor knockout mice show reduced 
behavioural indices of depression.8-13 In humans, fewer large epidemiological studies points 
towards a possible association between activation of inflammatory system and future depressive 
symptoms5,14,15, although controversy still exists.16
A possible explanation for this controversy is the hypothesis that activation of the inflammatory 
system distinguishes a particular subset of patients i.e. those who have a more severe form of 
depression. In agreement, an activation of the inflammatory system was particularly observed in 
major depressive patients who are older17, have recurrent episodes17,18; have comorbid depression 
with other mental and physical illnesses19-21; present earlier onset of the disorder17 and are 
resistant to antidepressant treatment.22,23 Consistent with the hypothesis that inflammation is 
present in a particular subgroup of depressed patients, the anti-inflammatory drug infliximab 
showed antidepressant properties only in treatment resistant depressed patients who have high 
levels of the inflammatory marker C-reactive protein.24
In this study, we take a longitudinal approach to examine the temporal relationship between 
the inflammatory biomarkers IL-6, alpha-1-antichymotrypsin (ACT), CRP at baseline and incident 
depressive symptoms 5 years later or persistent depressive symptoms over 5 years. Participants 













































The present study is embedded within the Rotterdam Study, a population-based cohort study in 
which all inhabitants age 55 and over living in a defined geographic area of Rotterdam have been 
invited to participate.25 The Medical Ethics Committee approved the study according to the Wet 
Bevolkingsonderzoek: ERGO (Population Study Act: Rotterdam Study) executed by the Ministry 
of Health, Welfare and Sports of the Netherlands. Written informed consent was obtained from 
all participants. During the third survey (1997 – 1999), participants were assessed for depressive 
symptoms. For the present study, of the 3 571 persons who were screened for depressive 
symptoms, only 1 211 had available information on serum level of inflammatory biomarkers. 
Moreover, thirty-seven participants were excluded for being on antidepressants, leaving 1 175 
participants eligible for analysis. In the present analysis, we studied the association of inflammatory 
proteins and depressive symptoms in 656 participants free of antidepressant medications. Out of 
these participants, 102 were on anti-inflammatory medications. In this study, we do not have 
repeated measures of inflammatory cytokines (IL-6, ACT, and CRP), and therefore could not 
analyse whether long-term exposure to high levels of inflammatory markers are associated with 
depression. Sequential exclusions occurred according to the flow chart represented in Figure 1.
Depression assessment
Depressive symptoms were assessed through participant’s completion of the Dutch version of the 
original Center for Epidemiological Studies Depression scale (CES-D) during a home interview.26,27 
The CES-D is a self-reporting 20-item measure of depressive symptoms scored on a scale from 
0 to 3. For the analysis of persistent depressive symptoms, we used a score of 16 as a cut-
off, to indicate clinically significant depressive symptoms in each wave.26,28 Persistent depressive 
symptoms were defined by having CES-D scores ≥ 16 in 1997 - 1999 (baseline) and when re-
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Figure 1. Flow chart for sample selection in the study 
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At baseline, a venepuncture was performed by application of minimal stasis with a 21-gauge 
butterfly needle with tube (Surflo winged infusion set, Terumo). Fasting blood was collected in the 
morning and all tubes were put on ice directly and centrifuged at 2000×g for 10 minutes. Plasma 
was separated and dispensed into two 1.5-ml aliquots and then frozen within 3 hours at - 80°C. 








































Inflammatory markers and depression  |  47
2
Marburg, Germany). The IL-6 concentrations were determined with quantitative enzyme-linked 
immunosorbent assay with a test kit from R&D systems (Minneapolis, MN). The intra-assay and 
interassay coefficients for all measurements were < 5% and < 8%, respectively. High-sensitivity 
CRP was measured in a serum, which was stored at - 20°C until performance of the CRP 
measurements, using a Rate Near Infrared Particle Immunoassay (IMMAGE, Immunochemistry 
System, Beckman Coulter, San Diego, CA, detection limit 0.2 mg/L, coefficient of variation (CV) 
3.2%). In this matter a fully automated Hitachi 747 system (Hitachi, Tokyo, Japan, detection limit 
1 mg/L, CV<5%) was used. IL-6 plasma levels were determined using a quantitative enzyme-
linked immunosorbent assay (ELISA) technique (Quantikine HS IL-6 kit, R&D Systems, Oxon, 
UK, detection limit 0.094 pg/mL, CV 8.7%) and ACT plasma levels using kinetic nephelometry 
(Behring Nephelometer BN200, Marburg, Germany, detection limit 1.5 mg/dL, CV 2.8%).
Other measurements
The following variables were considered as possible confounding variables: age, sex, education 
(low, middle, high), physical illness (including prevalent stroke, cardiovascular disease and 
diabetes), cognitive function (as measured by the mini mental-state examination), smoking 
and body mass index (BMI). A history of stroke was obtained through direct questioning and 
computerized linkage with general practitioner medical records.29 Smoking was coded as number 
of cigarettes currently smoked per day and in categories of current, former and never smoker. 
To exclude for obvious sings of inflammation when we analysed IL-6 and ACT, we adjusted for 
acute inflammation as defined by C-reactive protein level > 10mg/L. BMI was defined by > 18.50 
kg/m2 underweight, 18.50-24.99 kg/m2 normal, 25-29.99 kg/m2 overweight, > 30 kg/m2 obese.
DATA ANALYSIS
All data analysis was performed with IBM SPSS Statistics 22. We normalized the distribution 
of IL-6, ACT and CRP by natural logarithmic transformation and used binary logistic regression 
to estimate odds ratios (OR) and 95% confidence intervals (CIs) of inflammatory markers for 
depressive symptoms at baseline (1997 - 1999). We treated inflammatory markers, IL-6, ACT, 
and CRP as continuous variables. To assess the association between the log of the mean IL-6, 
ACT, CRP and depressive symptoms at 5 year follow-up, we performed linear regression analysis 
of the CES-D scores at 5 year follow-up (2002-2004) with adjustment for depressive symptoms 
at baseline (1997-1999). To further explore the association between inflammatory proteins and 
persistent depressive symptoms over the 5 years (1997/1999 - 2002/2004), multinomial binary 
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Age (continuous) and sex were controlled for in all analyses. To further analyse the effect of 
confounding factors, we added potential confounders to the basic model. If this changed the 
effect estimate meaningfully, the contribution of each variable was individually explored. In 
subgroup analyses, we assessed the age- and sex-adjusted association following exclusion of 




Table 1 represents information on socio-demographic and clinical baseline characteristics of the 
participants. The average age of the study participants was 73 years (range 61.1 - 105.8); 59.9% 
of whom were women. Among the study participants, the majority was either classified as being 
overweight or obese (65.3%). Most participants were past smokers 48.4%. Only the minority 
of participants reported history of physical illness (34%) or were screened positive for cognitive 
impairment (13.7%). Mean scores of levels of pro-inflammatory biomarkers in study participants 
are reported.
No association of IL-6, ACT or CRP and depressive symptoms at baseline
To determine if there was a cross-sectional relationship between serum levels of inflammatory 
biomarkers IL-6, ACT, or CRP and current depressive symptoms at baseline, we performed logistic 
regression analysis with CES-D scores at baseline. Our data indicate no association between 
inflammatory proteins IL-6 (OR, 1.08; p = 0.731), ACT (OR, 1.069; p = 0.670) and CRP (OR, 
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Table 1. Demographic characteristics of participants in the Rotterdam Study
Demographics Characteristics





















Interleukin-6 (pg/mL) 4.07 (0.53-80)
α1-Antichymotrypsin (mg/dL) 40.3 (19.5-128.5)
C-Reactive protein (mg/L) 3.39 (0.06-88.8)
BMI body mass index, physical illness stroke, history of cardiovascular disease and diabetes, MMSE mini-
mental state examination.
IL-6 and CRP predict depressive symptoms at 5 year follow-up in older people
To investigate if inflammatory markers are predictive of depressive symptoms at 5-year follow-up, 
stepwise linear regression were performed with the CES-D scores at 5-year follow-up (Table 2). In 
our basic model we corrected for age, gender and depressive symptoms at baseline. Subsequently, 
corrections included acute inflammation, socio-demographic and health characteristics. Our 
data indicate that IL-6 (B, 0.084; p = 0.016) and CRP (B, 0.086; p = 0.013) were significant 
predictors of depressive symptoms at 5-year follow-up and remained so after correction for 
all socio-demographic and health characteristics. ACT (B, 0.057; p = 0.083) showed a trend 
association with depressive symptoms at 5-year follow-up, following adjustment for age, gender 
and depressive symptoms at baseline. The trend association for ACT disappeared after correcting 
for additional socio-demographic and health characteristics including BMI, smoking, physical 
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Table 2. The association between inflammatory proteins and depressive symptoms after 5 years
Inflammatory proteins No. of cases B (95 % CI) p value
Log IL-6 (per 1 SD increment)α
Model 1 656 0.107 (1.32, 5.38) 0.001
Model 2 650 0.105 (1.16, 5.33) 0.002
Model 3 650 0.084 (0.48, 4.73) 0.016
Log ACT (per 1 SD increment)α
Model 1 655 0.057 (-0.67, 10.76) 0.083
Model 2 650 0.048 (-1.57, 10.04) 0.153
Model 3 650 0.020 (-4.20, 7.75) 0.561
Log CRP (per 1 SD increment)α
Model 1 656 0.090 (0.55, 3.19) 0.006
Model 2 650 0.086 (0.38, 3.16) 0.013
The category “depressive symptoms” includes all subjects who were screened positive. α=levels of 
inflammatory biomarkers from measurements of 1997-1999: new onset of depressive symptoms at 5-years 
follow-up in participants with no depressive symptoms at baseline. Subjects on antidepressant medications 
were excluded from the analysis. Model 1 linear regression analysis adjusted for sex and age. Model 2 as 
model 1 and additionally adjusted for body mass index (BMI), smoking, physical illness (including stroke, 
history of cardiovascular disease and diabetes) and mini-mental state examination (MMSE). Model 3 as model 
2 and additionally adjusted for acute inflammation. No model 3 was created for CRP as acute inflammation 
was calculated as CRP >10 mg/mL; therefore, no adjustment for acute inflammation could be done when 
CRP was used as predictor. IL-6 interleukin-6, ACT α1-antichymotrypsin, CRP C-reactive protein, SD standard 
deviation, B standardized beta, CI cumulative interval.
The contribution of individual covariates in the association between inflammatory 
markers and depressive symptoms at 5 year follow-up
Association with IL-6 and CRP
In the secondary analysis, we included adjustments for individual covariates to further assess 
the effect of each variable on the association between inflammatory markers at baseline and 
depressive symptoms at 5 year follow-up (Table 3 and 4). Our results indicate that the association 
between the levels of IL-6 or CRP and depressive symptoms remained strong and was not 
substantially affected by age, gender, BMI, smoking status, physical illness, low MMSE scores, or 
acute inflammation (specific to IL-6 analysis only), when adjusted individually or in combination. 
As acute inflammation was calculated as CRP >10 mg/mL, no adjustment for acute inflammation 
could be done when CRP was used as a predictor.
In the IL-6 subgroup, exclusion of participants with acute inflammation (B, 0.089; p = 0.010) or 
low MMSE scores (B, 0.170; p = 0.001) did not alter the significance of the association between 
levels of IL-6 and depressive symptoms at 5 year follow-up (Table 3).
Similarly, in the fully adjusted model, IL-6 predicted incident depressive symptoms after 5 years 
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In contrast to IL-6, associations between CRP and incident depressive symptoms) were no longer 
observed (Full Model: B, 0.044; p = 0.223; N = 622) following exclusion of subjects with CRP 
values > 10 mg/l and adjustments of all covariates.
Table3. The association between levels of IL-6 and depressive symptoms after 5 years
Inflammatory proteins No. of cases B (95 % CI) p values
Log IL-6 (per 1 SD increment)α
Age, sex 656 0.107 (1.32, 5.38) 0.001
Age, sex, BMI (kg/m2) 652 0.109 (1.31, 5.46) 0.001
Age, sex, smoking status 656 0.105 (1.24, 5.32) 0.002
Age, sex, physical illness 656 0.106 (1.26, 5.34) 0.002
Age, sex, MMSE 654 0.106 (1.27, 5.33) 0.002
Age, sex, acute inflammation 656 0.088 (0.68, 4.83) 0.009
Fully adjusted* 650 0.084 (0.48, 4.73) 0.016
Subgroups (age and sex adjusted)
Excluding those with acute inflammation 627 0.089 (0.68, 4.91) 0.010
Excluding those with MMSE 416 0.170 (2.99, 8.12) 0.001
Individual contribution of each covariate. The category “depressive symptoms” includes all subjects who were 
screened positive. α = levels of Il-6 from measurements of 1997-1999: new onset of depressive symptoms 
at 5-year follow-up in participants with no depressive symptoms at baseline. Subjects on antidepressant 
medications were excluded from the analysis. IL-6 interleukin-6, SD standard deviation, B standardized beta, 
CI cumulative interval, BMI body mass index, MMSE mini-mental state examination
Similarly to IL-6, in the CRP subgroup, exclusion of participants with low MMSE scores (B, 0.108; 
p = 0.008), did not affect the association between CRP levels and depressive symptoms (Table 4). 
Our data reported no significant gender and IL-6 or CRP-interaction in the prediction of depressive 
symptoms at 5 year follow-up (following adjustment for age); thus, no further analysis stratified 
for gender were performed.
Table 4. The association between levels of CRP and depressive symptoms after 5 years
Inflammatory proteins No. of cases B (95 % CI) p values
Log CRP (per 1 SD increment)α
Age, sex 656 0.090 (0.55, 3.19) 0.006
Age, sex, BMI (kg/m2) 652 0.090 (0.46, 3.23) 0.009
Age, sex, smoking status 656 0.088 (0.50, 3.15) 0.007
Age, sex, physical illness 656 0.089 (0.51, 3.16) 0.007
Age, sex, MMSE 654 0.089 (0.53, 3.16) 0.006
Fully adjusted* 650 0.086 (0.68, 3.16) 0.013
Subgroups (age and sex adjusted)
Excluding those with MMSE 416 0.108 (0.63, 4.06) 0.008
Individual contribution of each covariate. The category “depressive symptoms” includes all subjects who were 
screened positive. α = levels of CRP from measurements of 1997-1999: new onset of depressive symptoms 
at 5-year follow-up in participants with no depressive symptoms at baseline. Subjects on antidepressant 
medications were excluded from the analysis. CRP C-reactive protein, SD standard deviation, B standardized 
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Association with ACT
As no association was found between ACT and depressive symptoms at 5 year follow-up, no 
further analysis was conducted.
IL-6 and CRP are associated with persistent depressive symptoms over 5 years
To investigate whether there was any association between inflammatory proteins and persistent 
depressive symptoms over 5 years, we generated cut-off scores CES-D > 16 at baseline and at 5 
year follow-up and subsequently performed logistic analysis. In the basic model 1, IL-6 (OR, 2.32; 
p = 0.035) and CRP (OR, 1.79; p = 0.043) were positively associated with persistent depressive 
symptoms over 5 years (Table 5). In model 2, this association remained relatively unchanged 
after adjusting for age, gender, BMI, smoking status, physical illness and low MMSE scores for 
IL-6 (OR, 2.44; p = 0.03) and CRP (OR, 1.81; p = 0.052) respectively. In contrast to the previous 
observations on the depressive symptoms at 5-year follow-up (incident depression-Table 2.), acute 
inflammation largely explained the association between IL-6 and persistent depressive symptoms 
in the fully adjusted model 3 (OR, 2.02; p = 0.107), (Table 5). Levels of ACT (OR, 1.38; p = 0.80) 
were not positively associated with persistent depressive symptoms following adjustment for age 
and gender. No gender interaction was found for IL-6, ACT or CRP in the prediction of persistence 
depressive symptoms over 5 years following adjustment for age, thus no further analysis stratified 
for gender was performed.
Table 5. The association between inflammatory proteins and persistent depressive symptoms over 
5 years
Inflammatory proteins No. of cases Odds ratio (95 % CI) p value
Log IL-6
Model 1 656 2.32 (1.06, 5.06) 0.035
Model 2 650 2.44 (1.09, 5.45) 0.030
Model 3 649 2.02 (0.86, 4.77) 0.107
Log ACT
Model 1 654 1.38 (0.12, 16.06) 0.80
Model 2 649 1.23 (0.09, 15.27) 0.871
Model 3 649 0.63 (0.05, 8.81) 0.729
Log CRP
Model 1 655 1.79 (1.02, 3.13) 0.043
Model 2 649 1.81 (0.99,3.29) 0.052
The category “depressive symptoms” includes all subjects who were screened positive: CES-D ≥ 16 at baseline 
and at 5-year follow-up. Subjects on antidepressant medications were excluded from the analysis. Model 1 
multinomial binary logistic regression analysis adjusted for sex and age. Model 2 as model 1 and additionally 
adjusted for body mass index (BMI), smoking, physical illness (including stroke, history of cardiovascular 
disease and diabetes) and mini-mental state examination (MMSE). Model 3 as model 2 and additionally 
adjusted for acute inflammation. No model 3 was created for CRP as acute inflammation was calculated 
as CRP >10 mg/mL; therefore, no adjustment for acute inflammation could be done when CRP was used 
as predictor. IL-6 interleukin-6, ACT α1-antichymotrypsin, CRP C-reactive protein, SD standard deviation, B 
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The contribution of individual covariates on the association between levels of IL-6 or 
CRP and persistent depressive symptoms over 5 years
Associations with IL-6 and CRP
We further investigated whether the individual covariates could explain the correlation between 
IL-6 or CRP and persistent depressive symptoms during the 5 years (Table 6 and 7). Our results 
indicate that the association between the levels of IL-6 and persistent depressive symptoms was 
little explained by age, gender, BMI, smoking status, physical illness or MMSE, when adjusted 
individually. In contrast, acute inflammation, largely explained the association between the levels 
of IL-6 and persistent depressive symptoms. Indeed correcting for (OR, 1.96; p = 0.113), or 
excluding (OR, 2.19; p = 0.068) participants with acute inflammation reduced this association to 
insignificant levels (Table 6).
However, IL-6 predicted persistent depressive symptoms following exclusion of CRP values > 10 
mg/L and adjustments of all covariates (full model: OR, 2.37; p = 0.049; N = 622). In contrast, 
associations between CRP and persistent depressive symptoms were no longer observed following 
exclusion of subjects with CRP values > 10 mg/l (full model: OR, 1.45; p = 0.310; N = 621). The 
data suggest that the association between depression and inflammation seems to be stronger 
for IL-6 than CRP.
In the subgroup analysis, exclusion of participants with low MMSE scores (OR, 2.64; p = 0.046) 
did not affect the positive relationship between levels of IL-6 and persistent depressive symptoms. 
In contrast to IL-6, association between levels of CRP and persistent depressive symptoms over 
5 years were largely explained by adjustment for physical illness (OR, 1.70; p = 0.067) and by 
exclusion (OR, 1.68; p = 0.138), but not adjustment for low MMSE scores (OR, 1.80; p = 0.042). 
Associations between CRP and depressive symptoms were little explained by age, gender, BMI, 
or smoking status. 
Associations with ACT
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Table 6. The association between levels of IL-6 and persistent depressive symptoms over 5 years
Inflammatory proteins No. of cases Odds ratio (95 % CI) p values
Log IL-6
Age, sex 656 2.32 (1.06, 5.06) 0.035
Age, sex, BMI (kg/m2) 652 2.54 (1.15, 5.60) 0.021
Age, sex, smoking status 656 2.28 (1.04, 5.00) 0.040
Age, sex, physical illness 656 2.23 (1.01, 4.93) 0.048
Age, sex, MMSE 654 2.38 (1.09, 5.18) 0.030
Age, sex, acute inflammation 655 1.96 (0.85, 4.50) 0.113
Fully adjusted* 649 2.02 (0.86, 4.77) 0.107
Subgroups (age and sex adjusted)
Excluding those with acute inflammation 626 2.19 (0.94, 5.01) 0.068
Excluding those with MMSE 416 2.64 (1.02, 6.88) 0.046
Individual contribution of each covariate. The category “depressive symptoms” includes all subjects who 
were screened positive: CES-D ≥ 16 at baseline and at follow-up. Subjects on antidepressant medications 
were excluded from the analysis. IL-6 interleukin-6, CI cumulative interval, BMI body mass index, MMSE mini-
mental state examination.
Table 7. The association between levels of CRP and persistent depressive symptoms over 5 years
Inflammatory proteins No. of cases Odds ratio (95 % CI) p values
Log CRP
Age, sex 656 1.79 (1.02, 3.13) 0.043
Age, sex, BMI (kg/m2) 651 1.93 (1.07, 3.49) 0.03
Age, sex, smoking status 655 1.76 (1.01, 3.09) 0.048
Age, sex, physical illness 655 1.70 (0.97, 2.98) 0.067
Age, sex, MMSE 653 1.80 (1.02, 3.16) 0.042
Fully adjusted* 649 1.81 (0.99, 3.29) 0.052
Subgroups (age and sex adjusted)
Excluding those with MMSE 415 1.68 (0.85, 3.35) 0.138
Individual contribution of each covariate. The category “depressive symptoms” includes all subjects who 
were screened positive: CES-D ≥ 16 at baseline and at follow-up. Subjects on antidepressant medications 
were excluded from the analysis. CRP C-reactive protein, CI cumulative interval, BMI body mass index, MMSE 
mini-mental state examination.
DISCUSSION
In this large population based study of elderly persons, we found that the inflammatory 
biomarkers IL-6 and CRP were longitudinally associated with depressive symptoms. Both IL-6 and 
CRP levels predicted persistent depressive symptoms over 5 years independently of age, gender, 
BMI, smoking status or MMSE. Furthermore, we found that IL-6 and CRP predicted incident 
depressive symptoms at 5 year follow-up after adjustment for all socio-demographic and health 
characteristics. In contrast, no longitudinal association was observed between the levels of ACT 
and depressive symptoms. None of the inflammatory biomarkers were associated with depressive 
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To the best of our knowledge, this is the first population-based study to investigate whether 
inflammation predicts persistent depressive symptoms over 5 years. Persistent depressive symptoms 
and inflammation had been previously associated in a small study in individuals who were at 
high risk for coronary heart disease.30 Our results are consistent with the literature suggesting 
that activation of inflammatory response system contributes significantly to the maintenance 
of symptoms of depression, and might be more relevant in people who are more severely ill. 
Inflammation is particularly observed in major depressive patients who are older17, have comorbid 
depression with physical 19,21 and mental illnesses20, present recurrent18 or earlier age of onset of 
the disorder17; and in those who are resistant to antidepressant treatment.22,23 Consistent with 
this hypothesis, we found that the association between inflammation and persistent depression is 
lost when adjusted for physical illnesses. It is possible that inflammation distinguishes a subgroup 
of depressed patients. In line with this idea, Raison et al. showed that the anti-inflammatory drug 
infliximab showed antidepressant properties only in treatment resistant depressed patients who 
have high levels of the inflammatory marker C-reactive protein.24
Secondly, in this study we report a positive longitudinal relationship between IL-6 or CRP levels 
and incident depressive symptoms at 5 year follow-up. Our data is consistent with findings from 
previous literature, which demonstrated a positive longitudinal association between inflammation 
and incident mental health. Similar to our study, Gimeno et al. found a positive association 
between CRP, IL-6 and incident depressive symptoms in healthy participants.31 However, in their 
research only cognitive depressive symptoms were reported; and mental health was conducted 
by using the general health questionnaire (GHQ) which is less specific for depressive symptoms. In 
our study, depressive symptoms were measured using the CES-D scale which is reported to have 
an excellent sensitivity (100%) and specificity (88%) for major depression in a community based 
sample of older subjects.26 Also, in agreement with the present results, Kivimaki et al. showed 
that persistent elevation of IL-6 levels increases risk of common mental disorder.32. Likewise, van 
den Biggelaar and colleagues showed that baseline levels of CRP significantly predicted incident 
depression at five year follow-up in elderly participants of > 85 years old.5
Further investigations on the link between inflammation and incident depression have also been 
conducted in different population groups compared to ours. For example, it has been reported 
that inflammation also predicts depression in females after an accident33 and in middle-aged 
adults4; but not in younger adults16,34 This study does not report a cross-sectional association 
between inflammatory biomarkers and depressive symptoms at baseline. Our data is consistent 
with findings from Matsushima et al. who reported no cross sectional association between 
baseline values of hsCRP and IL-6 and depressive symptoms in a community dwelling older 
participants.35 Our data is also consistent with that of Krogh et al. 2014 who showed no cross-
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depression.36 The fact that no cross-sectional association was found suggest that the response 
to peripheral infection on producing inflammatory cytokines that act on the brain to cause 
depression might occur only when this inflammatory stimuli is persistent; and might not occur in 
a normal acute and transitional response of the inflammatory system.10
Several mechanisms have been speculated on how inflammation and depression may be 
associated. Both clinical and experimental data strongly point toward the involvement of the 
enzyme indoleamine 2,3 dioxygenase in the development of inflammation-associated major 
depressive disorders.10 Reduced function of the hypothalamus-pituitary-adrenal (HPA) axis 
has been observed in the presence of chronic inflammation in severely ill patients with major 
depression.22,23 Inflammation also induces a reduction in the brain derived-neurotrophic factor 
(BDNF), which negatively influences neurogenesis and neuroplasticity.37-39 Over time, a decrease in 
neurogenesis could contribute to the reduction in hippocampal volume seen in major depression40 
and cognitive dysfunction41 which is positively correlated with a longer duration of depressive 
symptoms in the community.42 Furthermore, it has been suggested that pro-inflammatory 
cytokines can modulate the tryptophan/kynurenine pathway and decrease tryptophan availability 
for serotonin synthesis.10,38,43
We did not find a longitudinal association between levels of ACT and depressive symptoms. Our 
findings seem surprising because ACT is an acute phase serum glycoprotein, which is positively 
associated with CRP.44 A possible explanation for this could be that ACT is a less sensitive marker 
for inflammation than CRP, which signals early inflammation when other clinical parameters are 
yet unchanged and therefore, the latter reveals early inflammation when other clinical parameters 
are equivocal.45-47
This study has several strengths. First, the assessment of depressive symptoms at baseline and at 
5 year follow-up, allowed us to examine the direction of the association between inflammatory 
biomarkers and depressive symptoms. Furthermore, we controlled for several confounding 
factors, which can influence the association between inflammatory markers and depression. 
Several limitations of our study need also to be addressed. First, our study was restricted to 
older population of men and women and thus our findings cannot be generalised for the 
younger population. A second limitation was the fact that we excluded participants who were on 
antidepressants, and thus the findings might be not generalizable for patients more severely ill 
and with clinical depression. Finally, we do not have repeated measures of inflammatory cytokines 
(IL-6, ACT, and CRP), and therefore could not analyse whether long term exposure to high levels 
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To conclude, our findings indicate that inflammatory biomarkers IL-6 and CRP are longitudinally 
associated with persistence and incident depressive symptoms in older men and women, after 
adjustment for socio-demographic and health characteristics. Inflammation seems to distinguish 
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APPENDIX of CHAPTER 2.1
Supplementary material 1
Longitudinal analysis of the association between serum vitamin D levels and incident major 
depressive disorder with Cox regression analysis 5 years follow-up time (N = 2 466)
Vitamin D serum levels Major depressieve disorder
events
Model 1 Model 2
HR (95%CI) p HR (95%CI) P
Continuously
Vitamin D √SD nmol/la 91 0.96 (0.75 to 1.23) 0.77 0.92 (0.80 to 1.05) 0.53
Cut-off
<37.5 nmol/L 45 0.90 (0.58 to 1.41) 0.66 1.03 (0.65 to 1.63) 0.91
>37.5 nmol/L 46 Reference Reference
<50 nmol/L 61 0.90 (0.56 to 1.43) 0.65 0.96 (0.75 to 1.22) 0.86
>50 nmol/L 30 Reference Reference
<75 nmol/L 86 1.65 (0.66 to 4.14) 0.29 1.51 (0.94 to 2.42) 0.37
>75 nmol/L 5 Reference Reference
Quartiles
<28,57 nmol/L 25 0.68 (0.41 to 1.12) 0.13 0.74 (0.44 to 1.27) 0.29
28,58-43,81 nmol/L 29 1.27 (0.81 to 1.98) 0.30 1.31 (0.99 to 1.06) 0.25
43,82-63,21 nmol/L 28 1.62 (1.03 to 2.54) 0.039 1.37 (0.86 to 2.18) 0.20
 >63.21 nmol/L 9 Reference Reference
Abbreviations: SD, standard deviation; HR, hazard ratio; CI, confidence interval.
a Standard Deviation of the square root of the Vitamin D serum levels (nmol/L)
Model 1. Adjusted for gender, age and baseline depressive symptoms; Model 2. Additionally adjusted for: 
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Longitudinal analysis of the association between serum vitamin D levels and incident major 
depressive disorder with Cox regression analysis 2 years follow-up time (N = 2 466)
Vitamin D serum levels Major depressieve disorder
events
Model 1 Model 2
HR (95%CI) p HR (95%CI) p
Continuously
Vitamin D √SD nmol/la 32 1.10 (0.70 to 1.75) 0.67 0.88 (0.68 to 1.15) 0.63
Cut-off
<37.5 nmol/L 16 0.87 (0.41 to 1.86) 0.72 1.24 (0.81 to 1.91) 0.61
>37.5 nmol/L 16 Reference Reference
<50 nmol/L 21 0.64 (0.28 to 1.47) 0.29 1.1 (0.70 to 1.72) 0.83
>50 nmol/L 11 Reference Reference
<75 nmol/L 30 0.72 (0.16 to 3.22) 0.66 0.70 (0.32 to 1.52) 0.65
>75 nmol/L 2 Reference Reference
Quartiles
<28,57 nmol/L 10 0.77 (0.35 to 1.69) 0.51 1.20 (0.73 to 1.97) 0.71
28,58-43,81 nmol/L 9 0.99 (0.45 to 2.19) 0.99 1.02 (0.46 to 2.27) 0.97
43,82-63,21 nmol/L 10 1.63 (0.74 to 3.61) 0.23 1.33 (0.86 to 2.06) 0.51
 >63.21 nmol/L 3 Reference Reference
Abbreviations: SD, standard deviation; HR, hazard ratio; CI, confidence interval.
a Standard Deviation of the square root of the Vitamin D serum levels (nmol/L)
Model 1. Adjusted for gender, age and baseline depressive symptoms Model 2. Additionally adjusted for: 
body mass index, alcohol consumption, smoking status, marital status and activity of daily living score.
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ABSTRACT
Despite a substantial genetic component, efforts to identify common genetic variation underlying 
depression have largely been unsuccessful. In the current study we aimed to identify rare genetic 
variants that might have large effects on depression in the general population. Using high coverage 
exome-sequencing, we studied the exonic variants in 1 265 individuals from the Rotterdam 
study (RS) who were assessed for depressive symptoms. We identified a missense Asn396Ser 
mutation (rs77960347) in the endothelial lipase (LIPG) gene, occurring with an allele frequency 
of 1% in the general population, that was significantly associated with depressive symptoms 
(p value = 5.2*10-08, β = 7.2). Replication in three independent datasets (N = 3 612) confirmed 
the association of Asn396Ser (p value = 7.1*10-03, β = 2.55) with depressive symptoms. LIPG is 
predicted to have enzymatic function in steroid biosynthesis, cholesterol biosynthesis and thyroid 
hormone metabolic processes. The Asn396Ser variant is predicted to have a damaging effect on 
the function of LIPG. Within the discovery population, carriers also showed an increased burden 
of white matter lesions (p value = 3.3*10-02) and a higher risk of Alzheimer’s disease (odds ratio 
= 2.01; p value = 2.8*10-02) compared to the non-carriers. Together, these findings implicate the 
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INTRODUCTION
Depression is a common psychiatric illness with a substantial heritability (h2 = 40-50%).1 Despite 
decades of research, its genetic origin remains largely obscure. Previously candidate gene studies 
suggested a role of various genes in the monoaminergic neurotransmission pathways. These 
include MTHFR, 5-HTTLPR, HTR1A, HTR2A, TPH1 and BDNF. However, these findings were not 
replicated in recent large case-control studies based on array-based genome-wide association 
studies (GWAS). The hypothesis-free large-scale GWAS have led to the discovery of hundreds of 
genetic variants contributing to the risk of a wide diversity of common human traits and diseases2,3, 
however, the Psychiatric Genetics Consortium (PGC) Working Group for Major Depressive 
Disorder (MDD) did not identify a genome-wide significant locus for depression that could be 
replicated.3 Also PGC could not replicate the two common genetic variants that were recently 
implicated in MDD in a GWAS in the Han-Chinese population.4,5 The failure to elucidate the 
genes underlying MDD is mainly attributed to the fact that MDD is more common, less heritable 
and more heterogeneous compared to other psychiatric diseases like Schizophrenia6, genes for 
which were successfully identified by the same consortium.7 High heterogeneity of the disease 
phenotype and inclusion of a substantial number of non-genetic patients that develop a major 
depression due to life-events dilutes the effects of the genetic variants and diminishes statistical 
power.3 To overcome the issues with statistical power relating to heterogeneity, large-scale 
GWAS (N > 30 000) of sub-domains of depression and quantitative endophenotypes have been 
performed.8,9 Endophenotypes are heritable quantitative factors10,11, that have been successfully 
used to unravel the genetics of other heterogeneous diseases with major misclassification such as 
hypertension.12 For depression, however, these were also not successful.8,9
Two important lessons learned from the array-based GWAS in general. First, common variants 
have small effects and consortia of mega-sizes are needed to detect these. Second, a substantial 
part of the heritability is not accounted for by the common variants. The variance of MDD 
explained by common genomic variation across the entire genome is estimated to be ~21%6,13 
and 4% for quantitative outcomes.8 These estimates suggest there may be various alternative 
genetic mechanisms that explain the heritability such as rare variants. Also the search for rare 
variants has a long history starting with linkage analysis – a method studying co-segregation 
of chromosomal regions with the disease in families. These regions presumably harbour rare-
causal variants that have relatively large effects on the disease risk.14 The identified linked regions 
are followed up with various fine-mapping techniques to identify the putative causal variant.14 
Linkage of depression has been reported to large genomic regions including 15q2515,16, 17p17, 
7p18, 8p17, 12q2319,20, 18q18, 1p3620 and 13q311,20. The presumed underlying rare-causal variants 
were never identified. Notably such rare variants are usually not present on microarrays used 
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the reference haplotypes used for genetic imputations21, are difficult to impute with sufficient 
confidence. An alternative approach is next generation sequencing (NGS). This is a highly effective 
method for identifying rare variants with relatively large effects. Such variants may be anticipated 
in exonic or coding regions.
In this study, we performed exome sequencing in a large population-based cohort to search 
for rare exonic variants associated with depressive symptoms measured using the Centre for 
Epidemiologic Studies Depression (CES-D)22, as an endophenotype of MDD. Findings were 
replicated in three independent studies. As endophenotypes are not 1:1 related to disease, we 
further studied the relation of the variants associated with depressive symptoms to a range of 




Our discovery population consists of subjects from the Rotterdam study (RS). RS is a prospective, 
population-based study from the well-defined district of Ommoord within the city of Rotterdam, 
designed to investigate the occurrence and determinants of diseases in the elderly.23 The RS 
cohort was initially defined in 1990 among 7 983 persons who underwent a home interview 
and extensive physical examination at baseline and during follow-up examinations occurring 
every 3 - 4 years (RS-I). The cohort was further extended in 2000 (RS-II) and 2005 (RS-III), 
establishing a total of 14 926 participants.23 The Rotterdam Study was approved by the Medical 
Ethics Committee of the Erasmus MC and by the Ministry of Health, Welfare and Sport of the 
Netherlands. All participants provided written informed consent to participate in the study and to 
obtain information from their treating physicians.
Participants from RS-I were assessed for depressive symptoms using the 20-item version of the 
CES-D scale. CES-D is a self-report measure of symptoms experienced during the prior week. It 
has shown to be relatively stable over time (82% of older adults had stable CES-D scores over four 
measurement rounds in 10 years)9,24,25 and covers the following major dimensions of depression: 
depressed mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, 
psychomotor retardation, loss of appetite, and sleep disturbance.9 The total score ranges from 
0 - 60, with higher scores indicating a greater burden of depressive symptoms. The heritability 
of the CES-D is estimated to be 0.2426 and it detects current MDD cases with high sensitivity and 
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maximize the number of eligible participants, data from the third follow-up visit was used in this 
study.
Since 2005, magnetic resonance imaging (MRI) of the brain has been acquired at 1.5 Tesla during 
RS study examinations. The MRI protocol incorporates several sequences, including a T1-weighted 
sequence, a proton density weighted sequence, and a fluid-attenuated inversion recovery (FLAIR) 
sequence. These sequences were automatically processed using custom-developed multimodal 
algorithms to quantify brain tissue volumes.30,31 The processed images distinguished between 
grey matter, white matter, white matter lesions, and cerebrospinal fluid, and the volumes of each 
of these tissues were calculated by multiplying the number of voxels with that label with the 
volume of an individual voxel, expressed in ml.
Various other disease related to depressive systems have been characterized in the discover cohort. 
Alzheimer’s disease (AD) was characterized using the National Institute of Neurological Disorders 
and Stroke–Association Internationale pour la Recherche et l’Enseignement en Neurosciences - 
Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA).32 Thyroid stimulating 
hormone (TSH) and free thyroxine (FT4) measurements were performed in serum samples stored 
at - 80°C in samples collected between 1997 and 2000. Thyroxine, thyrotropin, and thyroid 
perioxidase antibodies were quantified by electrochemiluminescence immunoassay (ECLIA, 
Roche).33
Independent replications were performed in the Erasmus Rucphen Family (ERF) study. ERF is a 
family-based study that includes inhabitants of a genetically isolated community in the South-
West of the Netherlands, ascertained as part of the Genetic Research in Isolated Population 
(GRIP) program.34 The ERF cohort includes approximately 3 000 living descendants of 22 founder 
couples who had at least six children baptized in the community church. All data were collected 
between 2002 and 2005. The population shows minimal immigration and high inbreeding and 
therefore the frequency of many rare alleles is increased in this population.34 All participants 
provided informed consent. The Medical Ethical Committee of the Erasmus University Medical 
Centre approved the ERF study. All study participants were assessed for depressive symptoms 
using Hospital Anxiety and Depression Scale (HADS) and CES-D. HADS is a 14-item scale of which 
7 items relate to anxiety and 7 items to depression. For depression, the total score ranges from 0 
to 21, with higher scores indicating a greater burden of depressive symptoms. A cut off of ≥ 8 is 
considered indicative of likely clinical depressive episodes.35
Subjects were extensively profiled for metabolomics using either plasma or serum samples 
collected at the time of visit and stored at - 80°C. Metabolic profiling was performed either by 
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one set by the AbsoluteIDQTM p150 Kit (Biocrates Life Sciences AG) (N = 937)36, two sets by 
either liquid chromatography coupled MS or Electro-Spray Ionization coupled MS37,38 (N = 2 416 
and N = 822 respectively), two sets measured by NMR using small molecular compounds39 (N = 
2 416, measured by Center for Proteomics and Metabolomics, Leiden University Medical Center, 
Leiden, the Netherlands) and lipoprotein extraction windows (N = 2 609, measured by Center 
for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands and 
deconvoluted by the commercial algorithm of Bruker Corporation NMR service protocol). The 
majority of the blood samples (97%) were obtained during fasting. In total, 2 864 participants 
from the ERF study were profiled for metabolomics on at least one of the five platforms and 563 
metabolites were annotated, which consisted of lipoprotein sub-particles, amino acids, a large 
array of (lyso)phosphatidylcholines, sphingolipids, ceramides, triglycerides and low-molecular-
weight compounds.
Exome sequencing
In the Rotterdam study, exomes of randomly selected subset of 2 628 individuals from the RS-I 
population were sequenced at the Human Genotyping facility of the department of Internal 
Medicine, at Erasmus MC, the Netherlands. The sequencing was performed at an average depth 
of 54x using the Nimblegen SeqCap EZ V2 capture kit on an Illumina Hiseq2000 sequencer 
using the TrueSeq Version 3 protocol. The sequence reads were aligned to hg19 using Burrows-
Wheeler Aligner (BWA).40 Subsequently, the aligned reads were processed further using Picard’s 
MarkDuplicates, SAMtools41 and the Indel Realignment and Base Quality Score Recalibration tools 
from Genome Analysis Toolkit (GATK).42 Genetic variants were called using the HaplotypeCaller 
from GATK. Samples with low concordance to genotyping array (< 95%), or that differed 4 
standard deviations from the mean on either the number of detected variants per sample, 
transition to transversion ratio or high heterozygote to homozygote ratio and low call rate (< 
90%) were removed from the data. Single Nucleotide Variants (SNVs) with a low call rate (< 
90%) and out of Hardy-Weinberg equilibrium (HWE; p-value < 10-8) were also removed from 
the data. The final dataset consisted of 600 806 SNVs in 2 356 individuals. Of these, 1 265 were 
assessed for depressive symptoms and were used in this study. The average age at examination 
was 72.3 years and the majority were women (59%; Supplementary Table 1). File handling and 
formatting was done using VCFtools43 and PLINK44. Annotation of the variants was performed 
using SeattleSeq annotation138 (http://snp.gs.washington.edu/SeattleSeqAnnotation138/). 
Exomes of 1 336 randomly selected individuals from the ERF study cohort were sequenced at 
the Center for Biomics of the Cell Biology department, at the Erasmus MC, The Netherlands. 
Sequencing was done at a median depth of 57x using the Agilent version V4 capture kit, on an 
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aligned to the human genome build 19 (hg19), using Burrows-Wheeler Aligner (BWA) and 
the NARWHAL pipeline.40,45 Subsequently, the aligned reads were processed further, using the 
IndelRealigner, MarkDuplicates and Table Recalibration tools from the Genome Analysis Toolkit 
(GATK)42 and Picard (http://picard.sourceforge.net). This was necessary to remove systematic 
biases and to recalibrate the PHRED quality scores in the alignments. After processing, genetic 
variants were called, using the Unified Genotyper tool from the GATK.42 For each sample, at 
least 4 Gigabases of sequence was aligned to the genome. Functional annotations were also 
performed using the SeattleSeq annotation 138 database. About 1.4 million SNVs were called. 
After removing variants with a low quality, out of HWE (p value < 10-6) and low call rate (< 99%), 
and samples with a low call rate (< 90%), we retrieved 543 954 very high quality SNVs in 1 327 
individuals. Of these, 1 247 individuals (60% women, mean age = 48.5 years) were assessed for 
depressive symptoms and included in the replications analysis.
Exome-chip genotyping
Study participants from the ERF cohort whose exomes were not sequenced (N = 1 527) were 
genotyped on the Illumina Infinium HumanExome BeadChip, version 1.1, which contains over 
240 000 exonic variants selected from multiple sources together spanning 12 000 samples from 
multiple ethnicities. Calling was performed with GenomeStudio. We removed subjects with a call 
rate < 0.95, IBS > 0.99 and heterozygote ratio > 0.60. Ethnic outliers identified using a principal 
component analysis with 1 000 Genomes data (Supplementary Figure 1) and individuals with sex 
discrepancies were also removed. The SNVs that were monomorphic in our sample or had a call 
rate < 0.95 were removed. After quality control we retrieved about 70 000 polymorphic SNVs in 
1 515 subjects. Of these, 840 individuals (54% women, mean age = 50 years) were assessed for 
depressive symptoms and included in the replication analysis.
In the RS cohort, 3 163 (1 949 independent) samples were genotyped using the Illumina Human 
Exome BeadChip v1.0. Genotype calling was performed according to the CHARGE joint calling 
protocols.46 For replication, we used 1 525 individuals (52.6% women, mean age = 73.7 years) 
who were assessed for depressive symptoms but not exome sequenced.
DATA ANALYSIS
Single variant quantitative trait association analysis of depressive symptoms was performed 
using the seqMeta (v1.4) library of the R software in RS. We included only missense, nonsense, 
frameshift, or essential splice site bi-allelic variants that had a minor allele count > 7 in the RS 
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model in seqMeta (V1.4) using the kinship matrix estimated from the pedigree data in the 
kinship2 library of R. For the exome-chip data, we used FamScore test implemented in RVtests 
(http://zhanxw.github.io/rvtests/) using the kinship matrix estimated from the genotyped data 
to adjust for familial relationships. Analysis of the RS exome-chip data was performed using 
seqMeta library of the R software. All analyses were adjusted for age and sex. Meta-analysis 
of the replication studies was performed in R using the library rmeta. Association analyses with 
other dichotomous and quantitative traits were performed using logistic and linear regression 
analysis respectively, adjusted for age and sex in PLINK v1.0744 (http://pngu.mgh.harvard.edu/
purcell/plink/) or SPSS v21. Analysis of the metabolomics data in the ERF cohort was performed 
using linear regression adjusted for age and sex. Skewed metabolites were transformed using 
either natural logarithm or inverse-normal transformation. We used polygenic residuals of the 
metabolites after regressing out the effect of relationships in a linear mixed model in GenABEL. 
We used Bonferroni corrected p-value thresholds in ERF (0.05/563 metabolites = 8.8*10-05) to 
declare significance.
RESULTS
Genome-wide association and quantile-plots are provided in Supplementary Figures 2 and 
3. We observed significant association of depressive symptoms with a low frequency variant 
(rs77960347-G; MAF = 1%, N (carriers) = 60; p value = 5.2*10-08) on chromosome 18 (Table 1a, 
Figure 1). The estimated additive effect of the minor allele (G) on depressive symptoms was large 
(β = 7.2) (Figures 2 and 3), suggesting that each allele yields an increase of depressive symptoms 
by 7.2 units. Rs77960347 is a highly conserved missense variant in the LIPG gene (Asn396Ser 
phastCons = 1) and predicted to be damaging (polyPhen = 1). In the replication cohort ERF, 
rs77960347-G was observed with a similar frequency to the discovery sample. The replication 
sample demonstrated a significant association (p value = 7.1*10-03) of rs77960347-G with the 
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Apart from having large effects on depressive symptoms, the carriers of rs77960347-G on 
average had a smaller brain volume (both white and grey matter) and a higher burden of white 
matter lesions (p value = 3.3*10-02; based on the subset of 10/60 carriers with an MRI available), 
compared to non-carriers (Table 2).
Table 2. Brain imaging characteristics of carriers and non-carriers of Asn396Ser
  A/A (N=398) A/G (N=10) p value
Demographics
Age, years 79.0 (4.8) 79.0 (4.8) 0.97
Females 222 (55.8%) 7 (70.0%) 0.37
Brain volumetry, mL
Intracranial volume 1137.2 (119.6) 1136.5 (93.8) 0.99
Grey matter volume 508.6 (52.1) 501.2 (49.8) 0.66
White matter volume 378.9 (55.1) 377.9 (51.1) 0.96
Cerebrospinal fluid volume 247.4 (51.2) 255.0 (47.8) 0.64
White matter lesion volume 8.3 (3.9 - 17.1) 24.6 (5.4 - 34.5) 0.03









































































46.5 47 47.5 48
Position on chr18 (Mb)
Plotted SNPs
Vertical axis shows the strength of association in terms of negative principal logarithm of the association 
p-value. Dots represent the SNVs tested in the region. Top variant rs77960347 is indicated in purple. Colors 
of the dots indicate the extent of linkage disequilibrium with the top hit. All genes in the region are shown 
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Vertical axis shows the CES-D score. Purple box region shows the interquartile range. The horizontal bar in the 
box indicates the median. Lower and upper whiskers indicate the first and the fourth quartiles respectively. 
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Vertical axis represents all the studies. Horizontal axis shows the size of the effect of the variant. Size of 
the blue boxes indicates the precision. The horizontal lines adjacent the blue boxes indicate the confidence 
interval for the study. The red diamond indicates the summary effect estimate. The width of the diamond 
indicates the confidence interval for the summary effect. 
Given that the LIPG gene is expressed in the thyroid gland and has been implicated in several 
cardiometabolic disorders, including dyslipidemia47, atherosclerosis48,49, cardiovascular diseases50, 
and inflammation51, we additionally tested the association of Asn396Ser with these conditions 
and their related phenotypes (Table 3). No association with thyroid functioning, cardiovascular 
outcomes, inflammation, atherosclerosis, or hypertension was observed (Table 3). Total cholesterol 
was increased in carriers (p value = 5.3*10-03; Table 3). The association of Asn396Ser with 
depressive symptoms was relatively decreased after adjusting for total cholesterol (adjusted β = 
7.0, adjusted p value = 5.3*10-06), using a slightly reduced sample size (N = 1 112). Furthermore, 
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the minor allele (14/60 carriers) compared to non-carriers (p value = 2.8*10-02; Table 3). The 
association of Asn396Ser with depressive symptoms remained significant (p value = 3.7*10-
08) after adjusting for AD. However, the association with AD disappeared (p value = 0.46) 
after adjusting for depressive symptoms. Metabolomic profiles of carriers and non-carriers of 
Asn396Ser in the ERF study demonstrated significantly increased levels of high density lipoprotein 
(HDL) sub-particles and Apolipoprotein A1 (APOA1) (p value < 6.7*10-05; Supplementary Table 2).
Table 3. Association results of various diseases with Asn396Ser
Disease Phenotype Effect (OR)§ SE p value
Cardiovascular
Myocardial infarction (MI) -0.32 0.48 0.51
Coronary heart disease (CHD) -0.18 0.49 0.72
Coronary artery calcification (CAC) -0.27 0.58 0.64
Inflammation
C-reactive protein (CRP) -0.06 0.13 0.65
Thyroid function
Thyroid stimulating hormone (TSH) 0.05 0.17 0.79
Free Thyroxine (FT4; pmol/l) -0.72 0.49 0.14
Cholesterol
High density lipoprotein (HDL; mg/dl) 6.96 2.94 0.02
Low density lipoprotein (LDL; mg/dl) 15.16 7.42 0.04
Total cholesterol (TC; mg/dl) 21.09 7.57 5.0*10-03
Triglycerides (TG; mg/dl) -0.05 0.10 0.59
Atherosclerosis
Intima media thickness (IMT) -0.03 0.03 0.31
Hypertension
Diastolic blood pressure 0.20 2.29 0.93
Systolic blood pressure 0.01 4.21 0.99
Hypertension 0.27(1.31) 0.52 0.60
Neurological
Alzheimer’s disease (AD) 0.70(2.01) 0.32 0.03
Cognitive function (G-factor) -0.10 0.28 0.72
§ all effects/ORs are reported for the minor allele (G) 
DISCUSSION
Using a comprehensive exome-based association study of depressive symptoms, we have 
identified a rare (MAF = 1%) Asn396Ser coding variant (rs77960347-G) in the LIPG gene in 
chromosome 18q21. This variant is conserved and predicted to have damaging effects on the 
LIPG protein. The estimated effect of Asn396Ser on depressive symptoms is large and significantly 
replicates in three independent samples. Carriers of the rare allele (G) manifest smaller brains and 
more white-matter lesions compared to non-carriers. When considering pleiotropic effects, the 
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Rs77960347 is relatively less frequent in the general population (1000Genomes MAF = 0.5%; 
10/2174 alleles) compared to the cohorts used in this study. Comparing across ethnicities, it 
is more frequent in non-Finnish Europeans (1.35% in non-Finnish Europeans versus 0.35% in 
Finnish and 0.18% in Africans). In the RS cohort, we observed 60 carriers of the minor allele 
(G). The variant overlaps both transcripts of the endothelial lipase (LIPG) gene. Common variants 
in LIPG have consistently been associated with blood cholesterol levels.52 Previous reports on 
the association of cholesterol levels with depression have been contradictory.53 In our study, we 
observed significantly increased levels of serum cholesterol in carriers of Asn396Ser compared to 
non-carriers. Notably however, the association with cholesterol was not nearly as strong as with 
the depressive symptoms. Furthermore, the lipidomics/metabolomics profiles of the carriers and 
non-carriers in the ERF cohort demonstrated significantly increased levels of HDL sub-particles 
and plasma APOA1. 
Carriers of rs77960347-G had a higher burden of white matter lesions than non-carriers. White 
matter lesions in patients with depression have been well recognized in the elderly.54-57 The 
severity of subcortical white matter lesions in the elderly has been associated with the presence 
of depressive symptoms and to a history of late-onset depression.57 White matter lesions are 
also frequently found in AD patients.58-60 In this context, the higher prevalence of AD in carriers 
of Asn396Ser is interesting. Depression is also one of the most widely studied risk factors for 
AD.61 Previous reports suggest that the one-month prevalence of major depressive episodes in 
AD patients is as high as 25%.61 While there is a general consensus about the existing complex 
relationship between the two diseases, the direction of causality remains unclear. However, a 
few longitudinal epidemiological studies suggest that people with a history of depression are 
at an increased risk of AD.62,63 It is of interest that the association of genetic variant loses its 
significance after adjusting from depressive symptoms but its association to depressive symptoms 
remains significant when adjusting for AD. This findings is compatible with a mechanism in which 
the depressive symptoms are an intermediate in the association between Asn396Ser and AD. 
Given the marginal level of significance of the association to AD, this hypothesis requires further 
confirmation in other cohort studies.
LIPG is highly expressed in the thyroid gland (AUC = 0.96, p value = 1*10-49) and is predicted 
to be involved in the metabolism of steroids, cholesterol, thyroid hormone, tryptophan, 
butanoate (butyrate), vitamins A and D, and the platelet amyloid precursor protein (APP) 
pathway (http://129.125.135.180:8080/GeneNetwork/?gene=LIPG).64 Hypothalamus-pituitary-
thyroid (HPT) axis abnormalities have been documented in some depressed patients.65 Thyroid 
dysfunction, including both hypothyroidism and hyperthyroidism, are known to be associated 
with mood disorders.66-68 In our study we did not find evidence of thyroid function abnormalities 
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butanoate (butyrate) and tryptophan is notable given that tryptophan is a precursor of serotonin 
and depletion in plasma tryptophan has been previously reported in depressed individuals.69,70 
Sodium butyrate is also known to reverse depressive-like behaviors in animals.71
Our study is the first to have used exome-sequencing on a large scale with a specific aim to 
identify rare variants with large effects on depressive symptoms. One of the strengths of this 
study is the use of a quantitative depression scale for gene discovery. The CES-D detects cases of 
MDD with high sensitivity and specificity28 and has proven to be relatively stable over time.25,72 In 
association studies quantitative endophenotypes provide an improved power to detect genetic 
variants compared to a dichotomous trait. This is likely to be especially true for trait such as MDD, 
for which the severity and duration of illness can be highly heterogeneous.73 Another strength of 
our study is the use of high coverage sequencing (> 50 x on average) necessary to reliably detect 
rare variants.
In conclusion, we have discovered a novel missense variant rs77960347-G (Asn396Ser) in the 
LIPG gene that confers a large effect on depressive symptoms in the general population. We 
have also confirmed that this association is not confounded or mediated by the presence of an 
underlying somatic disorder. Moreover, the combination of the predicted functioning of LIPG, 
the association of rs77960347-G with white matter lesions, and its pleiotropic effects on various 
phenotypes linked with major depressive disorder substantiates LIPG as a candidate gene for 
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ABSTRACT
Background: Despite high heritability, little success was achieved in mapping genetic determinants 
of depression-related traits by means of genome-wide association studies (GWAS).
Methods: To identify genes associated with depressive symptomology, we performed a gene-
based association analysis of non-synonymous variation captured using exome-sequencing and 
exome-chip genotyping in a genetically isolated population from the Netherlands (N = 1 999). 
Finally, we reproduced our significant findings in an independent population-based cohort (N = 
1 604).
Results: We detected significant association of depressive symptoms with a gene NKPD1 (p 
value = 3.7 × 10-08). Non-synonymous variants in the gene explained 0.9% of sex-age-adjusted 
variance of depressive symptoms in the discovery study, which is translated into 3.8% of the total 
estimated heritability (h2 = 0.24). Significant association of depressive symptoms with NKPD1 
gene was also observed (N = 1 604, p value = 1.5 x 10-03) in the independent replication sample 
despite little overlap with the discovery cohort in the set of non-synonymous genetic variants 
observed in the NKPD1 gene. Meta-analysis of the discovery and replication studies improved the 
association signal (p value = 1.0 x 10-09).
Conclusion: Our study suggests that non-synonymous variation in the gene NKPD1 affects 
depressive symptoms in the general population. NKPD1 is predicted to be involved in the de-novo 
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INTRODUCTION
Major depressive disorder (MDD) is the most prevalent psychiatric disease1 and is known to be 
influenced by both genetic and non-genetic factors. The heritability of MDD is estimated to be ~ 
40%.1-3 Up until recently all efforts to identify common genetic variation involved in depression 
using large scale genome-wide association studies (GWAS) were unsuccessful.4,5 Two common 
variants on chromosome 10 were detected, one near the SIRT1-DNAJC12 locus (minor allele 
frequency (MAF) = 0.45; p value = 2.4 × 10-10), the other in an intron of the LHPP gene (MAF = 
0.26; p value = 6.4 × 10-12), each with a small effect on the disease risk (odds ratios of 1.15 and 
0.84). Despite successful replication in an independent sample of Chinese origin, the two variants 
could not be reproduced in the European MDD case/control samples.6,7
The limited success of GWAS in case of depression has been attributed to the specifics of the 
disease.1 The patients with MDD have heterogeneous phenotypes, they differ from one another 
in frequency, severity and the duration of episodes of MDD.5 Those with a family history of 
MDD more often have clinically severe illness, earlier age of onset, and suffer higher rates of 
recurrence.8 Because MDD is more prevalent and less heritable than other psychiatric traits, for 
instance, schizophrenia1, it has been speculated that common genetic variants involved in MDD 
have effects even smaller than the effects of genetic variants observed for schizophrenia.1,9 The 
proportion of variance of MDD explained by common genetic variants is estimated to be 21%10 
asking for a sample size of more than 75K for the discovery of such variants.1
One of the approaches that was successfully followed for other complex and prevalent outcomes 
that are liable to misclassification (e.g., hypertension) is to study the genetics of quantitative traits 
of liability (e.g. blood pressure).11 Following this reasoning, large-scale attempts were made to 
identify common genetic variants associated with depressive symptoms and somatic complaints 
in depression (N > 30 000). However, these efforts also failed.2,12 Of note is that, the percentage 
of variance explained by common genetic variation was estimated to be rather low (< 4%).12
Besides common variants, rare variants may be involved in MDD. Recently, two studies identified 
rare variants in a gene ZNF3413 and Cav2-adaptor gene set14 to be nominally associated with 
depression. As these variants may be private to individual (sub-) families even at a single locus, 
different variants in the same gene may be involved in the disease (allelic heterogeneity). Statistical 
approaches to aggregate rare variants across genes can help overcome the problem of allelic 
heterogeneity.15 Further increase in power of statistical association analysis may be achieved by 
using founder populations for gene discovery.15 Because of their unique characteristics including 
genetic, environmental and cultural homogeneity, and enrichment of some rare alleles due to 
genetic drift, founder populations are considered more powerful than general populations for 
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In the current study we aim to identify genetic variants implicated in depressive symptomology using 
exome-sequencing and exome-chip genotyping in a genetically isolated European population. 
We conduct single variant and gene-based analyses to discover variants and genes associated 
with depressive symptoms and replicate our findings into a population-based prospective cohort 
study from the same source population.
METHODS
Discovery population
The Erasmus Rucphen Family (ERF) study is a cross-sectional cohort including 3 000 living 
descendants (age range 18 - 96 years) of 22 couples who lived in the middle of 18th century in 
an isolated village in the Southwest of the Netherlands and had at least 6 children baptized in 
the community church. Until the last few decades descendants of these founders have lived in 
social isolation with minimal immigration (less than 5%). From the year 1848, the population 
has expanded from 700 up to 20 000 inhabitants.17 77% of the fathers and 79% of the 
mothers in this population have inbreeding coefficient greater than zero. The participants are 
not selected for any disease or outcome. Detailed information regarding the ERF isolate can 
be found elsewhere.17-19 The study protocol was approved by the medical ethics board of the 
Erasmus MC Rotterdam, the Netherlands. Written informed consents were provided by all the 
subjects participating in the study. Symptoms of depression were assessed with the Center for 
Epidemiological Studies Depression Scale (CES-D) in 2,353 participants.20 The questionnaire is a 
valid and reliable self-report measure of current symptoms of depression.20,21 The scale consists 
of 20 items with total scores ranging from 0 to 60. Higher scores correspond to more depressive 
symptoms. A CES-D score of >16 is indicative of possible depression.20 The descriptive data of ERF 
study are provided in Supplementary Table 1.
Exome sequencing
Exomes of 1 336 participants from the ERF pedigree were sequenced at the Center for Biomics, 
Erasmus MC Rotterdam, the Netherlands. Sequencing was performed at a median depth of 57 x 
(mean depth = 74x) using Agilent SureSelect V4 capture kit on an Illumina Hiseq2000 sequencer 
and the TruSeq Version 3 protocol. Sequence reads were aligned to the human genome build 19, 
using Burrows-Wheeler Aligner22 and the NARWHAL pipeline.23 Subsequently, the aligned reads 
were processed further, using the IndelRealigner, MarkDuplicates and Table Recalibration tools 
from the Genome Analysis Toolkit (GATK). For each sample, at least 4 Gigabases of sequence 
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the GATK24 v2.3. About 1.4 million Single Nucleotide Variants (SNVs) were called. Genotype 
concordance checks were performed with the available genome-wide array data. The SeattleSeq 
annotation 138 database (http://snp.gs.washington.edu/SeattleSeqAnnotation138/) was used to 
perform functional annotations of the identified SNVs. After removal of individuals with low 
concordance, inconsistent genomic and pedigree kinship estimate and ethnic-outliers detected 
using principal components analysis (Supplementary Figure 1), and filtering out variants with low 
quality (QUAL < 30), > 5% Mendelian errors per sample and out of Hardy-Weinberg equilibrium 
(p value < 10-08) we retrieved 528 617 polymorphic SNVs in 1 308 individuals. Of these, 1 209 
had depressive symptoms measured.
Exome chip
Study participants from the ERF cohort whose exomes were not sequenced (N = 1 527) were 
genotyped on the Illumina Infinium HumanExome BeadChip, version 1.1, which contains over 
240 000 exonic variants selected from multiple sources together spanning 12 000 samples from 
multiple ethnicities. Calling was performed with GenomeStudio and the ZCall variant calling 
tool25(Broad Institute). We removed subjects with a call rate < 0.95, IBS > 0.99, heterozygote 
ratio > 0.60, XXY individuals and ethnic-outliers (Supplementary Figure 1). SNPs that were 
monomorphic in our sample or had a call rate < 0.95 were removed from the dataset. After 
quality control we retrieved 71 320 genetic variants in 1 512 individuals. Of these, 794 had 
depressive symptoms measured and 62 246 variants were polymorphic within this sample.
DATA ANALYSIS
Single variant association analysis of depressive symptoms was performed using a linear-
mixed model (mmscore function) in GenABEL (30) incorporating genomic kinship matrix to 
account for relatedness. Gene-based association analysis of depressive symptoms including 
only nonsynonymous variants (missense, missense near splice, stop-gained, stop-gained near 
splice, stop-lost, stop-lost near splice mutations) was performed using the famSKAT-O test in 
the FFBSKAT function of the FREGAT R-package26 (http://mga.bionet.nsc.ru/soft/FREGAT/). 
FamSKAT-O is a powerful tool for family-based analyses.27 It combines a sequence kernel 
association test (SKAT) with a classical burden test and retains the advantages of both. SKAT 
compares the average similarity of a set of genetic variants in the analyzed region for each pair 
of individuals with pairwise phenotypic similarities. Pairwise genetic similarity is measured by 
using a kernel weighting function, which reduces the information on multiple genetic variants 
for a pair of individuals into a single scalar factor. Weights for genetic variants were assigned as a 
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set from 0 to 1 with an increment of 0.1.29 Genomic kinship was used to correct for relatedness. 
The kinship matrix was calculated with the IBS function of GenABEL 30 using autosomal genetic 
variants with a MAF ≥ 5%. Since the two ERF subsamples had little overlapping in individuals 
(4 individuals in common) they were analyzed separately. Of 88 565 nonsynonymous variants in 
exome sequence data, 85 858 formed 13 707 gene regions with > 1 polymorphic genetic variants 
(ranging from 2 to 222 variants, median 5). In exome chip data, 47 469 nonsynonymous variants 
were present and 43 563 of them were within 9 677 gene regions with > 1 polymorphic genetic 
variants (ranging from 2 to 123 variants, median 3). Meta-analysis of the two ERF subsamples (as 
well as of the discovery and replication samples) was performed using Fisher’s method 31, which 
has been shown to have a high power in regional meta-analysis.32 All analyses were adjusted for 
age and sex (Supplementary Table 2). Exome-wide significance for gene-based analysis was set at 
p value < 2.5×10-6 corresponding to a Bonferroni correction for ~20 000 protein-coding genes in 
the genome.33 The proportion of total variance explained by a single region was estimated with 
the ‘return.variance.explained’ option of FFBSKAT.
Replication study
Significant findings from the discovery population were selected for replication in the independent 
population-based Rotterdam Study (RS) study. RS is a prospective, population-study from a well-
defined district in Rotterdam (Ommoord) that investigates the occurrence and determinants of 
diseases in the elderly.34 The cohort was initially defined in 1990 among approximately 7 900 
persons who underwent a home interview and extensive physical examination at the baseline and 
during follow-up rounds every 3-4 years. The cohort was extended in 2000 and 2005. RS is an 
outbred population, predominantly of Dutch origin. The Medical Ethics Committee of the Erasmus 
Medical Center, Rotterdam, approved the study. Written informed consent was obtained from 
all study participants. Participants from RS-I are assessed at four follow-up visits for depressive 
symptoms using the 20 item version of the CES-D scale. Because of maximum participation, data 
from the third visit was used in this study.
Exomes of 2 628 individuals from the RS-I population were sequenced at the Human Genotyping 
facility of the Internal Medicine department, at the Erasmus MC, the Netherlands, at an average 
depth of 54x using the Nimblegen SeqCap EZ V2 capture kit on an Illumina Hiseq2000 sequencer 
and the TruSeq Version 3 protocol. The sequenced reads were aligned to human genome build 
19 using Burrows-Wheeler Aligner.22 The aligned reads were processed further using Picard’s 
MarkDuplicates, SAMtools35, and the Indel Realignment and Base Quality Score Recalibration 
tools from GATK.24 Genetic variants were called using the HaplotypeCaller and genotypeGVCFs 
tools of GATK. Samples with low concordance to genotyping array (< 95%), or that were 4 








































92  |  Chapter 3.2
transversion ratio or heterozygous to homozygous ratio and low call rate (< 90%) were removed 
from the data. Initial variant QC was done using the Variant Quality Score Recalibration tool from 
GATK, additionally SNVs with a low call rate (< 90%) and out of HWE (p value < 10-08) were also 
removed from the data. The final dataset consisted of 600,806 SNVs in 2,356 individuals. File 
handling and formatting was done using vcftools and PLINK36 (http://pngu.mgh.harvard.edu/
purcell/plink/). Annotation of the variants was performed using SeattleSeq annotation 138.
The SeqMeta library (https://cran.r-project.org/web/packages/seqMeta/index.html) for the R 
statistical analysis software was used to perform gene-based SKAT analysis of depressive symptoms 
for the genes identified in the discovery cohort. As in the discovery cohort only nonsynonymous 
mutations were used in the SKAT analysis. The analysis was adjusted for age and sex.
RESULTS
The discovery sample (ERF) included 1 999 individuals. The percentage of women (57%) and 
the mean age (49 years) were similar to that of the whole ERF study (Supplementary Table 1). 
The heritability of depressive symptoms was estimated at 0.24. Results of the single variant and 
gene-based analysis are illustrated in Figure 1 and quantile-quantile (QQ) plots are provided 
in Supplementary Figure 2. None of the single variants surpassed the standard genome-wide 
significance threshold (Figure 1). Genome-wide results of gene-based analysis are provided in 
Supplementary Table 3. Significant association of depressive symptoms was observed with the 
gene NKPD1 (p value = 3.7 x 10-08) (Supplementary Table 3). Nine non-synonymous variants 
were observed in the NKPD1 gene in the ERF study (Supplementary Table 4). Except for one 
variant, minor alleles of all non-synonymous variants were associated with higher CES-D scores 
(Supplementary Table 4). Two variants were relatively frequent (rs28469095, MAF = 0.11 and 
rs117934605, MAF = 0.13). The variant that showed the lowest p value (rs75291769, p value 
= 2.5 x 10-04) was four times more frequent in ERF (MAF = 0.046) compared to 1 000 genomes 
(0.012). The region covering the NKPD1 showed good coverage in sequencing with a mean read 
depth of 46.5x. Non-synonymous variants in NKPD1 gene explained 0.9% of the age- and sex-
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Significant association of NKPD1 with depressive symptoms was also observed in the replication 
cohort (RS) (p value = 1.5 x 10-03). A total of 15 nonsynonymous variants were tested in the 
NKPD1 gene in the RS with MAFs varying from 0.03% to 0.7%. (Supplementary Table 5). The 
association signal improved to p value = 2.9 x 10-05 when we limited the analyses to mutations 
that were predicted damaging by PolyPhen (10 mutations (9 missense, 1 stop-gained) within 
NKPD1 gene; Supplementary Table 5). Figure 2 compares the results of exome single-point and 
gene-based analysis for NKPD1 in the two samples. Different variants were identified within 
NKPD1 gene in ERF and RS. In ERF, the second NKPD1 exon gave the strongest association signal 
while the third and fourth exons contained only modest signals. In the replication, association 
signals were present in the fourth exon only but the p values were stronger compared to that seen 
in ERF. When meta-analyzing the discovery and replication studies the significance of association 
increased to a p value of 1.0 x 10-09. 
Figure 2. Single-point and gene-based association signals of NKPD1 gene in the discovery sample 
(ERF, blue) and the replication sample (RS, pink).
Dotted blue and red lines indicate the regional statistically significant levels for discovery and replication, 
respectively. Size of the points is proportional to the MAF.
None of the previously identified genes i.e., SIRT-DNAJC12, LHPP, ZSNF34 or Cav2 adaptor genes 
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DISCUSSION
We have identified and replicated association of (rare) non-synonymous variants in NKPD1 gene 
with depressive symptoms. These coding variants explained 0.9% of the age- and sex-adjusted 
variance and 3.8% of heritability of depressive symptoms in the ERF population. To our knowledge 
this is the first study that explores the gene-based association of non-synonymous variants for 
depressive symptoms using large scale whole exome-sequencing.
To date, little success was achieved in mapping genetic determinants of depression-related 
traits by means of GWAS and whole genome/exome sequencing.1,2,4 We did not find evidence 
of association of previously reported genes including SIRT-DNAJC12, LHPP, ZSNF34 and Cav2 
adaptor gene set in our study. In previously published GWAS of MDD and depressive symptoms, 
only five intronic variants were mapped on to the NKPD1 gene, of which three showed modest 
association signals (p value < 0.1; Supplementary Tables 6-7). These variants may be in low linkage 
disequilibrium with coding variants not typed in these studies.
Our study had several strengths that ultimately led to the discovery of a novel gene associated 
with depressive symptoms. In association studies, quantitative measurements give better chances 
to detect genetic variants compared to the dichotomous trait, especially for traits like depression, 
which represents an arbitrarily selected extreme of the continuum of varying severity and 
duration.37 Secondly, we used high coverage exome sequencing (average depth = 74x) in a large 
discovery set that allowed us to determine rare variants with high precision. Finally, our discovery 
is based within a genetically isolated population. Samples from genetic isolates are expected to 
have reduced genetic variation and shifted allele frequencies due to long-time genetic drift.19 Rare 
alleles can accumulate in large numbers in these populations, thus empowering the association 
analysis.15 In our study, the missense variant that showed the strongest association within the 
NKPD1 gene (rs75291769/exm1479956, p value = 2.5 x 10-04) had a frequency of 4.6% in ERF 
(Supplementary Table 3) but was monomorphic in RS despite the fact that both populations go to 
the same source population. Yet, several other variants within NKPD1 showed modest associations 
with depressive symptoms in RS, with the strongest signal in exon 4 of NKPD1, 6K apart from the 
strongest signal obtained in ERF. None of these single-point association signals achieved genome-
wide significance, illustrating the advantage of a regional gene-based association analysis over a 
single point study of rare variants. 
NKPD1 encodes NTPase KAP family P-loop domain–containing protein 1, and it was found to 
express strongly in skin and, to a lesser extent, in cerebellum, other brain tissues and thyroid 
(http://www.gtexportal.org/home/gene/NKPD1).38 NTPases are nucleoside-triphosphatases 
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membrane NTPase activity is substantially altered in Lesch–Nyhan disease fibroblasts.39 Lesch–
Nyhan syndrome (also known as juvenile gout) is caused by a defect of the purine metabolism 
and its symptoms include mental retardation, dystonia, spasticity, delayed motor development 
and a compulsive form of self-injurious behavior.40 Functional prediction of NKPD1 suggests that 
this gene is involved in the de novo biosynthesis of sphingolipids (http://129.125.135.180:8080/
GeneNetwork/?gene=NKPD1). De novo synthesis of sphingolipids results in the formation of 
ceramides.41-46 Sphingolipid metabolism is also proposed to be a therapeutic target for MDD.47,48 
Some antidepressants (amitriptyline and fluoxetine) are known to inhibit sphingomyelin 
phosphodiesterase 1 acid lysosomal (SMPD1).49 SMPD1 is a membrane protein facing the lysosomal 
lumen that converts sphingomyelin into ceramide.47,49 Earlier, we found various sphingomyelin 
levels in the blood to be associated with depressive symptoms.50 
In summary, we have discovered association of non-synonymous variation in the gene NKPD1 
with depressive symptoms in the general population. The variants explain 0.9% of the age- 
and sex-adjusted variance of depressive symptoms, which translates into 3.8% of the estimated 
genetic variance of depressive symptoms. The predicted involvement of NKPD1 in the biosynthesis 








































Nonsynonymous variation in NKPD1 increases depressive symptoms  |  97
3
REFERENCES
1. Levinson DF, Mostafavi S, Milaneschi Y, et al. Genetic studies of major depressive disorder: why are 
there no genome-wide association study findings and what can we do about it? Biol Psychiatry. 
2014;76(7):510-512.
2. Hek K, Demirkan A, Lahti J, et al. A genome-wide association study of depressive symptoms. Biol 
Psychiatry. 2013;73(7):667-678.
3. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-
analysis. Am J Psychiatry. 2000;157(10):1552-1562.
4. Dunn EC, Brown RC, Dai Y, et al. Genetic determinants of depression: recent findings and future 
directions. Harv Rev Psychiatry. 2015;23(1):1-18.
5. Flint J, Kendler KS. The genetics of major depression. Neuron. 2014;81(3):484-503.
6. consortium C. Sparse whole-genome sequencing identifies two loci for major depressive disorder. 
Nature. 2015;523(7562):588-591.
7. Sullivan PF. Genetics of disease: Associations with depression. Nature. 2015;523(7562):539-540.
8. Weissman MM, Wickramaratne P, Nomura Y, Warner V, Pilowsky D, Verdeli H. Offspring of depressed 
parents: 20 years later. Am J Psychiatry. 2006;163(6):1001-1008.
9. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-
associated genetic loci. Nature. 2014;511(7510):421-427.
10. Cross-Disorder Group of the Psychiatric Genomics C, Lee SH, Ripke S, et al. Genetic relationship 
between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet. 2013;45(9):984-
994.
11. International Consortium for Blood Pressure Genome-Wide Association S, Ehret GB, Munroe PB, et al. 
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 
2011;478(7367):103-109.
12. Demirkan A, Lahti J, Direk N, et al. Somatic, positive and negative domains of the CES-D scale: a meta-
analysis of genome-wide association studies. Psychol Med. 2015;accepted.
13. Subaran RL, Odgerel Z, Swaminathan R, Glatt CE, Weissman MM. Novel variants in ZNF34 and other 
brain-expressed transcription factors are shared among early-onset MDD relatives. Am J Med Genet B 
Neuropsychiatr Genet. 2016;171(3):333-341.
14. Pirooznia M, Wang T, Avramopoulos D, Potash JB, Zandi PP, Goes FS. High-throughput sequencing of 
the synaptome in major depressive disorder. Mol Psychiatry. 2016;21(5):650-655.
15. Hatzikotoulas K, Gilly A, Zeggini E. Using population isolates in genetic association studies. Brief Funct 
Genomics. 2014;13(5):371-377.
16. Heutink P, Oostra BA. Gene finding in genetically isolated populations. Hum Mol Genet. 
2002;11(20):2507-2515.
17. Aulchenko YS, Heutink P, Mackay I, et al. Linkage disequilibrium in young genetically isolated Dutch 
population. Eur J Hum Genet. 2004;12(7):527-534.
18. Lopez-Leon S, Choy WC, Aulchenko YS, et al. Genetic factors influence the clustering of depression 
among individuals with lower socioeconomic status. PLoS One. 2009;4(3):e5069.
19. Pardo LM, MacKay I, Oostra B, van Duijn CM, Aulchenko YS. The effect of genetic drift in a young 
genetically isolated population. Ann Hum Genet. 2005;69(Pt 3):288-295.
20. Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Appl 
Pshycol Measurement 1977(3):385-401.
21. Weissman MM, Sholomskas D, Pottenger M, Prusoff BA, Locke BZ. Assessing depressive symptoms in 








































98  |  Chapter 3.2
22. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 
2009;25(14):1754-1760.
23. Brouwer RW, van den Hout MC, Grosveld FG, van Ijcken WF. NARWHAL, a primary analysis pipeline for 
NGS data. Bioinformatics. 2012;28(2):284-285.
24. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for 
analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297-1303.
25. Goldstein JI, Crenshaw A, Carey J, et al. zCall: a rare variant caller for array-based genotyping: genetics 
and population analysis. Bioinformatics. 2012;28(19):2543-2545.
26. Belonogova NM, Svishcheva GR, Axenovich TI. FREGAT: an R library for Family REGional Association 
Tests. European Journal of Human Genetics. 2015;23:473.
27. Jiang D, McPeek MS. Robust rare variant association testing for quantitative traits in samples with 
related individuals. Genet Epidemiol. 2014;38(1):10-20.
28. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with 
the sequence kernel association test. Am J Hum Genet. 2011;89(1):82-93.
29. Lee S, Wu MC, Lin X. Optimal tests for rare variant effects in sequencing association studies. Biostatistics. 
2012;13(4):762-775.
30. Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: an R library for genome-wide association 
analysis. Bioinformatics. 2007;23(10):1294-1296.
31. Fisher RA. Combining independent tests of significance. American Statistician. 1948;2(5):30.
32. Zakharov S, Wang X, Liu J, Teo YY. Improving power for robust trans-ethnic meta-analysis of rare and 
low-frequency variants with a partitioning approach. Eur J Hum Genet. 2015;23(2):238-244.
33. Pennisi E. Genomics. ENCODE project writes eulogy for junk DNA. Science. 2012;337(6099):1159, 
1161.
34. Hofman A, Brusselle GG, Darwish Murad S, et al. The Rotterdam Study: 2016 objectives and design 
update. Eur J Epidemiol. 2015;30(8):661-708.
35. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 
2009;25(16):2078-2079.
36. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-
based linkage analyses. Am J Hum Genet. 2007;81(3):559-575.
37. van der Sluis S, Posthuma D, Nivard MG, Verhage M, Dolan CV. Power in GWAS: lifting the curse of the 
clinical cut-off. Mol Psychiatry. 2013;18(1):2-3.
38. Fehrmann RS, Karjalainen JM, Krajewska M, et al. Gene expression analysis identifies global gene 
dosage sensitivity in cancer. Nat Genet. 2015;47(2):115-125.
39. Pinto CS, Jinnah HA, Shirley TL, Nyhan WL, Seifert R. Altered membrane NTPase activity in Lesch-Nyhan 
disease fibroblasts: comparison with HPRT knockout mice and HPRT-deficient cell lines. J Neurochem. 
2005;93(6):1579-1586.
40. Nyhan WL, Wong DF. New approaches to understanding Lesch-Nyhan disease. N Engl J Med. 
1996;334(24):1602-1604.
41. Causeret C, Geeraert L, Van der Hoeven G, Mannaerts GP, Van Veldhoven PP. Further characterization 
of rat dihydroceramide desaturase: tissue distribution, subcellular localization, and substrate specificity. 
Lipids. 2000;35(10):1117-1125.
42. Merrill AH, Jr. Characterization of serine palmitoyltransferase activity in Chinese hamster ovary cells. 
Biochim Biophys Acta. 1983;754(3):284-291.
43. Merrill AH, Jr., Williams RD. Utilization of different fatty acyl-CoA thioesters by serine palmitoyltransferase 
from rat brain. J Lipid Res. 1984;25(2):185-188.
44. Pewzner-Jung Y, Ben-Dor S, Futerman AH. When do Lasses (longevity assurance genes) become 









































Nonsynonymous variation in NKPD1 increases depressive symptoms  |  99
3
45. Pruett ST, Bushnev A, Hagedorn K, et al. Biodiversity of sphingoid bases (“sphingosines”) and related 
amino alcohols. J Lipid Res. 2008;49(8):1621-1639.
46. Zitomer NC, Mitchell T, Voss KA, et al. Ceramide synthase inhibition by fumonisin B1 causes 
accumulation of 1-deoxysphinganine: a novel category of bioactive 1-deoxysphingoid bases 
and 1-deoxydihydroceramides biosynthesized by mammalian cell lines and animals. J Biol Chem. 
2009;284(8):4786-4795.
47. Osherovich L. Depressing sphingolipids. SciBX. 2013;6(27).
48. Gulbins E, Palmada M, Reichel M, et al. Acid sphingomyelinase-ceramide system mediates effects of 
antidepressant drugs. Nat Med. 2013;19(7):934-938.
49. Kornhuber J, Tripal P, Reichel M, et al. Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel 
pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem. 2010;26(1):9-
20.
50. Demirkan A, Isaacs A, Ugocsai P, et al. Plasma phosphatidylcholine and sphingomyelin concentrations 
are associated with depression and anxiety symptoms in a Dutch family-based lipidomics study. 








































100  |  Appendix 3.1
APPENDIX of CHAPTER 3
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Supplementary Figure1: Ethnicity information provided by the principal components analysis. Black circles represent the samples analyzed, red: Caucasian, blue: Chinese, green: African, yellow: Colombian (AMR), cyan: Mexican (AMR), coral: Puerto Rican (AMR), brown: African (AMR).  
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Genome-wide association plot. Horizontal axis shows all chromosomes. Vertical axis shows the strength of 
association in terms of negative principal logarithm of the association p-value. Each dot represents a SNV. The 
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Supplement Table 1
RS (seqeunce) RS (exomechip) ERF (sequence) ERF (exomechip)
N 1265 1525 1247 840
Age mean(SD) 72.3 (7.1) 73.7 (7.2) 48.5 (14.6) 50.0 (15.8)
% women 59.1 52.6 60 54
CES-D mean(SD) 4.5 (6.9) 4.7 (7.1) 11.7 (10.3) 9.2 (9.0)
Supplement Table 2
Name BETA SE t-value p-value N
M-HDL-ApoA1 2.8811 0.6684 4.31 1.70E-05 2186
L-HDL-cholesterol 1.2789 0.3148 4.06 5.01E-05 2187
M-HDL-phospholipids 2.3569 0.5854 4.03 5.86E-05 2187
HDL-phospholipids 9.0311 2.2490 4.02 6.13E-05 2186
plasma-ApoA1 9.7158 2.4312 4.00 6.65E-05 2186
L-HDL-phospholipids 2.2543 0.5746 3.92 9.01E-05 2186
M-HDL-Free cholesterol 0.2622 0.0679 3.86 0.000116 2188
L-HDL-Free cholesterol 0.3130 0.0813 3.85 0.000121 2188
M-HDL-cholesterol 1.1438 0.3017 3.79 0.000154 2187
L-HDL-ApoA1 2.3032 0.6189 3.72 0.000203 2186
XL-HDL-Free cholesterol 0.7118 0.1937 3.67 0.000244 2177
Ethanol -0.2681 0.0731 -3.67 0.000249 1991
HDL-cholesterol 5.0928 1.4056 3.62 0.000298 2186
L-HDL-ApoA2 0.4994 0.1394 3.58 0.000346 2186
XL-HDL-phospholipids 0.1480 0.0415 3.57 0.000369 2178
Phosphatidylcholine diacyl (38:7) 0.2853 0.0825 3.46 0.00055 2258
HDL-ApoA1 9.0328 2.6479 3.41 0.000658 2185
M-HDL-ApoA2 0.6115 0.1831 3.34 0.000852 2185
Phosphatidylcholine diacyl (36:4) 0.8600 0.2624 3.28 0.001061 2262
S-VLDL-cholesterol 0.2625 0.0830 3.16 0.001583 2187
HDL-Free cholesterol 1.1654 0.3752 3.11 0.001921 2186
S-VLDL-phospholipids 0.2874 0.0947 3.03 0.002441 2181
Ceramide C24:1 0.3180 0.1059 3.00 0.002766 648
Phosphatidylcholine diacyl (40:4) 0.0147 0.0050 2.95 0.003218 2251
Phosphatidylethanolamine 38:4 1.4875 0.5070 2.93 0.003463 647
HDL-APOA2 1.6880 0.5989 2.82 0.004871 2185
Lysophosphatidylcholine(18:2) -0.2889 0.1049 -2.75 0.005927 2258
Phosphatidylethanolamine(38:4) 0.0361 0.0134 2.69 0.00715 2254
Phosphatidylcholine diacyl (32:0) 0.0441 0.0164 2.69 0.007191 2260
Sphingomyeline C 16:0 22.8932 8.4976 2.69 0.007241 647
Phosphatidylcholine diacyl C 38:0 1.9246 0.7309 2.63 0.008662 649
M-VLDL-cholesterol 0.9207 0.3597 2.56 0.010539 2181
Isoleucine -8489.8937 3340.3312 -2.54 0.011108 2009
Sphingomyeline C 16:1-OH 1.0739 0.4217 2.55 0.011114 651
XL-HDL-ApoA2 0.1398 0.0552 2.53 0.01134 2172
XL-LDL-triglycerides 0.1755 0.0702 2.50 0.012455 2186








































The LIPG gene associated with depressive symptoms  |  103
3
Name BETA SE t-value p-value N
Phosphatidylcholine diacyl (34:3) 0.0700 0.0281 2.49 0.01276 2259
Phosphatidylcholine diacyl C42:4 0.0265 0.0108 2.45 0.014385 794
Phosphatidylethanolamine 38:5 0.4631 0.1887 2.45 0.014397 647
glutamine -991.2650 409.1073 -2.42 0.015481 2015
Ornithine -178.3774 73.9146 -2.41 0.015898 2006
L-VLDL-cholesterol 0.1080 0.0449 2.40 0.016391 2178
Lysophosphatidylcholine(22:6) -0.0120 0.0050 -2.40 0.016637 2255
XL-HDL-cholesterol 0.1235 0.0516 2.39 0.016766 2173
Phosphatidylethanolamine 38:2 0.0397 0.0167 2.39 0.017297 647
Lysophosphatidylcholine(18:1) -0.1436 0.0609 -2.36 0.018419 2256
Lysine -177.0992 75.8465 -2.33 0.019643 2014
Phosphatidylcholine diacyl (34:2) 0.8670 0.3737 2.32 0.020426 2261
Phosphatidylethanolamine 36:4 0.2993 0.1336 2.24 0.02542 648
Phosphatidylethanolamine 34:2 0.2988 0.1355 2.21 0.02779 647
Phosphatidylcholine diacyl C 38:1 3.0173 1.3726 2.20 0.028281 651
M-VLDL-Free cholesterol 0.2980 0.1361 2.19 0.02863 2182
Phosphatidylcholine alkyl-acyl C42:5 0.3665 0.1674 2.19 0.028907 648
Hexadecenoylcarnitine 0.0050 0.0023 2.19 0.029 794
Phosphatidylcholine diacyl C34:3 2.3860 1.0976 2.17 0.030018 794
S-LDL-Free cholesterol -0.3569 0.1645 -2.17 0.030139 2185
M-LDL-Free cholesterol -0.5330 0.2460 -2.17 0.030399 2187
plasma-Free cholesterol 2.4840 1.1572 2.15 0.031931 2188
Phosphatidylcholine diacyl (34:4) 0.0055 0.0026 2.14 0.03224 2251
Phosphatidylcholine diacyl (36:3) 0.4598 0.2146 2.14 0.032254 2263
Phosphatidylethanolamine 38:6 0.3097 0.1444 2.14 0.032328 648
Phosphatidylcholine diacyl C40:5 1.5985 0.7519 2.13 0.033813 791
Lysophosphatidylcholine(O-16:1) -0.0037 0.0018 -2.12 0.034018 2260
Phosphatidylcholine diacyl (38:4) 0.3551 0.1692 2.10 0.035946 2262
Leucine -4708.2738 2255.4395 -2.09 0.036967 2014
S-LDL-cholesterol -1.6397 0.7943 -2.06 0.039114 2185
Lysophosphatidylcholine(O-18:1) -0.0029 0.0014 -2.05 0.040424 2257
Phosphatidylcholine diacyl C38:5 6.8767 3.3750 2.04 0.041927 792
XS-VLDL-phospholipids 0.0422 0.0208 2.03 0.042923 2186
Phosphatidylcholine diacyl (34:1) 0.6373 0.3152 2.02 0.043282 2260
XXL-LDL-cholesterol 163.1383 80.9920 2.01 0.044106 2182
Phosphatidylcholine diacyl (32:1) 0.1196 0.0596 2.01 0.044668 2249
Lysophosphatidylcholine(18:0) -0.1969 0.0980 -2.01 0.044669 2262
plasma-ApoA2 1.0394 0.5181 2.01 0.04495 2186
XXL-LDL-Free cholesterol 162.9651 81.4730 2.00 0.045598 2185
Phosphatidylcholine diacyl C 34:4 -0.5293 0.2647 -2.00 0.045958 651
Phosphatidylethanolamine 34:1 0.2943 0.1474 2.00 0.046312 648
XXL-LDL-ApoB 151.1427 76.2554 1.98 0.047598 2186
Decadienylcarnitine 0.0057 0.0029 1.98 0.0477 793
Phosphatidylethanolamine(34:2) 0.1340 0.0677 1.98 0.047836 2204
Phosphatidylethanolamine alkyl-acyl 40:3 0.1621 0.0819 1.98 0.048181 648
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Name BETA SE t-value p-value N
Phosphatidylethanolamine 40:5 0.2829 0.1432 1.98 0.048645 648
IDL-ApoB 0.3683 0.1871 1.97 0.049135 2182
M-LDL-cholesterol -1.7971 0.9265 -1.94 0.052548 2187
Phosphatidylcholine alkyl-acyl C40:5 0.5589 0.2880 1.94 0.052754 650
Sphingomyeline C 18:0 3.8163 1.9669 1.94 0.052775 651
L-VLDL-Free cholesterol 0.0783 0.0406 1.93 0.05388 2180
Phosphatidylcholine diacyl (38:2) 0.0119 0.0062 1.93 0.054025 2259
Phosphatidylcholine diacyl C32:2 0.5833 0.3035 1.92 0.05496 794
Hydroxytetradecenoylcarnitine 0.0020 0.0010 1.92 0.055369 792
XXL-LDL-triglycerides 123.5163 64.6331 1.91 0.056131 2180
IDL-Free cholesterol 0.3210 0.1681 1.91 0.056353 2187
Phosphatidylcholine diacyl C 42:5 0.1727 0.0907 1.90 0.05733 650
Phosphatidylethanolamine 36:2 0.2449 0.1288 1.90 0.057706 648
S-LDL-phospholipids -0.8458 0.4468 -1.89 0.058478 2184
Sphingomyeline C 18:2 0.3667 0.1937 1.89 0.05877 650
Sphingomyeline C 24:1 9.8264 5.2068 1.89 0.059578 649
Phosphatidylcholine diacyl C40:6 4.0630 2.1548 1.89 0.059717 792
plasma-cholesterol 8.8493 4.7207 1.87 0.060986 2188
M-VLDL-phospholipids 0.5778 0.3095 1.87 0.062069 2183
Ceramide C23:0 0.1458 0.0783 1.86 0.063143 648
Phosphatidylcholine alkyl-acyl C42:6 0.2532 0.1368 1.85 0.064659 651
Phosphatidylcholine diacyl C36:5 0.1639 0.0890 1.84 0.065981 790
XL-HDL-triglycerides 0.1156 0.0629 1.84 0.066065 2170
XXL-LDL-phospholipids 146.5294 79.9350 1.83 0.066923 2180
Phosphatidylethanolamine 42:7 0.2279 0.1247 1.83 0.068173 645
Phosphatidylcholine diacyl C 40:1 0.2408 0.1321 1.82 0.068711 651
Phosphatidylethanolamine 36:3 0.2568 0.1410 1.82 0.068956 650
Phosphatidylethanolamine 40:4 0.0392 0.0216 1.82 0.069951 648
Lysophosphatidylcholine C 18:3 -0.1599 0.0883 -1.81 0.070663 650
Phosphatidylcholine diacyl C42:5 0.0496 0.0276 1.80 0.072586 792
Phosphatidylcholine diacyl C40:4 0.4455 0.2481 1.80 0.072998 792
Phosphatidylethanolamine 38:1 0.0364 0.0204 1.79 0.073877 649
Phosphatidylcholine diacyl (38:5) 0.1528 0.0858 1.78 0.0753 2257
Phosphatidylcholine diacyl C 34:2 66.9234 37.6360 1.78 0.075844 648
M-HDL-triglycerides 0.0839 0.0472 1.78 0.07592 2182
Pimelylcarnitine 0.0058 0.0033 1.76 0.078856 794
Hydroxysphingomyeline C22:2 -0.9502 0.5416 -1.75 0.079769 794
Phosphatidylcholine diacyl C 40:3 0.2123 0.1223 1.74 0.083094 650
L-HDL-triglycerides 0.0753 0.0435 1.73 0.083145 2175
Phosphatidylcholine diacyl C 36:4 28.5307 16.5341 1.73 0.0849 650
Lysophosphatidylcholine 16:1 -0.4205 0.2441 -1.72 0.085425 648
S-LDL-ApoB -0.6864 0.3994 -1.72 0.085814 2186
Hydroxybutyrate_2 141.3856 82.4395 1.72 0.086496 2005
IDL-phospholipids 0.6283 0.3705 1.70 0.090089 2187
Methylglutarylcarnitine 0.0028 0.0017 1.70 0.090163 783
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Name BETA SE t-value p-value N
XL-HDL-ApoA1 0.2082 0.1251 1.66 0.096193 2175
S-VLDL-Free cholesterol 0.0473 0.0285 1.66 0.09699 2187
IDL-cholesterol 1.3646 0.8228 1.66 0.097369 2183
Phosphatidylcholine diacyl (32:2) 0.0133 0.0080 1.66 0.0979 2257
Methionine -3860.7325 2344.4098 -1.65 0.099759 2014
Lysophosphatidylcholine(20:3) -0.0109 0.0067 -1.62 0.104468 2256
Phosphatidylcholine diacyl C42:6 0.0573 0.0356 1.61 0.107882 790
Decenoylcarnitine 0.0259 0.0161 1.61 0.107923 791
Phosphatidylethanolamine 36:1 0.2314 0.1442 1.61 0.108925 649
Phosphatidylcholine alkyl-acyl C34:0 0.3015 0.1899 1.59 0.112722 650
M-LDL-phospholipids -0.8264 0.5275 -1.57 0.117373 2187
Creatinine 3421.9775 2224.6016 1.54 0.124147 2005
Lysophosphatidylcholine C 20:3 -0.4603 0.3033 -1.52 0.129503 647
Phosphatidylcholine alkyl-acyl C36:2 1.7172 1.1367 1.51 0.131344 648
Sphingomyeline C 16:1 2.2652 1.5040 1.51 0.132524 648
S-VLDL-triglycerides 0.0863 0.0574 1.50 0.132933 2186
lysoPhosphatidylcholine acyl C18:2 -3.3201 2.2083 -1.50 0.13312 792
Hydroxytetradecadienylcarnitine 0.0010 0.0007 1.50 0.134354 794
Alpha-ketoglutarate 140.5460 93.9052 1.50 0.134634 2007
Phosphatidylcholine diacyl C 34:3 -2.9436 1.9661 -1.50 0.134845 649
Phosphatidylethanolamine 34:3 0.2035 0.1374 1.48 0.13897 646
Phosphatidylcholine diacyl C32:0 0.8981 0.6076 1.48 0.139798 793
Phosphatidylcholine diacyl C36:6 0.1238 0.0849 1.46 0.145278 791
L-VLDL-phospholipids 0.0728 0.0501 1.45 0.146333 2182
Phosphatidylethanolamine 42:5 0.0084 0.0058 1.45 0.146905 648
Phosphatidylcholine acyl-alkyl C42:0 0.0355 0.0246 1.44 0.149189 793
Glutaconylcarnitine 0.0018 0.0012 1.44 0.150427 793
Phosphatidylethanolamine 38:3 0.1137 0.0797 1.43 0.154356 645
lysoPhosphatidylcholine acyl C18:1 -1.7766 1.2508 -1.42 0.15589 793
Creatine -107.2443 75.7401 -1.42 0.156945 2014
Phosphatidylcholine alkyl-acyl C38:4 1.1903 0.8465 1.41 0.160173 648
Lysophosphatidylcholine C15:0 -0.1681 0.1196 -1.41 0.160322 650
Phosphatidylcholine diacyl C34:4 0.2012 0.1446 1.39 0.164438 794
Triglycerides(54:1) -0.0162 0.0117 -1.38 0.167058 2237
lysoPhosphatidylcholine acyl C17:0 -0.1123 0.0812 -1.38 0.167282 794
PE-plasmologen 18:0/18:2 0.5911 0.4284 1.38 0.16814 650
XL-LDL-phospholipids 0.8290 0.6038 1.37 0.169927 2187
Sphingomyeline C 24:2 3.6515 2.6928 1.36 0.175559 650
Phosphatidylcholine diacyl C38:3 4.1113 3.0512 1.35 0.17823 794
Phosphatidylcholine diacyl (36:5) 0.0810 0.0604 1.34 0.179706 2242
Phosphatidylcholine diacyl C 34:1 29.0610 21.7588 1.34 0.182149 647
Phosphatidylcholine alkyl-acyl C38:5 1.4855 1.1193 1.33 0.184943 647
Sphingomyeline C 23:0 1.8779 1.4273 1.32 0.188718 651
Phosphatidylcholine diacyl C24:0 -0.0702 0.0533 -1.32 0.188782 732
Methanol -0.0700 0.0534 -1.31 0.19043 2011
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Name BETA SE t-value p-value N
Phosphatidylcholine alkyl-acyl C38:3 0.5011 0.3857 1.30 0.194315 650
PE-plasmologen 16:0/18:2 0.3073 0.2406 1.28 0.201867 648
Sphingomyeline C 14:0 1.4318 1.1269 1.27 0.204338 650
Phosphatidylcholine diacyl C34:1 12.5520 9.9108 1.27 0.205706 793
Carnitine -98.4857 77.9250 -1.26 0.206429 2011
lysoPhosphatidylcholine acyl C24:0 -0.0208 0.0166 -1.25 0.210078 794
Phosphatidylcholine alkyl-acyl C34:3 1.0013 0.7990 1.25 0.210552 650
Alanine 28500.7753 22802.4272 -1.25 0.211481 2014
M-VLDL-triglycerides 0.5922 0.4742 1.25 0.21185 2182
Phosphatidylcholine diacyl C30:0 0.3928 0.3157 1.24 0.213793 793
Phosphatidylcholine alkyl-acyl C36:4 1.6566 1.3316 1.24 0.213923 648
Phosphatidylcholine diacyl C 40:2 0.1421 0.1143 1.24 0.213948 647
Ceramide C24:0 0.2999 0.2417 1.24 0.215263 648
Hexadecadienylcarnitine 0.0009 0.0007 1.23 0.21772 793
Serine -5.2465 4.2630 -1.23 0.218797 794
Phosphatidylcholine diacyl C38:6 6.4927 5.2831 1.23 0.219451 793
Phosphatidylethanolamine 36:5 0.1543 0.1258 1.23 0.220495 646
Phosphatidylcholine diacyl C36:1 3.4804 2.8498 1.22 0.222347 792
Sphingomyeline C 23:1 1.5702 1.2873 1.22 0.223007 650
HDL-Triglycerides 0.1254 0.1033 1.21 0.224612 2181
Phosphatidylcholine diacyl C 38:7 0.3707 0.3055 1.21 0.225516 649
Phosphatidylcholine alkyl-acyl C40:6 0.4005 0.3318 1.21 0.227858 650
Phosphatidylcholine diacyl (38:3) 0.0851 0.0708 1.20 0.229341 2261
S-HDL-Free cholesterol 0.1211 0.1015 1.19 0.232627 2183
Sphingomyeline C 22:1 2.9411 2.4818 1.19 0.23643 650
1,5-Anhydrosorbitol -246.0655 209.3522 -1.18 0.239987 2012
Phosphatidylcholine diacyl C 32:2 -0.7894 0.6719 -1.17 0.240492 648
Lysophosphatidylcholine C 20:4 -0.1275 0.1085 -1.17 0.240499 646
Tryptophan -2.9284 2.4992 -1.17 0.241656 794
VLDL-cholesterol 1.6616 1.4209 1.17 0.242357 2178
Lactate -9454.6311 8112.9518 -1.17 0.244006 2008
Phosphatidylcholine alkyl-acyl C36:1 0.8637 0.7434 1.16 0.245757 648
Lysophosphatidylcholine(20:4) -0.0211 0.0184 -1.15 0.250424 2260
Phosphatidylcholine acyl-alkyl C44:6 0.0722 0.0637 1.13 0.257079 793
Phosphatidylcholine diacyl C36:3 7.7691 6.8679 1.13 0.258307 794
Hydroxysphingomyeline C14:1 -0.2966 0.2624 -1.13 0.258645 794
Phosphatidylcholine diacyl C36:4 10.2810 9.1160 1.13 0.259742 794
Lysophosphatidylcholine C 22:5 -0.0729 0.0653 -1.12 0.264636 647
Hydroxybutyrate_2 0.1030 0.0935 1.10 0.270762 1983
Decanoylcarnitine 0.0829 0.0754 1.10 0.272104 789
Lysophosphatidylcholine C 22:4 -0.1038 0.0945 -1.10 0.272391 650
Hydroxyhexadecenoylcarnitine 0.0009 0.0009 1.09 0.27388 782
Phosphatidylcholine acyl-alkyl C38:0 0.1570 0.1435 1.09 0.274208 792
LDL-Triglycerides 0.7844 0.7175 1.09 0.274425 2185
XL-LDL-ApoB 0.3159 0.2902 1.09 0.27651 2188
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Name BETA SE t-value p-value N
Lipids (CH=CH*CH2CH2) -80.2993 74.1875 -1.08 0.279213 2000
Phosphatidylcholine diacyl C38:4 6.2041 5.7969 1.07 0.284834 793
Sphingomyeline C dih 22:0 95.4900 89.4785 1.07 0.286286 649
lysoPhosphatidylcholine acyl C20:3 -0.1631 0.1540 -1.06 0.289769 794
Phosphatidylcholine diacyl C40:3 0.0364 0.0345 1.05 0.291782 791
Betaine 1400.0068 1334.6173 1.05 0.294306 2012
Hydroxyhexadecanoylcarnitine 0.0006 0.0006 1.05 0.294761 792
Glutamine -20.3888 19.4510 -1.05 0.29486 794
TMAO_Betaine 78.7771 76.2238 1.03 0.301495 2007
Sphingomyeline C dih 23:0 81.9513 79.3116 1.03 0.301855 651
Phosphatidylcholine diacyl C 30:0 -0.6958 0.6735 -1.03 0.301949 650
Hexenoylcarnitine 0.0010 0.0010 1.03 0.303113 794
PE-plasmologen 18:1/18:1 0.0744 0.0725 1.03 0.305148 651
S-HDL-ApoA2 -0.3972 0.3873 -1.03 0.305208 2184
Octenoylcarnitine 0.0131 0.0128 1.02 0.308574 785
Phosphatidylcholine diacyl C 36:3 11.6641 11.4826 1.02 0.3101 649
Phosphatidylcholine diacyl C40:1 0.0187 0.0184 1.02 0.310131 793
Phosphatidylcholine diacyl C 36:2 22.3630 22.0639 1.01 0.311173 648
Phosphatidylcholine diacyl C42:0 0.0319 0.0315 1.01 0.311565 794
Ceramide Glu C16:0 0.0330 0.0332 0.99 0.320287 648
PE-plasmologen 18:0/18:1 0.0984 0.0989 0.99 0.320344 651
Hydroxybutyrylcarnitine 0.0034 0.0034 0.99 0.320506 775
Phosphatidylcholine diacyl C32:1 0.0990 0.1002 0.99 0.323103 788
Formate -0.0367 0.0372 -0.99 0.323332 2006
Phosphatidylcholine acyl-alkyl(O-34:3) 0.0116 0.0118 0.98 0.325258 2259
Phosphatidylcholine diacyl C 32:0 1.2006 1.2219 0.98 0.326184 649
Phosphatidylcholine alkyl-acyl C32:1 -0.2789 0.2847 -0.98 0.327617 650
Phosphatidylethanolamine(38:2) 0.1365 0.1399 0.98 0.32941 2258
Phosphatidylcholine diacyl C 38:4 9.4543 9.7055 0.97 0.330362 649
Threonine -4.9665 5.1092 -0.97 0.331314 794
Hydroxysphingomyeline C16:1 -0.1327 0.1368 -0.97 0.332164 794
Tyrosine -3.0380 3.1432 -0.97 0.334073 794
S-HDL-phospholipids 0.4825 0.5000 0.96 0.334696 2185
Phosphatidylcholine diacyl C34:2 11.3734 11.8155 0.96 0.336049 794
S-LDL-triglycerides -0.0468 0.0487 -0.96 0.336649 2183
Phosphatidylcholine diacyl C 38:6 6.8689 7.2302 0.95 0.34245 650
VLDL-ApoB 0.2725 0.2876 0.95 0.343335 2181
Lysophosphatidylcholine(16:0) -0.2401 0.2538 -0.95 0.344153 2262
Phosphatidylcholine diacyl C38:1 0.1023 0.1083 0.94 0.344977 794
Ceramide C16:0 0.0748 0.0792 0.94 0.34533 650
Sphingomyeline C 18:1 1.1630 1.2321 0.94 0.345566 651
Phosphatidylethanolamine 32:2 0.1064 0.1128 0.94 0.345996 650
Hydroxysphingomyeline C24:1 -0.0697 0.0745 -0.94 0.349675 794
Triglycerides(54:2) -0.0510 0.0548 -0.93 0.352231 2245
Phosphatidylcholine alkyl-acyl C36:3 0.5918 0.6371 0.93 0.353257 648
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Tyrosine -1013.0963 1095.8059 -0.92 0.355326 2014
L-VLDL-triglycerides 0.0727 0.0790 0.92 0.357169 2181
Phosphatidylethanolamine(36:3) 0.0013 0.0014 0.92 0.358499 2254
Acetylcarnitine 0.4078 0.4482 0.91 0.363168 794
lysoPhosphatidylcholine acyl C28:1 -0.0203 0.0224 -0.91 0.365177 792
Sphingomyeline C 15:0 0.5819 0.6483 0.90 0.369739 650
XL-LDL-Free cholesterol 0.2323 0.2589 0.90 0.369799 2188
XL-VLDL-cholesterol 0.2079 0.2319 0.90 0.370136 2184
Lysophosphatidylcholine C 22:6 -0.0627 0.0707 -0.89 0.376067 646
Phosphatidylcholine alkyl-acyl C34:1 0.7240 0.8297 0.87 0.383226 649
Triglycerides(56:2) -0.0041 0.0047 -0.86 0.388454 2236
Phosphatidylcholine acyl-alkyl(O-44:5) 0.0020 0.0024 0.86 0.392304 2259
Glycine -14.1780 16.6154 -0.85 0.393748 787
Phosphatidylcholine diacyl C 32:1 -0.1200 0.1415 -0.85 0.396773 648
Phosphatidylcholine acyl-alkyl C32:1 0.0983 0.1161 0.85 0.397347 794
Phosphatidylcholine acyl-alkyl(O-38:7) -0.0019 0.0023 -0.84 0.398223 2256
Lysophosphatidylcholine C 18:2 -3.0736 3.6445 -0.84 0.399337 650
Spingomyeline C24:0 1.0422 1.2376 0.84 0.399976 793
plasma-Triglycerides 0.0368 0.0439 0.84 0.402157 2177
Phosphatidylcholine diacyl C 40:7 0.5245 0.6292 0.83 0.40477 650
XL-LDL-cholesterol 0.7663 0.9225 0.83 0.406276 2188
Phosphatidylcholine diacyl C 38:5 4.3620 5.2496 0.83 0.406325 649
Phosphatidylethanolamine 32:0 0.0145 0.0175 0.83 0.406514 647
Phosphatidylcholine acyl-alkyl C42:2 0.0261 0.0316 0.83 0.40845 794
Sphingomyeline C 20:0 1.9004 2.2998 0.83 0.408903 650
Phosphatidylcholine acyl-alkyl(O-36:6) -0.0411 0.0499 -0.83 0.409286 2244
lysoPhosphatidylcholine acyl C20:4 -0.3328 0.4112 -0.81 0.418531 793
Hydroxyoctadecenoylcarnitine 0.0006 0.0007 0.81 0.418969 794
Phosphatidylcholine diacyl C 30:1 0.1613 0.1994 0.81 0.419051 648
XL-VLDL-Free cholesterol 0.0324 0.0402 0.81 0.419238 2183
Lysophosphatidylethanolamine(18:0) -0.0077 0.0095 -0.81 0.42 2252
Phosphatidylcholine diacyl (40:6) -0.0437 0.0543 -0.80 0.421561 2251
Sphingomyeline C 22:0 2.6844 3.3666 0.80 0.425526 649
Phosphatidylcholine acyl-alkyl(O-36:5) 0.0162 0.0204 0.80 0.425807 2260
Lysophosphatidylcholine(16:1) -0.0064 0.0081 -0.79 0.429678 2248
Ceramide(d18:1/24:0) 0.0059 0.0075 0.79 0.431545 2261
Octadecadienylcarnitine 0.0034 0.0043 0.79 0.432248 794
Phosphatidylcholine diacyl C 42:4 0.0771 0.0991 0.78 0.436625 650
Spingomyeline C20:2 -0.0332 0.0428 -0.78 0.438471 794
Ceramide C18:0 0.0141 0.0183 0.77 0.44146 649
Ceramide Glu C24:1 0.0331 0.0438 0.75 0.450606 649
Lysophosphatidylcholine(14:0) -0.0041 0.0055 -0.75 0.451357 2261
Triglycerides(51:4) 0.0043 0.0057 0.75 0.453446 2248
PE-plasmologen 18:1/20:4 -0.3952 0.5304 -0.75 0.456418 650
Phosphatidylcholine diacyl C40:2 0.0155 0.0209 0.74 0.456985 791
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PE-plasmologen 18:1/18:2 0.1514 0.2040 0.74 0.458306 650
Acetate -0.0420 0.0568 -0.74 0.459246 1977
Phosphatidylcholine acyl-alkyl C34:1 0.3079 0.4166 0.74 0.460141 793
Phosphatidylcholine diacyl C 40:4 0.3484 0.4720 0.74 0.460747 649
Phosphatidylcholine acyl-alkyl C42:4 0.0322 0.0438 0.74 0.461432 794
Phosphatidylcholine diacyl C36:2 7.7112 10.4923 0.73 0.462594 794
Triglycerides(54:7) 0.0101 0.0137 0.73 0.463333 2246
Lipids (CH2) -55.1358 75.4446 -0.73 0.46498 2001
Methionine -1.1058 1.5218 -0.73 0.467651 794
Sphingomyeline(d18:1/20:1) -0.0038 0.0052 -0.73 0.468248 2263
Myoinositol -56.8363 78.7998 -0.72 0.470824 2009
Phosphatidylcholine diacyl C42:1 0.0103 0.0143 0.72 0.471821 794
XS-VLDL-cholesterol 0.0078 0.0109 0.72 0.472844 2187
Spingomyeline C18:1 -0.4150 0.5809 -0.71 0.475098 794
Hydroxysphingomyeline C22:1 -0.4984 0.7032 -0.71 0.478706 794
Proline 7.4088 10.5659 0.70 0.483387 789
Triglycerides(56:7) 0.0435 0.0626 0.69 0.487798 2246
Phosphatidylcholine diacyl C 38:2 0.6817 0.9963 0.68 0.494078 651
Sphingomyeline(d18:1/18:2) 0.0011 0.0016 0.68 0.49474 2260
Phosphatidylcholine acyl-alkyl C34:0 0.0471 0.0692 0.68 0.496504 794
Tetradecadienylcarnitine 0.0022 0.0032 0.68 0.49868 789
Ceramide C22:0 0.0630 0.0936 0.67 0.501078 649
Phosphatidylcholine diacyl C26:0 0.0167 0.0249 0.67 0.501168 731
Triglycerides(46:1) -0.0194 0.0289 -0.67 0.502614 2211
Phosphatidylcholine acyl-alkyl(O-34:1) 0.0039 0.0059 0.67 0.506041 2259
lysoPhosphatidylcholine acyl C14:0 0.0644 0.0970 0.66 0.507031 793
Triglycerides(52:1) -0.0500 0.0761 -0.66 0.510788 2242
Phosphatidylcholine acyl-alkyl C44:4 0.0116 0.0176 0.66 0.512032 794
XS-LDL-ApoB 0.4366 0.6696 0.65 0.514404 2183
Nonaylcarnitine 0.0482 0.0741 0.65 0.515314 791
VLDL-Free cholesterol 0.3656 0.5673 0.64 0.519371 2182
Lysophosphatidylcholine C 18:1 -1.4611 2.2729 -0.64 0.520543 648
Arginine -2.4807 3.8999 -0.64 0.524899 794
Triglycerides(53:1) -0.0023 0.0037 -0.63 0.530546 2207
XXL-VLDL-triglycerides -0.0580 0.0933 -0.62 0.534289 2174
L-LDL-triglycerides -0.0254 0.0414 -0.61 0.539607 2185
Phosphatidylcholine diacyl (38:6) 0.0850 0.1389 0.61 0.540482 2254
Dodecenoylcarnitine 0.0053 0.0086 0.61 0.542218 788
Triglycerides(54:6) 0.0385 0.0635 0.61 0.544317 2246
Phosphatidylcholine diacyl (40:5) 0.0085 0.0141 0.60 0.545483 2256
Proline -509.4497 845.3949 -0.60 0.546831 2010
Phosphatidylcholine diacyl C28:1 -0.0960 0.1596 -0.60 0.547744 794
Triglycerides(50:3) 0.0418 0.0697 0.60 0.548103 2251
Triglycerides(52:4) 0.0358 0.0604 0.59 0.553434 2253
Phosphatidylcholine alkyl-acyl C32:0 0.1918 0.3237 0.59 0.553767 650
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Triglycerides(51:3) 0.0376 0.0644 0.58 0.559294 2239
Sphingomyeline(d18:1/24:0) 0.0128 0.0222 0.58 0.565135 2260
Glutarylcarnitine 
(Hydroxyhexanoylcarnitine)
0.0010 0.0017 0.57 0.565601 788
Lipids_CH2CO -44.0181 76.6504 -0.57 0.565849 2001
Sphingomyeline C 20:1 44.9383 78.4664 0.57 0.567041 650
Phosphatidylethanolamine 32:1 0.0841 0.1480 0.57 0.569939 644
Triglycerides(50:2) 0.0387 0.0683 0.57 0.571087 2256
XL-VLDL-phospholipids 0.0330 0.0583 0.57 0.571338 2182
lysoPhosphatidylcholine acyl C28:0 -0.0281 0.0501 -0.56 0.57447 789
Leucine / Isoleucine -5.6052 10.1280 -0.55 0.580119 793
Phosphatidylcholine diacyl (36:2) 0.1515 0.2756 0.55 0.582477 2262
Dimethylglycine 42.0366 77.2745 0.54 0.586508 2009
S-HDL-ApoA1 -0.5308 0.9847 -0.54 0.589925 2188
VLDL-phospholipids 0.7279 1.3644 0.53 0.593733 2182
Acetone 0.0277 0.0520 0.53 0.594045 2006
Sphingomyeline C 24:3 -0.4168 0.7847 -0.53 0.595494 651
Sphingomyeline(d18:1/23:1) -0.0047 0.0091 -0.52 0.603933 2262
Phosphatidylethanolamine 40:3 0.0043 0.0083 0.52 0.606339 647
Phosphatidylcholine acyl-alkyl C38:5 -0.4371 0.8491 -0.51 0.606833 794
Phenylalanine -0.9544 1.9295 -0.49 0.620986 794
Lipids_CH3 -36.2720 74.0097 -0.49 0.624118 2004
Spingomyeline C16:0 -2.0123 4.1675 -0.48 0.62933 794
Phosphatidylcholine diacyl (36:1) 0.0367 0.0762 0.48 0.63038 2254
Octadecenoylcarnitine 0.0242 0.0502 0.48 0.630581 792
Phosphatidylethanolamine 42:6 -0.0033 0.0068 -0.48 0.630713 650
Ornithine -1.9861 4.1330 -0.48 0.630966 794
Sphingomyeline C dih 18:0 -0.1815 0.3783 -0.48 0.631499 651
Sphingomyeline(d18:1/17:0) -0.0010 0.0022 -0.48 0.632139 2253
Phosphatidylcholine acyl-alkyl C38:2 0.0483 0.1011 0.48 0.633098 794
Hexose -90.3905 190.0176 -0.48 0.634422 792
Dodecanedioylcarnitine 0.0009 0.0018 0.47 0.635353 792
lysoPhosphatidylcholine acyl C26:0 0.0321 0.0678 0.47 0.636075 788
plasma ApoB 0.7405 1.6156 0.46 0.646764 2188
lysoPhosphatidylcholine acyl C18:0 -0.6846 1.4943 -0.46 0.646978 794
Triglycerides(56:5) 0.0227 0.0498 0.46 0.648325 2125
Phosphatidylcholine diacyl C 40:6 1.4246 3.1226 0.46 0.648383 649
Triglycerides(48:2) -0.0453 0.1000 -0.45 0.650715 2244
Sphingomyeline C dih 24:0 -40.0546 88.4365 -0.45 0.650758 649
Phosphatidylcholine acyl-alkyl C40:0 0.1407 0.3151 0.45 0.655347 792
Phosphatidylcholine alkyl-acyl C36:5 0.4329 0.9732 0.44 0.6566 650
Hydroxypropionylcarnitine 8.9460 20.1257 0.44 0.656798 789
Sphingomyeline(d18:1/22:1) -0.0091 0.0206 -0.44 0.657658 2263
Phosphatidylcholine acyl-alkyl C30:0 0.0087 0.0198 0.44 0.659196 794
Phosphatidylcholine alkyl-acyl C34:2 0.4665 1.0574 0.44 0.65923 650
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Phosphatidylcholine diacyl C 40:5 0.5817 1.3474 0.43 0.666077 647
Spingomyeline C24:1 -0.9208 2.1338 -0.43 0.666183 794
XS-VLDL-triglycerides 0.0136 0.0319 0.43 0.670875 2183
Phosphatidylcholine acyl-alkyl(O-36:2) -0.0015 0.0035 -0.42 0.672867 2259
Lysophosphatidylcholine C 22:0 0.0302 0.0729 0.41 0.678915 651
Pyruvate_Oxaloacetate 4071.9179 9939.2325 0.41 0.682083 2010
Phosphatidylethanolamine(O-38:5) -0.0054 0.0131 -0.41 0.6829 2253
XXL-VLDL-phospholipids -0.0266 0.0660 -0.40 0.686687 2177
Triglycerides(54:5) 0.0229 0.0570 0.40 0.688598 2247
Triglycerides(52:3) 0.0181 0.0458 0.39 0.692943 2260
LDL-cholesterol -1.4978 3.8434 -0.39 0.696798 2188
Phosphatidylcholine acyl-alkyl(O-34:2) -0.0051 0.0131 -0.39 0.699704 2255
Ceramide C20:0 0.0054 0.0143 0.38 0.705939 649
Hydroxyhexadecadienylcarnitine -0.0003 0.0007 -0.38 0.706733 794
Triglycerides(56:8) 0.0087 0.0233 0.37 0.709907 2249
Sphingomyeline(d18:1/24:1) -0.0202 0.0544 -0.37 0.710105 2261
lysoPhosphatidylcholine acyl C16:0 -1.4995 4.0408 -0.37 0.710679 794
IDL-Triglycerides 0.0197 0.0532 0.37 0.710729 2178
L-LDL-Free cholesterol 0.0965 0.2650 0.36 0.7158 2188
PE-plasmologen 18:1/22:6 0.0685 0.1883 0.36 0.716139 650
Phosphatidylcholine diacyl C 36:5 1.1213 3.1010 0.36 0.717769 645
Phosphatidylcholine acyl-alkyl C42:1 0.0072 0.0206 0.35 0.724643 794
PE-plasmologen 16:0/20:4 -0.2042 0.5801 -0.35 0.724947 648
Phosphatidylcholine acyl-alkyl C30:1 0.0049 0.0139 0.35 0.726045 791
Triglycerides(46:2) -0.0048 0.0136 -0.35 0.726556 2223
Phosphatidylcholine alkyl-acyl C40:4 0.0731 0.2099 0.35 0.727829 648
Triglycerides(50:4) 0.0250 0.0717 0.35 0.727955 2250
Phosphatidylcholine diacyl (40:7) 0.0026 0.0073 0.35 0.728051 2252
Hydroxyisobutyrate_3 -321.4775 925.3928 -0.35 0.728331 2005
PE-plasmologen 18:0/22:6 0.1055 0.3051 0.35 0.729713 648
Sphingomyeline(d18:1/25:0) 0.0004 0.0012 0.34 0.730474 2258
Sphingomyeline(d18:1/18:1) -0.0030 0.0090 -0.34 0.734911 2259
Phosphatidylcholine acyl-alkyl C36:2 -0.2273 0.6772 -0.34 0.737227 794
PE-plasmologen 18:0/20:4 -0.3108 0.9327 -0.33 0.739019 649
Phosphatidylcholine acyl-alkyl C30:2 -0.0021 0.0064 -0.33 0.740243 794
Spingomyeline C26:1 -0.0090 0.0278 -0.32 0.746477 794
Spingomyeline C18:0 -0.3357 1.0451 -0.32 0.748156 794
Triglycerides(52:5) 0.0210 0.0655 0.32 0.74873 2250
Phosphatidylcholine acyl-alkyl(O-38:6) -0.0027 0.0083 -0.32 0.74907 2260
Dimethylamine -27.6135 86.7613 -0.32 0.750313 2010
Phosphatidylcholine acyl-alkyl C42:5 0.0275 0.0893 0.31 0.758343 794
Phosphatidylethanolamine alkyl-acyl 38:7 -0.0059 0.0193 -0.31 0.759982 647
L-LDL-cholesterol 0.3414 1.1199 0.30 0.76054 2188
XL-VLDL-triglycerides 0.0297 0.0975 0.30 0.760755 2181
Sphingomyeline(d18:1/16:1) -0.0032 0.0109 -0.30 0.765331 2262
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Valine -4.0565 13.7895 -0.29 0.768701 794
Phosphatidylcholine acyl-alkyl C38:3 -0.0559 0.1927 -0.29 0.771753 794
Phosphatidylcholine acyl-alkyl C40:1 0.0214 0.0756 0.28 0.777053 794
XS-LDL-phospholipids -0.1554 0.5548 -0.28 0.779398 2182
XXL-VLDL-cholesterol -0.1516 0.5422 -0.28 0.779781 2176
Hydroxyvalerylcarnitine 
(Methylmalonylcarnitine)
-0.0005 0.0017 -0.28 0.780933 791
Triglycerides(46:0) -0.0055 0.0199 -0.28 0.781351 2157
Phosphatidylcholine acyl-alkyl C40:4 0.0293 0.1069 0.27 0.783972 794
Phosphatidylcholine acyl-alkyl C40:2 -0.0240 0.0882 -0.27 0.785219 794
Carnitine -0.4899 1.8088 -0.27 0.786592 794
VLDL-Triglycerides -1.3683 5.1113 -0.27 0.788947 2176
Tetradecenoylcarnitine 0.0018 0.0069 0.27 0.789881 790
Phosphatidylcholine diacyl C 38:3 1.2547 4.7558 0.26 0.791992 647
Phosphatidylcholine acyl-alkyl C38:4 -0.1667 0.6320 -0.26 0.792033 794
Phosphatidylcholine diacyl C 36:1 1.0831 4.1101 0.26 0.792239 647
Succinate -21.7916 83.8768 -0.26 0.795041 2006
LDL-phospholipids 0.5059 1.9634 0.26 0.79669 2188
Phosphatidylcholine acyl-alkyl C36:3 -0.1038 0.4031 -0.26 0.796911 794
Phosphatidylcholine diacyl C42:2 -0.0035 0.0138 -0.26 0.796979 787
Triglycerides(58:8) 0.0026 0.0101 0.25 0.799365 2235
Phosphatidylcholine alkyl-acyl C38:2 -0.0928 0.3688 -0.25 0.80141 651
Phosphatidylcholine acyl-alkyl C42:3 0.0091 0.0378 0.24 0.809781 794
LDL-Free cholesterol 0.2666 1.1139 0.24 0.810893 2188
PE-plasmologen 18:1/20:5 -0.0353 0.1511 -0.23 0.815332 650
Citrate -16.3810 70.3089 -0.23 0.815796 2014
Phosphatidylcholine diacyl C 36:0 0.1048 0.4568 0.23 0.818696 650
Triglycerides(50:0) -0.0213 0.0935 -0.23 0.819562 2232
Phosphatidylcholine acyl-alkyl C32:2 -0.0077 0.0338 -0.23 0.820224 794
lysoPhosphatidylcholine acyl C26:1 -0.0081 0.0359 -0.22 0.822359 794
Phosphatidylcholine diacyl C36:0 0.0335 0.1492 0.22 0.822634 794
L-LDL-ApoB -0.0767 0.3432 -0.22 0.823214 2187
Triglycerides(50:5) -0.0013 0.0058 -0.22 0.828031 2242
Sphingomyeline(d18:1/24:2) -0.0053 0.0245 -0.22 0.828094 2262
Phosphatidylcholine diacyl C 40:0 -0.0453 0.2089 -0.22 0.828306 647
Triglycerides(50:1) -0.0158 0.0748 -0.21 0.83305 2253
lysoPhosphatidylcholine acyl C16:1 0.0428 0.2042 0.21 0.833967 790
Phosphatidylcholine acyl-alkyl(O-36:3) 0.0007 0.0032 0.21 0.835596 2257
Sphingomyeline C 24:0 0.4460 2.1962 0.20 0.839133 649
Phosphatidylcholine alkyl-acyl C36:0 0.0325 0.1606 0.20 0.83947 650
Sphingomyeline(d18:1/22:0) 0.0069 0.0342 0.20 0.839647 2262
Phosphatidylcholine acyl-alkyl(O-36:4) -0.0040 0.0202 -0.20 0.843835 2255
S-HDL-cholesterol -0.0848 0.4409 -0.19 0.84753 2183
PE-plasmologen 16:0/22:5 -0.0273 0.1430 -0.19 0.848578 650
Octanoylcarnitine 0.0029 0.0151 0.19 0.849731 788
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Sphingomyeline(d18:1/20:0) 0.0028 0.0152 0.19 0.8514 2263
PE-plasmologen 16:0/20:5 0.0284 0.1532 0.19 0.85289 643
Triglycerides(51:2) -0.0127 0.0688 -0.19 0.853036 2247
Phosphatidylcholine diacyl C38:0 0.0349 0.1900 0.18 0.85408 794
Phenylalanine -45.4450 249.6529 -0.18 0.855575 2015
Phosphatidylcholine acyl-alkyl(O-38:5) -0.0027 0.0152 -0.18 0.860024 2260
Phosphatidylethanolamine(O-38:7) -0.0024 0.0136 -0.18 0.860276 2241
Triglycerides(56:3) -0.0093 0.0534 -0.17 0.861199 2238
Phosphatidylethanolamine 34:0 0.0042 0.0263 0.16 0.873179 649
Phosphatidylcholine acyl-alkyl C36:0 -0.0056 0.0375 -0.15 0.881088 792
Triglycerides(48:3) -0.0139 0.0939 -0.15 0.882245 2241
Phosphatidylcholine acyl-alkyl C36:1 -0.0552 0.3730 -0.15 0.882348 793
Phosphatidylcholine diacyl C 26:0 0.0237 0.1648 0.14 0.885881 648
Triglycerides(51:1) -0.0021 0.0145 -0.14 0.886137 2232
Triglycerides(58:9) -0.0013 0.0093 -0.14 0.887377 2230
PE-plasmologen 16:0/18:1 0.0103 0.0738 0.14 0.888968 650
Sphingomyeline(d18:1/15:0) 0.0006 0.0043 0.14 0.889676 2255
Phosphatidylcholine acyl-alkyl C36:5 0.0826 0.6147 0.13 0.89308 792
L-LDL-phospholipids -0.0737 0.5607 -0.13 0.895395 2187
Phosphatidylcholine diacyl (36:6) 0.0002 0.0015 0.13 0.895829 2239
Butenylcarnitine 0.0001 0.0010 0.13 0.899509 794
Glycerol -10.2162 81.2641 -0.13 0.899969 2007
LDL-ApoB -0.1633 1.3267 -0.12 0.902052 2188
Phosphatidylcholine acyl-alkyl C44:3 -0.0009 0.0071 -0.12 0.902938 794
Tiglylcarnitine -0.0002 0.0014 -0.12 0.906041 794
Phosphatidylcholine acyl-alkyl C34:2 -0.0711 0.6043 -0.12 0.906316 794
Lysophosphatidylcholine C 20:0 8.8906 78.3525 0.11 0.909694 649
Phosphatidylcholine acyl-alkyl C34:3 -0.0429 0.4192 -0.10 0.918444 794
Phosphatidylcholine acyl-alkyl C44:5 0.0081 0.0792 0.10 0.918814 794
Phosphatidylcholine acyl-alkyl(O-38:4) 0.0007 0.0073 0.10 0.922692 2260
Triglycerides(56:6) 0.0054 0.0578 0.09 0.92536 2233
XS-LDL-Free cholesterol 0.0231 0.2501 0.09 0.92629 2184
XS-LDL-cholesterol 0.1048 1.1674 0.09 0.92846 2186
Glutamate -6.5508 75.4108 -0.09 0.930785 2008
XXL-VLDL-Free cholesterol 0.0052 0.0600 0.09 0.930978 2178
Phosphatidylcholine diacyl C32:3 -0.0025 0.0311 -0.08 0.935986 794
Sphingomyeline(d18:1/14:0) 0.0006 0.0081 0.08 0.937455 2259
Phosphatidylcholine acyl-alkyl C38:6 0.0365 0.4652 0.08 0.937534 793
Sphingomyeline(d18:1/18:0) 0.0015 0.0191 0.08 0.938558 2260
Histidine 0.2177 2.8664 0.08 0.939469 793
PE-plasmologen 16:0/22:6 0.0204 0.3044 0.07 0.9467 646
Phosphatidylethanolamine(O-36:5) 0.0006 0.0096 0.06 0.952598 2253
S-HDL-triglycerides 0.0089 0.1514 0.06 0.953293 2187
Glucose -0.0010 0.0178 -0.06 0.953938 2004
Triglycerides(48:0) 0.0022 0.0408 0.05 0.956873 2154
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Name BETA SE t-value p-value N
Phosphatidylcholine diacyl C 34:0 -0.0317 0.6225 -0.05 0.959342 651
Phosphatidylcholine acyl-alkyl C38:1 -0.0024 0.0486 -0.05 0.960266 794
Triglycerides(54:4) 0.0028 0.0580 0.05 0.960843 2251
Sphingomyeline C 22:2 4.3857 89.2959 0.05 0.960843 649
XS-LDL-triglycerides -0.0085 0.1740 -0.05 0.961046 2182
Alpha-ketoisovalerate 18.3234 397.6434 0.05 0.963251 2014
Sphingomyeline C dih 16:0 0.0304 0.6692 0.05 0.963774 649
PE-plasmologen 18:0/20:5 -0.0073 0.1706 -0.04 0.965662 648
Triglycerides(58:10) 0.0002 0.0040 0.04 0.968962 2200
Lysophosphatidylcholine C 16:0 -0.3769 10.0728 -0.04 0.970164 650
Phosphatidylcholine acyl-alkyl C40:3 -0.0017 0.0500 -0.03 0.973658 794
Sphingomyeline(d18:1/23:0) -0.0004 0.0131 -0.03 0.973792 2262
Sphingomyeline(d18:1/21:0) 0.0002 0.0054 0.03 0.977014 2259
lysoPhosphatidylcholine acyl C6:0 0.0001 0.0018 0.03 0.977302 792
Triglycerides(52:2) -0.0013 0.0473 -0.03 0.977692 2262
Sphingomyeline(d18:1/25:1) -0.0001 0.0025 -0.03 0.978594 2256
Phosphatidylcholine acyl-alkyl C40:6 0.0063 0.2606 0.02 0.980731 794
Phosphatidylcholine acyl-alkyl C40:5 0.0042 0.1736 0.02 0.980733 794
Triglycerides(52:6) 0.0008 0.0616 0.01 0.990163 2248
Lysophosphatidylcholine C 18:0 -0.0364 3.9873 -0.01 0.992723 649
Sphingomyeline(d18:1/16:0) -0.0007 0.0831 -0.01 0.99333 2261
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APPENDIX of CHAPTER 3.2
Non-synonymous Variation in NKPD1 Increases Depressive Symptoms in the European Populations
Supplement 1
Table S1. Descriptive data of ERF study (N = 2 353)
Characteristics Median (Range) Mean (SD)
Sex (% women) 56
Age, Years 48.84 (18 – 96) 48.73 (14.96)
CES-D 8.24 (0 – 59) 10.74 (9.65)
Table S2. Association of depressive symptoms (CES-D) with age
Intercept Age
Estimate ± s.e. p value Estimate ± s.e. p value
Males 2.893 ± 0.928 0.0019 0.131 ± 0.018 8.40x10-13
Females 4.802 ± 0.916 1.85x10-07 0.145 ± 0.018 1.74x10-15
Table S3. Genome-wide results of gene-based analysis


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Nonsynonymous variation in NKPD1 increases depressive symptoms  |  119
3
Figure S1. 
Ethnicity information provided by the principal components analysis. Black circles represent the samples 
included in this study, red: Caucasian, blue: Chinese, green: African, yellow: Colombian (AMR), cyan: Mexican 
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Figure S2. 
Quantile-quantile (QQ) plots of the single-variant and gene-based association analysis. Observed distribution 
is depicted on the vertical axis and expected distribution is depicted on the horizontal axis.  
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ABSTRACT
Depression is determined by the interplay between environmental and genetic risk. Epigenetic 
mechanisms, like DNA methylation, can mediate the association between depression and it’s 
environmental and genetic risk factors. By performing the largest (N = 11 256) cross-ethnic 
epigenome-wide association study of depressive symptoms, we identified hypermethylation of 
cg04987734 (p value = 1.51 × 10-8, CDC42BPB gene), cg12325605 (p value = 5.24 × 10-09, 
ARHGEF3 gene) and cg14023999 (p value = 5.99 × 10-08, intergenic) associated with depressive 
symptoms. These candidate loci for depression are involved in the regulation of serotonin and 
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INTRODUCTION
Depression is one of the most common mental health disorders that results in major disability and 
shorter life-expectancy1,2, and it is projected to play a leading role in disease burden by the year 
2030.3,4 Limited understanding of the molecular mechanisms underlying depression is a major 
bottleneck in the development of innovative treatment, prognostic markers, and prevention 
strategies.
Studying depression is challenging as it is a heterogeneous disorder with a multifactorial etiology, 
including genetic and environmental risk factors.5,6 The contribution of genetics to the risk of 
depression is substantial with heritability estimates of 40 to 50%.7 Genome-wide association 
studies (GWASs) have recently identified numerous rare and common genetic variants associated 
with depression and related traits.8-12 However, genetic sequence variation alone does not 
completely explain an individual’s risk for developing depression. Among environmental factors, 
adverse life-events and stress are major risk factors for depression.13-15 Converging evidence 
from animal and human studies suggest that psychosocial stressors trigger depression onset 
by inducing elevations in pro-inflammatory cytokines.16 These environmental and psychosocial 
stressors are also known to influence epigenetic mechanisms, such as DNA methylation.17 These 
stress-triggered DNA methylation changes can drive sustained changes in gene expression that 
may link stress exposures with mental health outcomes.18,19 Thus, an increasing interest in the role 
of DNA methylation in depression has emerged.20
DNA methylation may be global or tissue-specific.20,21 Tissues likely to be involved in complex 
psychiatric disorders, such as brain, are not directly accessible from living patients. The, use of 
post-mortem brain tissue to study DNA methylation is a possible solution, although obtaining a 
sufficient sample size is challenging.22,23 To study differential DNA methylation associated with 
mental health symptoms on a large scale, peripheral tissues such as blood constitutes a useful 
proxy for detecting trans-tissue changes and the most appropriate tissue for biomarkers.22,24 
Moderate correlation has been demonstrated between blood and brain tissues at non-tissue 
specific regulatory regions across the methylome.25 To date, several studies have assessed the 
correlation between depression and blood DNA methylation.26,27 However, these studies have 
been limited to a small number of DNA methylation sites (CpGs) and/or small samples. For 
instance, the largest published epigenome-wide association study (EWAS) assessed brain DNA 
methylation in 76 cases persons who died during a depressive episode and 45 controls.28
In the current study, we performed an EWAS of depressive symptoms using whole blood samples 
of 7 948 individuals of European ethnicity from the Cohorts for Heart and Aging Research in 
Genomic Epidemiology (CHARGE) consortium. We replicated our findings in 3 308 individuals of 
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a genome-wide gene expression analysis followed by pathway analyses of the differentially 
methylated and expressed genes.
METHODS
Study populations
The study sample for the discovery analysis included a total of 7 948 participants of European 
ancestry from nine population-based cohorts of the CHARGE consortium (Table 1): Cardiovascular 
Health Study (CHS)29, Framingham Heart Study (FHS)30, Helsinki Birth Cohort Study (HBCS)31, 
Cooperative Health Research in the Augsburg Region (KORA) study32, two sub-cohorts from 
Lothian Birth-Cohort born in 1921 (LBC1921)33 and 1936 (LBC1936)34, two sub-cohorts from 
Rotterdam Study (RS-III and RS-BIOS)35 and Generation Scotland: Scottish Family Health Study 
(GS) study.36 These cohorts included community dwelling individuals, who were not selected 
based on disease status. Informed consent was obtained from all participants. The protocol for 
each study was approved by the institutional review board of each institution.















CHS 323 194 (60.1) 75.6 (5.2) 173 (53.6) CES-D (0-30) 19 (5.9)
FHS 2,722 1,508 (53.6) 58.5 (11.6) 948 (34.8) CES-D (0-20) 251 (16.1)
HBCS 122 0 (0) 65.2 (2.7) 24 (19.7) CES-D (0-20) 11 (9.0)
KORA 1,727 882 (51.1) 61.0 (8.9) 250 (14.5) PHQ-9 82 (4.7)
LBC 1921 432 261 (60.4) 79.1 (0.6) 194 (44.9) HADS 15 (3.5)
LBC 1936 916 452 (49.3) 69.6 (0.8) 504 (55) HADS 30 (3.3)
RS III 722 391 (54.2) 59.8 (8.1) 167 (23.1) CES-D (0-20) 38 (5.3) 
RS BIOS 757 319 (42.1) 67.6 (5.9) 78 (10.3) CES-D (0-20) 51 (6.7)
GS 227 151 (64.5) 52.4 (8.1) 46 (19.7) SCID¥ 44 (18.8)
Total 7,948 4,158 (48.4) 65.4 (5.8) 2,384 (30.6) - 541 (8.1)
Replication
ARIC 2,297 1,445 (63) 56.1 (5.7) 584 (25.4) 21-MQ 74 (3.3)
WHI-EMPC 1,011 1,011 (100) 64.6 (7.1) 509 (50.3) CES-D/DIS 61 (6.0)
Total 3,308 2,456 (74.2) 60.3 (6.4) 1,093 (37.9) - 135 (4.7)
Characteristics are depicted as mean (SD), unless otherwise specified.
CHC Cardiovascular health cohort, FHS Framingham Heart Study, HBCS Helsinki Birth Cohort Study, KORA 
Cooperative Health Research in the Augsburg Region, LBC Lothian Birth Cohort, RS Rotterdam Study, GS 
Generation Scotland Study, and ¥CASE-CONTROL STUDY, ARIC Atherosclerosis Risk in Communities Study 
and WHI-EMPC the Women’s Health Initiative - Epigenetic Mechanisms of PM-Mediated Cardiovascular 
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The replication sample included 3 308 participants from the Atherosclerosis Risk in Communities 
Study (ARIC)37 and the Women’s Health Initiative - Epigenetic Mechanisms of PM-Mediated 
Cardiovascular disease (WHI-EMPC).38,39 More detailed information for each cohort can be found 
in the Supplementary Text.
Depressive symptoms assessment
Depressive symptoms were measured using self-reported questionnaires or structured interview 
performed by a trained researcher, psychologist, or psychiatrist at the same time point when blood 
samples were obtained for DNA methylation quantification (Table 1). Four cohorts (FHS, HBCS, 
RS-III, and RS-BIOS) assessed depressive symptoms using the 20-item Centre for Epidemiologic 
Studies Depression (CES-D) scale40, while CHS used the 10-item CES-D scale. Participants could 
score from zero to 60 (or 30 for CHS) points, where higher scores indicate more depressive 
symptoms. WHI-EMPC used a cohort specific CES-D/DIS screening instrument, which is described 
in detail in the Supplementary Text. The LBC1921 and LBC1936 assessed self-reported depressive 
symptoms using the Hospital Anxiety and Depression Scale-depression subscale (HADS-D),41 
which consists of seven items. Participants could score from zero to 21. The KORA study used 
the self-administered Patient Health Questionnaire (PHQ-9)42 representing a depression module 
that scores each of the nine Diagnostic and Statistical Manual of Mental Disorders, 4th Edition 
(DSM-IV) criteria for depression from zero to three. The GS study assessed life-time history 
of depression using the Structured Clinical Interview for DSM-IV Disorders (SCID).43 The ARIC 
study assessed depressive symptoms using the 21-item Maastricht Questionnaire (21-MQ). In all 
cohorts depressive symptoms were analyzed as continuous variable except for GS, which studied 
depression status as binary trait.
DNA methylation sample and measurement
In all cohorts, DNA was extracted from whole blood and methylation levels were assessed using 
the Illumina-Infinium Human Methylation 450K BeadChip (Illumina Inc, San Diego, CA, USA) 
using standard manufacturer’s protocols. The 450K array includes more than 450,000 CpGs and 
is enriched for genic regions, covering 99% of all genes. DNA methylation data pre-processing, 
including quality control (QC) and normalization, was conducted per cohort using study-specific 
methods. In all cohorts, DNA methylation levels were quantified as β-values, which range from 
zero to one, and indicate the proportion of DNA strands in a sample methylated at a specific CpG. 
Detailed information about cohort specific DNA extraction, bisulfite conversion, DNA methylation 
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Gene expression
For the expression analyses, data from the RS-III cohort was used where whole-blood was 
collected (PAXGene Tubes – Becton Dickinson). All RNA samples with an RNA Quality Score > 7 
were amplified, labelled (Ambion TotalPrep RNA), and hybridized to the Illumina HumanHT12v4 
Expression Beadchips as described by the manufacturer’s protocol. All samples were scanned 
on the Illumina iScan System (combined with an AutoLoader) using Illumina iScan image data 
acquisition software. Illumina GenomeStudio software (version 1.9.0) was used to generate 
output files for statistical analysis using R. In R Probes were quantile normalized to the median 
distribution, log2-transformed, and centered to the mean. Further, a sample Z transformation 
(mean = 0, standard deviation = 1) was applied. 44 877 probes measured over the whole 
genome. All probes that showed a detection p value < 0.05 in > 10% of samples were retained 
for the analysis (N = 21 238).44
DATA ANALYSIS
Epigenome-wide association analysis
In all cohorts, the association between depressive symptoms and CpG sites was assessed using 
linear regression analysis in the R software. In the regression analyses, DNA methylation β values at 
each CpG site was specified as the dependent variable and the depressive symptoms/depression 
as the predictor of interest. Further, as DNA methylation patterns significantly associate with 
age45, sex46 and smoking47, the regression analysis included these as covariates in addition to 
methylation batch effects and white blood cell composition (imputed or directly measured, 
depending on availability within each cohort). All cohorts used principal components estimated 
using genome-wide genotype data to control for population stratification. Familial relationships 
were also accounted for in the model when applicable (FHS). Cohort specific details of these 
analyses are provided in the Supplementary Text.
It is unclear whether antidepressant medication use confounds the association between depressive 
symptoms and DNA methylation.48,49 Therefore, we performed sensitivity analyses by adjusting 
the initial model additionally for antidepressant medication use at the time of sample collection.
Finally, we performed sample-size weighted meta-analysis of the cohort-specific results using 
METAL.50 Due to the variability of available CpG sites after quality control steps, we excluded 
CpG sites missing in more than three of the participating cohorts. In total, 484 516 probes were 








































130  |  Chapter 4.1
RefSeq database for the intergenic sites, the UCSC database (GRCh37/hg19) was explored to 
further annotate the CpGs. Bonferroni correction was applied to adjust for multiple testing giving 
a genome-wide significance threshold of 0.05/484 516 methylation sites = 1.03 × 10-7. All CpG 
sites suggestive of association (p value ≤ 10-5) were tested for association in the independent 
replication cohort using the same model as used in the discovery EWAS. Finally, a sample size 
weighted meta-analysis was performed for all cohorts included in the discovery and replication 
phases in METAL.
Gene pathway analysis
Pathway analysis was performed for genes containing one or more nominally significant CpG 
sites from the meta-analysis of discovery and replication cohorts with PANTHER (see URLs). 
Genes that were included in the pathway analysis are provided in the Supplementary Table 1. 
Pathway analysis was performed using PANTHER51 over-representation test using annotations 
from Reactome version 58 release 2016-12-07. In total 1 775 pathways were tested for over 
representation resulting in a Bonferroni corrected significance threshold of 0.05/1 775 = 2.82 × 
10-05.
Gene expression analysis
Linear regression analysis was used to associate identified methylation sites with each of the 21 
238 expression probes using probes as dependent, CpG site as the independent variable, and 
age, sex, fasting state, blood cell counts and technical covariates (plate ID and RNA quality score) 
as covariates. Correction for multiple testing was performed using false discovery rate using 
Benjamini-Hochberg method implemented the stats library of R. Finally, pathway analysis of all 
significantly associated genes with CpG sites was performed in PANTHER.51
RESULTS 
The characteristics of each individual cohort included in this meta-analysis are summarized in 
Table 1. The mean age in the discovery cohorts ranged from 52.4 years (SD = 8.1) in GS to 79.1 
years (SD = 0.57) in LBC1921. Forty-eight percent of the total discovery sample were female. 
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Epigenome-wide association analysis
In the meta-analysis of depressive symptoms of European ancestry, we identified one CpG site 
on chromosome 14q32.32 (cg04987734, CDC42BPB, p value = 4.93 × 10-8) that passed the 
Bonferroni threshold for significance (Table 2, Supplementary Figure 1). Suggestive association 
was observed at 19 additional CpG sites (Table 2). Adjusting for anti-depressive medication use 
did not meaningfully change the results (Supplementary Table 2). No inflation in the test statistic 
was observed (λ = 1.03, Supplementary Figure 2). We tested all 20 CpG sites for association 
in the replication sample. The top CpG site from the discovery sample (cg04987734) showed 
nominal association (p value = 0.048) with depressive symptoms in the validation data set (Table 
2). In addition, significant association of a CpG site (cg12325605; p value = 9.17 ×10-05, Table 
2) annotated to the ARHGEF3 gene with depressive symptoms was observed in the replication 
sample.
Meta-analysis of discovery and replication cohorts showed a significant association of both 
cg04987734 (p value = 1.51 × 10-08) and cg12325605 (p value = 5.24 × 10-09) with depressive 
symptoms (Table 2; Figures 1 & 2). Also, an additional intergenic CpG site (cg14023999; p value 
= 5.99 × 10-08) at chromosome 15q26.1 locus showed genome-wide significant association with 
depressive symptoms (Supplementary Table 3). Top results from the meta-analysis of discovery 
and replication cohorts are provided in the Supplementary Table 3. Genome-wide results are 
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Figure 1: Regional association plot for the top CpG site, Genome 19 (cg04987734). 
CDC42BPB
Chromosome 14 p12 p11.2 q11.2 q12 q21.1 q24.3
103397374 bp 103433189 bp































































































































































































































































































































































































































































































































































































Correlation Matrix Map Type: Spearman
Physical Distance: 35.8 kb













The horizontal axis depicts the position in base pair for the entire CDC42BPB gene region. The Vertical axis 
indicates the strength of association in terms of negative logarithm of the association p-value. Each circle 
represents CpG site. Red dashed line indicates the genome-wide significance threshold. Below the horizontal 
axis the figure shows the regulatory information and correlation matrix of other CpG sites in the region with 








































134  |  Chapter 4.1
Figure 2: Regional association plot for the top CpG site, Genome 19 (cg12325605). 
ARHGEF3
Chromosome 3
56762402 bp 57114657 bp






















































































































































































































































































































































































































































































































































































































Correlation Matrix Map Type: Spearman
Physical Distance: 352.3 kb














The horizontal axis depicts the position in base pair for the entire ARHGEF3 gene region. The Vertical axis 
indicates the strength of association in terms of negative logarithm of the association p-value. Each circle 
represents CpG site. Red dashed line indicates the genome-wide significance threshold. Below the horizontal 
axis the figure shows the regulatory information and correlation matrix of other CpG sites in the region with 
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From blood to brain
Since the brain is the most relevant tissue for psychiatric disorders like depression, we checked 
the correlation between methylation in blood and various brain regions at the three identified 
sites using a web-based tool, BECon.25 Methylation at cg04987734 in the CDC42BPB gene was 
highly correlated (r = 0.81) between blood and the Brodmann area 7 that spans the medial 
and lateral walls of the parietal cortex (Supplementary Figure 5). Methylation at the other two 
sites was negatively correlated with methylation in the Brodmann area 10 than spans anterior 
prefrontal cortex (cg12325605, r = -0.39; cg14023999, r = -0.42) suggesting strong but reverse 
methylation patterns in blood and brain (Supplementary Figures 6 & 7).
Gene pathway analysis
Pathway analysis of all genes annotated to at least one nominally significant CpG site (p < 0.05) 
showed significant over-representation of genes involved in axon guidance (1.41 fold increase, 
p value = 5.2 × 10-07), nerve growth factor (NGF) signaling (1.42 fold increase, p value = 1.31 × 
10-05), platelet-derived growth factor (PDGF) signaling (1.47 fold increase, p value = 4.5 × 10-09) 
and developmental biology (1.32 fold increase, p value = 3.95 × 10-06) (Supplementary Table 4).
Gene expression analysis
Methylation at cg04987734 was significantly associated with increased expression of four 
genes (Supplementary Table 5). Methylation at cg12325605 was significantly associated with 
differential expression of 422 genes (Supplementary Table 6) and methylation at cg14023999 
was significantly associated with differential expression of two genes (Supplementary Table 7). 
Pathway analysis of the 422 differentially expressed genes revealed only one significant pathway: 
immune system (fold enrichment = 2.56, p value = 6.93 × 10-10) and more specifically the adaptive 
immune system (fold enrichment = 2.99, p value = 7.37 × 10-07) rather than the innate immune 
system (fold enrichment = 2.53, p value = 1.77 × 10-03) (Supplementary Table 8). Results were 
more significant when we added the other six genes that were differentially associated with 
cg04987734 and cg14023999 (Supplementary Table 9).
DISCUSSION
In this large-scale EWAS of depressive symptoms, we identified hypermethylation of three CpG 
sites (cg04987734, cg12325605 and cg14023999) associated with depressive symptoms. 
Cg04987734 is annotated to the CDC42BPB gene, cg12325605 to the ARHGEF3 gene, and 
cg14023999 lies in an intergenic region on chromosome 15q26.1 locus. Pathway analyses of 
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involved in axon guidance, nerve growth factor (NGF) and platelet-derived growth factor (PDGF) 
signaling. The three CpG sites were significantly associated with the differential expression of 
428 genes. Pathway analysis of the differentially expressed genes show significant enrichment of 
genes involved in regulating the immune system.
CDC42BPB encodes a serine/threonine protein kinase that plays a role in the regulation of 
cytoskeleton reorganization, cell migration and regulation of neurite outgrowth52 and is 
highly expressed in the brain. Further, gene co-expression network suggests that it is involved 
in the synthesis, recycling, salvage and regulation of tetrahydrobiopterin (BH4) and cytotoxic 
T-lymphocyte-associated protein 4 (CTLA4) inhibitory signaling (see URLs). BH4 is an essential 
co-factor for the aromatic-amino-acid-hydroxylases and glyceryl-ether mono-oxygenase and 
regulates nitric-oxide synthase (NOS) activity.53 BH4 deficiency leads to dopamine and serotonin 
deficiency in the brain54, a characteristic pathophysiological hallmark of depression.55 BH4 has also 
been reported as an intrinsic regulator of inflammatory pain sensitivity and chronicity in animal 
studies56 and implicated in immune response.57 Inflammation-induced increases in inducible 
NOS activity can usurp available BH4, resulting in NOS uncoupling and increased oxidative stress 
affecting dopamine synthesis.58 Further, CTLA4 is a member of the immunoglobulin superfamily 
that is expressed by activated T-cells59 and soluble CTLA4 has been suggested as a biomarker 
for inflammation.60 Interestingly, methylation levels at this CpG site (cg04987734) in CDC42BPB 
gene were also previously associated with C-reactive protein (CRP) levels in blood61; a marker for 
inflammation. Hyper-methylation of cg04987734 has been associated with increased expression of 
CDC42BPB in blood (see URLs).62 Consistent with such an involvement in inflammatory processes, 
hyper-methylation of cg04987734 was also identified as an epigenetic marker associated with 
cigarette smoking.47 Life-style factors such as smoking and alcohol consumption reflect additional 
environmental effects that may induce epigenetic changes. In our study, however, we controlled 
for smoking in the regression model; therefore the association between depression and DNA 
methylation of this CpG site may be independent of smoking habits.
ARHGEF3 encodes for Rho Guanine Nucleotide Exchange Factor 3 protein. The gene is highly 
expressed in adrenal glands, brain and uterus (see URLs). Genetic variants in ARHGEF3 have 
been associated with platelet volume (see URLs). Functional analysis of ARHGEF3 (see URLs) 
suggests that this gene is involved in the regulation of innate immune response and sphingolipid 
metabolism. Earlier we identified rare missense variants in a gene NKPD111, a gene also predicted 
to be involved in de novo synthesis of sphingolipids, and plasma sphingolipid levels associated 
with depressive symptomology.63
The third associated CpG site, cg14023999 lies in an intergenic region on chromosome 15q26.1. 
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blood (see URLs). SEMA4B gene encodes for Semaphorin 4B protein. Semaphorins are implicated 
in axon guidance, regulation of cell migration, angiogenesis and immune response.64-68 Sema4B is 
believed to function through a direct interaction with post-synaptic density protein PSD-9569-71 to 
promote synapse maturation.69,72,73 The knock-down of Sema4B causes a decrease in GABAergic 
synapse number72 suggesting a role in the assembly of excitatory and inhibitory postsynaptic 
specializations.73
Interestingly, all the three top hits are connected directly or through regulatory effects to genes 
involved in the immune pathway. Further, the pathway analysis of all the differentially expressed 
genes associated with these three top hits point towards the immune pathway. Together these 
findings are compatible with the hypothesis that environmental stressors may trigger depression 
by inducing elevations in pro-inflammatory cytokines16. Testing this hypothesis, however, 
requires further work, as our cross-sectional design does not allow us to establish the direction 
of association. We can only carefully speculate, whether the epigenetic factors mediate the 
relation between some environmental exposure(s) and depression, whether the epigenetic factors 
mediate the relation between the genome and depression; or whether the epigenetic variants are 
biomarkers of depression but not causally related to the disorder. In contrast to the expression 
data of our top hits, in the formal pathway analysis of the methylation data, we did not observe 
a significant overrepresentation of genes involved in the immune pathway (see Supplementary 
Table 4). Rather, these pathway analysis suggested significant enrichment of genes involved in 
axon-guidance and growth factor signaling.
This is the largest epigenome-wide study of depressive symptoms reported to date. Our major 
strength is the sample size that enabled detection of a replicable epigenome-wide significant 
locus, which suggests that in blood, DNA methylation signatures associated with depression 
may be subtle and will require large samples to be detected. Using peripheral blood tissue 
for DNA methylation profiling is a limitation of this study, as DNA methylation is known to be 
tissue specific.20 While peripheral blood is not considered to be the most relevant tissue for 
the pathophysiology of depression, some sites show correlated methylation profiles between-
tissues.20,21 The three sites identified in our study show moderate to high correlation between 
methylation in blood and various brain regions. Previous studies have also reported epigenetic 
changes with similar effects in both peripheral tissue and brain.48 Secondly, we replicated our 
top hits in the African-American samples. This suggests that depression related differences 
in DNA methylation may be similar across ethnicities.74-76 However, the use of a multi-ethnic 
predominantly African-American replication sample may also have resulted in false negatives due 
to different genetic background. Third, in these analysis we mostly used quantitative measures 
of depressive symptoms. Quantitative endo-phenotypes provide powerful alternatives for several 
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depressive symptoms, for which the severity and duration of illness can be highly heterogeneous.78 
Studies that use depression as an arbitrary selected extreme of the continuum of varying severity, 
are highly susceptible to misclassification, resulting in the loss of the statistical power. Genome-
wide studies of depressive traits, using quantitative endo-phenotypes, have been suggested to 
improve statistical power.78 The majority of the cohorts used the CES-D depression scale to assess 
depressive symptoms in our study. However, the use of different phenotypic measures by different 
samples typically implies some loss of statistical power due to the heterogeneity in the phenotype 
assessment. Finally, although we adjusted for potential confounders, the possibility of residual 
confounding cannot be excluded. Antidepressant medication indicate treated depression but itself 
may result in epigenetic modifications involved in depression pathophysiology.49 Antidepressants 
can thus mediate or confound the relation between DNA methylation and depression. However, 
in sensitivity analysis additionally adjusted for antidepressant medication, our results did not 
change.
To summarize, we report the first EWAS of depressive symptoms. We identified hypermethylation 
of three sites in the genome significantly associated with depressive symptoms. The identified 
loci are implicated in axon guidance, nerve growth factor, regulation of serotonin and dopamine 
levels in the brain, sphingolipid metabolism, synaptic plasticity and inflammation. Our findings 
provide new insights into the molecular mechanisms underlying the complex pathophysiology of 
depression.
URLs. The expression of genes in various brain regions is available through the genome browser: 
http://genenetwork.org/webqtl/main.py. The associations between methylation of cg04987734 
with the expression of the CDC42BPB gene is available at http://genenetwork.nl/biosqtlbrowser/. 
The expression of the ARHGEF3 gene is available at https://www.gtexportal.org/home/gene/
ARHGEF3#geneExpression. The association between gene variants of ARHGEF3 and platelet 
activation is available at https://www.ebi.ac.uk/gwas/search?query=arhgef3. Functional analysis 
of ARHGEF3 are available at http://129.125.135.180:8080/GeneNetwork/?gene=ARHGEF3. 
Association between methylation of cg14023999 with expression of SEMA4B gene in blood is 
available at http://genenetwork.nl/biosqtlbrowser/. Pathway analysis was performed using the 
web based tool PANTHER (www.pantherdb.org). Correlation between methylation in blood and 
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APPENDIX of CHAPTER 4
Supplementary Text
Cardiovascular Health Study Cohort
Description
The Cardiovascular Health Study Cohort (CHS) is a population-based cohort study of risk factors 
for coronary heart disease and stroke in adults ≥ 65 years conducted across four field centers.1 
The original predominantly European ancestry cohort of 5 201 persons was recruited in 1989 - 
1990 from random samples of the Medicare eligibility lists. CHS was approved by institutional 
review committees at each field center and individuals in the present analysis had available DNA 
and gave informed consent including consent to use of genetic information for the study of 
cardiovascular disease.
DNA methylation was measured on a randomly selected subset of 323 European descent 
participants from study year. The samples were randomly selected among participants without 
presence of coronary heart disease, congestive heart failure, peripheral vascular disease, valvular 
heart disease, stroke or transient ischemic attack at study baseline or lack of available DNA at 
study year 5.
Methylation measurements were performed at the Institute for Translational Genomics and 
Population Sciences at the Harbor-UCLA Medical Center Institute for Translational Genomics and 
Population Sciences using the Infinium HumanMethylation450 BeadChip (Illumina Inc, San Diego, 
CA). Quality control was performed in in the minfi R package.2-4 (version 1.12.0, http://www.
bioconductor.org/packages/release/bioc/html/minfi.html). Samples with low median intensities of 
below 10.5 (log2) across the methylated and un-methylated channels, samples with a proportion 
of probes falling detection of greater than 0.5%, samples with QC probes falling greater than 
3 standard deviation from the mean, sex check mismatches, or failed concordance with prior 
genotyping were removed. Methylation values were normalized using the SWAN quantile 
normalization method.3 Since white blood cell proportions were not directly measured in CHS 
they were estimated from the methylation data using the Houseman method.5 All association 
analyses were performed in R using linear mixed models with DNA methylation beta values as 
the outcome. Analyses adjusted for age, gender, current smoking status and antidepressant 
medication. Additionally chip, chip row and column were adjusted for as random effects.
CHS was approved by institutional review committees at each field center and individuals in 
the present analysis had available DNA and gave informed consent including consent to use of 
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Framingham Heart Study
Description
The Framingham Heart Study (FHS) is a population-based, prospective study. In 1948, the 
Original cohort of 5 209 individuals were recruited from Framingham, MA.6 The offspring 
cohort was recruited in 1971, including 5 124 offspring and spouses of offspring of the FHS 
Original cohort.7 Offspring participants underwent examinations every four years (except eight 
years between the first and the second examinations).7 Peripheral whole blood samples were 
collected from these participants at the eighth examination (2005 - 2008). Buffy coat fractions 
were obtained and genomic DNA was extracted using the Gentra Puregene DNA extraction kit 
(Qiagen, Venlo, Netherlands). Bisulfite conversion of genomic DNA was performed with the EZ 
DNA Methylation Kit (Zymo Research, Irvine, CA). DNA methylation was measured by Infinium 
HumanMethylation450 BeadChip (Illumina, CA) in two separate labs. All participants provided 
written consent for genetic study.
QC procedures were performed. Bad samples were excluded if the samples were outliers 
in multidimensional scaling (MDS) analysis, high missing rate (> 1%), poor matching to SNP 
genotype. Low quality probes were excluded if these probes had high missing rate (> 20%), 
were mapped to multiple locations, had SNP (MAF > 5% in EUR 1000G) at CpG site or ≤ 10 
bp of Single Base Extension.8 About 440,000 probes remain in ~2,600 FHS participants. A total 
of 1 680 Offspring participants had both DNA methylation and CES-D phenotype. The sample 
characteristics are displayed in Table 1 in the manuscript.
Analysis
Two models of association were tested. In order to reduce the batch effects, we analyzed the 
DNA methylation in each lab: residuals were obtained by regressing a CpG against the batch 
effects (plate, row and col numbers) and lab-specific principle components that were related 
to the outcome. Residuals from two labs were put together and then regressed against the 
CES-D, adjusting for covariates and family structure. Plate ID and family structures were treated 
as random effects in linear mixed models.
Model 1. Resid (CpG ~ Batch effects + PCs) (lab-specific)
Pooled residuals from two labs ~ CES-D + Gender + Age + smoking + WBC + family structure
Model 2. Resid (CpG ~ Batch effects + PCs) (lab-specific)
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Helsinki Birth Cohort Study (HBCS)
Description
The Helsinki Birth Cohort Study (HBCS) comprises 13 345 individuals (6 370 women and 6 975 
men), born as singletons between 1934 and 1944 in one of the two main maternity hospitals in 
Helsinki and who were living in Finland in 1971 when a unique personal identification number 
was allocated to each member of the Finnish population. The HBCS, which has been described 
in detail elsewhere, has been approved by the Ethics Committee of the National Public Health 
Institute. Register data were linked with permission from the Finnish Ministry of Social Affairs and 
Health and the Finnish National Archives.
In 2001 – 2004 at an average age of 61.5 years (SD = 2.9 and range = 56.7 – 69.8 years), a 
randomly selected subsample of the cohort comprising 2 003 individuals (1 075 women and 928 
men) was invited to a clinical examination including collection of a blood sample for genetic, 
epigenetic and biochemical studies and a psychological survey including a measure of depressive 
symptoms. For 283 participants, extraction of DNA was not successful, or DNA showed gender 
discrepancy or close relatedness. From the remaining sample of 1 720 individuals, 115 women 
and 97 men had been evacuated to Sweden or Denmark during the World War II according to 
the Finnish National Archives’ register. To study the effects of early separation from parents on 
methylome, we selected 83 evacuated men with data on age at and length of evacuation and 
of father’s occupational status and 83 non-evacuated controls matched for sex, birth year and 
father’s occupational status in childhood for the methylation typing. In this study, the analyses are 
based on 62 evacuated men and 60 non-evacuated controls with full data on CES-D depressive 
symptoms, covariates, and methylation profiles. For this group the mean age was 63.5 years (SD 
= 2.8).
DNA methylation sample, measurement, normalization and quality control
DNA methylation analysis was performed at the Genetics Core of the Wellcome Trust Clinical 
Research Facility (Edinburgh, UK). Bisulphite conversion of 500 ng input DNA was carried out using 
the EZ DNA Methylation Kit (Zymo Research, Freiburg, Germany). Four microlitres of bisulphite-
converted DNA was processed using the Infinium HD Assay for Methylation. This was performed 
using the Illumina Methylation 450 k beadchip and Infinium chemistry (Illumina, Inc., San Diego, 
CA, USA). Each sample was interrogated on the arrays against 485 000 methylation sites. The 
arrays were imaged on the Illumina HiScan platform and genotypes were called automatically 








































146  |  Appendix 4.1
Quality control pipeline was set up using the R-package minfi, including intensity read outs, 
normalization, cell type composition estimation, β- and M-value calculation. We excluded 
samples with low intensity (badSampleCutoff < 10.6) or deviant beta distribution based on 
visual inspection (N = 5). We did not detect any gender discrepancy. Data were normalized with 
functional normalization (FunNorm). Of the probes, we excluded those with detection p value > 
0.01 in > 50% of samples9, non-autosomal and non-specific binding probes as well as probes with 
SNPs in the interval for which the Illumina probe is designed to hybridize and if they were located 
close (10bp from query site) to a SNP which had a minor allele frequency of ≥ 0.05. Probes located 
in the X and Y chromosome were also excluded. This yielded a total number of probes of 424 
844. Batch effects were identified by inspecting the association of principal components of the 
methylation levels with possible technical batches using linear regressions and visual inspection 
of PCA plots using the Bioconductor R package shinyMethyl (version 0.99.3). Identified batch 
effects (i.e. array column) were removed using the Empirical Bayes’ (EB) method ComBat10. Batch 
corrected M-values after ComBat were used for all further statistical analyses.
Depressive symptoms assessment
Frequency of depressive symptoms were self-reported with the 20-item Centre for Epidemiologic 
Studies Depression scale (CES-D). 
Covariates
Age, sex, current smoking status, evacuation status (evacuated in childhood or not), and 
antidepressant medication (Model 2) were self-reported at the clinical visit. Blood cell proportions 
were estimated with the Houseman method. First three genotype MDS components were derived 
from genome-wide genotype data.
Analysis
A linear regression of the CES-D depressive symptoms score and covariates on each individual 
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Cooperative Health Research in the Augsburg Region
Description
The Cooperative Health Research in the Region of Augsburg (KORA) study is an independent 
population-based cohort from the region of Augsburg, Southern Germany. Whole blood samples 
were obtained from the KORA F4 survey (examination 2006-2008), a seven-year follow-up study 
of the KORA S4 cohort. Participants gave written informed consent and the study was approved 
by the local ethics committee (Bayerische Landesärztekammer). 
DNA methylation sample, measurement, normalization and quality control
Whole blood genomic DNA was bisulfite converted using the EZ-96 DNA Methylation Kit (Zymo 
Research, Orange, CA, USA) according to the manufacturer’s procedure, with the alternative 
incubation conditions recommended when using the Illumina Infinium Methylation Assay. Raw 
methylation data were extracted using the Illumina GenomeStudio software (version 2011.1, 
Methylation module 1.9.0). Preprocessing was performed using R (version 3.0.1). Probes with 
signals from less than three functional beads, and probes with a detection p-value > 0.01 were 
defined as low-confidence probes. Probes that covered SNPs (MAF in Europeans > 5%) were 
excluded from the data set. A color bias adjustment was performed using the R package lumi 
(version 2.12.0) through smooth quantile normalization and background correction based on 
the negative control probes present on the Infinium HumanMethylation BeadChip. This was 
performed separately for the two color channels and chips. β-values corresponding to low-
confidence probes were set to missing. A 95% call rate threshold was applied on samples and CpG 
sites. Beta-mixture quantile normalization (BMIQ) was applied using the R package wateRmelon, 
version 1.0.3. Because KORA F4 samples were processed on 20 96-well plates in 9 batches, plate 
and batch effects were investigated using principal component analysis and eigenR2 analysis.
Depressive symptoms assessment
Depressive symptoms were assessed using the German version of the self-administered Patient 
Health Questionnaire (PHQ-9).11 PHQ-9 represents a depression module that scores each of the 
nine Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for 
depression from zero to three. PHQ-9 scores of 5, 10, 15, and 20 represents mild, moderate, 
moderately severe and severe depression. It is used to monitor the severity of the depressive 
symptoms. PHQ scores higher or equal to 10 have been shown to have a sensitivity of 88% and 
a specificity of 88% for major depression. PHQ-9 is recommended by the American Psychiatric 
Association (APA) working group for DSM-V as instrument to evaluate the severity of major 
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Covariates
The association between DNA methylation level as the outcome and depression as the 
independent variable was performed using linear regression models, adjusting for age, sex, 
smoking, antidepressants, white blood cell count, and technical covariates (analytic plate and 
chip position on plate).
Information on sociodemographic variables including sex, age, smoking status and use of 
antidepressants was collected by trained medical staff during a standardized interview. The 
estimated white blood cell proportions were obtained using the method by Houseman et al.5
Lothian Birth Cohorts of 1921 (LBC1921) and 1936 (LBC1936)
Description
The LBC1921 and LBC1936 represent relatively healthy older individuals, mostly living in the 
Lothian region of Scotland, born in 1921 and 1936, respectively. They have been involved in 
longitudinal assessments of psychological and medical traits from the age of 79 (LBC1921) or 70 
(LBC1936) years.12, 13 Here, we report the first wave, with the largest sample size: 433 (60.3% 
female) participants with a mean age of 79.1 ± 0.6 years (range = 77 - 80) in the LBC1921; 920 
(49.5% female) participants with a mean age of 69.6±0.8 years (range = 67 - 71) in the LBC1936.
DNA methylation sample, measurement, normalization and quality control
514 whole blood samples in LBC1921 and 1 004 samples in LBC1936 were taken and DNA 
extracted using standard methods at, respectively, MRC Technology, Western General Hospital, 
Edinburgh and the Wellcome Trust Clinical Research Facility (WTCRF), Western General Hospital, 
Edinburgh. 485 512 methylation probes were typed at the WTCRF. The R minfi package was 
used to background correct raw intensity data and to generate methylation beta-values.2 Probes 
with a low (< 95%) detection rate (at p < 0.01) were removed and manual quality control via 
inspection of the array control probe signals was used to locate and exclude low quality samples 
(e.g. samples with inadequate hybridisation, bisulfite conversion, nucleotide extension or staining 
signal). Samples with a low call rate (samples with < 450,000 probes detected at p < 0.01) 
were excluded based on the Illumina-recommended thresholds. Because the LBC samples had 
previously been genotyped (Illumina 610-Quadv1), genotypes derived from the 65 SNP control 
probes on the methylation array using the wateRmelon package14 were compared to those on 
the genotyping array. Exclusions were made for samples with a low match of genotypes with SNP 
control probes, potentially indicative of sample contamination or mix-up (N = 9). Additionally, 
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Depressive symptoms assessment
Depressive symptoms were assessed with the Hospital Anxiety Depression Scale15, containing 
seven items each for anxiety and depression. The total score of the seven depression items was 
used. Self-reported smoking behavior (current, former and never) and medication use was also 
ascertained in the clinical testing session. The Anatomical Therapeutical Chemical-Code was used 
to code anti-depressants for current- and non-users.
Covariates
Age, sex, the first four principal components obtained from genotyping array data to index 
population substructure, B cells, monocytes, CD8T cells, CD4T cells, NK cells, position on 
BeadChip, methylation sample plate, BeadChip, hybridization date (and smoking for model 2). 
White blood cell counts were imputed from the methylation array using the Houseman method.5
Analysis
A linear regression of the HADS depression score and covariates on each individual methylation 
probe in the array was performed in R (v3.2.3).
The Rotterdam Study
Description
The Rotterdam Study (RS) is a prospective population based cohort study in a well-defined suburb 
in the city of Rotterdam, the Netherlands. The design and prospective of the Rotterdam Study 
has been described in details elsewhere.16 For the current analysis we used data from individuals 
aged 45 years and older that participated in the third cohort of the Rotterdam Study. Samples 
were obtained in two stages. First stage included participants of the first visit of the third cohort 
(RS-III-1). Second stage was obtained as a part of the BBMRI-NL (Biobanking and Biomolecular 
Research Infrastructure Netherlands) – BIOS project and included participants of the fifth visit 
of the first cohort (RS-I-5), third visit of the second cohort (RS-II-3) and second visit of the third 
cohort (RS-III-2). The subsets from the two stages were analyzed individually and then meta-
analyzed, together with other cohorts. 
DNA methylation sample, measurement, normalization and quality control
In both subsets of in total 1 479 individuals a whole blood DNA methylation was quantified 
utilizing same methods. DNA was extracted from whole peripheral blood, stored in EDTA tubes, 
by standardized salting out methods. The genome-wide DNA-methylation levels were determined 
using the Illumina HumanMethylation 450K array (Illumina, Inc., San Diego, CA, USA).17 In short, 
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methylation kit (Zymo Research, Irvine, CA, USA). Next, in accordance with the manufacturers’ 
protocol the samples were hybridized to the arrays. The methylation percentage of a CpG site 
was reported as a β-value ranging between 0 for no methylation and 1 for full methylation.
Quality control (QC) of the samples was carried out using Illumina Genome Studio software 
(v2011.1, methylation module version 1.9.0; Illumina). During QC samples with incomplete bisulfite 
treatment, with a low detection rate (< 99%), or gender swaps, were excluded. Also, probes with 
a detection p value > 0.01 in > 1% samples, were filtered out. In total of 474 528 probes passed 
the QC in the first subset and 419 937 in the BIOS subset (excluding sex chromosome).Filtered 
β values were than normalized with DASEN implemented in the wateRmelon package of the R 
statistical software.14 
Depressive symptoms assessment
Depressive symptoms were assessed with the Dutch version of the Centre for Epidemiologic 
Studies Depression scale (CES-D).18 The CES-D scale was designed to assess presence and severity 
of self-reported depressive symptoms.19 Participants were asked 20 questions that correspond 
with criterion based-symptoms associated with depression, and they could score from 0 - 60. The 
screening for depressive symptoms was performed during the home interview by trained research 
assistants. 
Covariates
Age, sex, current smoking status and antidepressant medication were measured using standard 
cohort specific protocols at the time DNA samples were collected. During this interview participants 
reported on their smoking behavior (current, former and never) and psychotropic medication 
use. Moreover, to confirm the self-reported use of antidepressants prescription, the Anatomical 
Therapeutical Chemical-Code20 data was collected from pharmacies linked records. Exposure to 
an antidepressant was defined as current user and non-user of any antidepressant as described 
in detail elsewhere.20 White blood cells counts (monocytes, granulocytes and lymphocytes) were 
measured immediately at the research center using a standard hematology analyzer (Beckman 
Coulter, Pasadena, CA, USA).
Analysis
An epigenome-wide linear regression was performed per DNA methylation probe with CES-D 
depression score adjusting for covariates in R. Model 1 was adjusted for age, sex, smoking status, 













































Generation Scotland: Scottish Family Health Study (GS:SFHS) is a population- and family-based 
cohort comprising ~24 000 individuals from the Scottish population. The cohort has been described 
in detail previously.21 Two hundred and twenty-seven individuals (118 cases, 109 controls) were 
included in the current study. These individuals are of European descent and were aged 40 years 
or over at the time of recruitment to GS:SFHS. Antidepressant usage was determined by self-
report at the time of recruitment. Blood samples for DNA extraction were obtained at the time 
of recruitment to GS:SFHS.
DNA methylation sample, measurement, normalization and quality control
Whole blood genomic DNA (500 ng) was treated with sodium bisulphite using the EZ-96 DNA 
Methylation Kit (Zymo Research, Irvine, California), according to the manufacturer’s instructions. 
DNA methylation was assessed using the Infinium HumanMethylation450 BeadChip (Illumina 
Inc., San Diego, California), according to the manufacturers protocol. Samples were assigned to 
slides such that gender was counter-balanced. Methylation array processing was carried out at 
the Wellcome Trust Clinical Research Facility, The University of Edinburgh.
Raw intensity (.idat) files were read into R using the minfi package2, which was used to perform 
initial quality control assessments by assessing signal from the array’s internal control probes. All 
samples were deemed to have performed well based on the output of the control probes.
Probe and sample filtering was performed using the pfilter function in wateRmelon.14 Probes 
were excluded if they had a detection p value ≥ 0.05 in more than 5% samples (N = 1000) or had 
a beadcount of less than 3 in more than 5% samples (N = 466). All samples satisfied an inclusion 
criterion of having no more than 5% probes with a detection p value ≥ 0.01. The final dataset 
comprised 484 145 probes measured in 227 individuals.
The raw data (β values) were normalized using the dasen function in wateRmelon.14
Assessment of depression
Diagnoses of depression were established by trained researchers who administered the screening 
questions of the Structured Clinical Interview for DSM-IV (SCID)22 to all GS:SFHS participants. 
Those who screened positive were subsequently assessed using the mood disorder sub-sections 
of the SCID. Major depressive disorder (MDD) was diagnosed in those meeting the criteria for 
MDD whose symptoms could not be better explained by bipolar disorder, a general medical 
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Covariates
The following variables were included as covariates: sex, age, current smoking status, family, 
estimated blood cell counts, batch (methylation slide ID), and methylation-based principal 
components. Antidepressant usage was additionally included as a covariate in a sensitivity analysis 
carried out to assess the contribution of antidepressant use to depression-associated methylation 
differences.
Smoking status was determined by self-report at the time of blood sample collection and was 
recorded as a binary variable (current smokers vs. non-smokers (never smokers and ex-smokers)). 
Antidepressant usage was also determined by self-report at the time of blood sample collection. 
No data on antidepressant usage was available for seven individuals.
Estimated proportions of six blood cell types (monocytes, granulocytes, CD4+ T-cells, CD8+ T-cells, 
B-cells and natural killer cells) were obtained using the estimateCellCounts function in minfi.5, 23 
In order to avoid collinearity, one cell type, natural killer cells, was excluded from the analyses.
Methylation-based principal components were identified using prcomp without scaling. PCA 
was performed on the matrix of residualised β-values obtained after residualising for the other 
covariates included in the model used to identify differentially methylated positions (principal 
components were estimated separately for Model 1 and Model 2). Principal components that 
individually accounted for at least 1% of the variance were included as covariates. For both 
models, this resulted in the inclusion of the first six principal components.
As our sample comprised related individuals (100 discordant sib pairs and 27 singletons), it was 
necessary to account for relatedness. This was achieved using the duplicateCorrelation function 
in limma24, 25 to fit family as a random effect.
Atherosclerosis Risk In Communities (ARIC) Study
DNA methylation sample, measurement, normalization and quality control
DNA methylation analysis was conducted with the Infinium HumanMethylation450 BeadChip 
(HM450) array (Illumina Inc., San Diego, CA) on genomic DNA extracted from blood samples 
collected at ARIC Visit 2. Assay were performed on participants who had not restricted use 
of their DNA and for whom at least 1 μg of DNA and genome-wide genotyping data were 
available. Details of assay and QC procedures have been previously published.27 Briefly, genomic 
DNA was treated with sodium bisulfite using the EZ-96 DNA methylation kit (Zymo Research 
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amplified, enzymatically fragmented, purified and hybridized to the HM450 array in accordance 
with the manufacturer’s directions. Methylation typing at 485 577 CpG sites was performed 
using GenomeStudio 2011.1 (Illumina Inc., San Diego, CA). Methylation level for each probe was 
derived as a beta value representing the fractional level of methylation at that location. Quality 
control analysis was performed using the wateRmelon R package.14 Probe data were excluded 
if they had a low detection rate (< 95% at p < 0.01) and a high missing rate (greater than 1% 
across all samples). Sample data were excluded based on the following criteria: (1) greater than 
5% missing values across all probes; (2) possible gender mismatch based on principal component 
analysis; (3) genotype mismatch based on 24 SNPs present on the HM450 array. Methylation 
values were normalized using the Beta MIxture Quantile dilation (BMIQ) method.28 All ARIC Study 
participants have provided written informed consent for genomic studies and this work was 
conducted in compliance with the Helsinki Declaration. The Committee for the Protection of 
Human Subjects at the University of Texas Health Science Center at Houston has approved this 
research.
Depressive symptoms assessment
Depressive symptoms were assessed at visit 2 using the 21-item Maastricht Questionnaire.29 
Responses to the questionnaire are coded as yes = 2, don’t know = 1, and no = 0. Two items, 
questions 9 and 14, are reversed coded (yes = 0, don’t know = 1, no = 2). Responses are summed 
to obtain an overall vital exhaustion score, which ranges from 0 to 42, with higher scores 
representing more exhaustion. Cronbach alpha for internal consistency has been reported as 
0.89.29 Although designed to measure vital exhaustion, the 21-item Maastricht Questionnaire 
has been shown to correlate with measures of depressive symptoms30 and was previously used to 
assess depressive symptoms.31, 32
Covariates
Age, sex, current smoking status and antidepressant medication were measured using standard 
cohort specific protocols at visit 2. Blood cell proportions were imputed using the Houseman 
method.5 Genotype principal components were derived from genome-wide genotype data 
(Affymetrix 6.0).
Analysis
Analysis was performed according to a pre-specified analysis plan adjusting for biological and 
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Women’s Health Initiative - Epigenetic Mechanisms of PM-Mediated CVD
Description
Women’s Health Initiative - Epigenetic Mechanisms of PM-Mediated CVD (WHI-EMPC) is an 
ancillary study of epigenetic mechanisms underlying associations between ambient particulate 
matter (PM) air pollution and cardiovascular disease (CVD) in the Women’s Health Initiative clinical 
trials (CT) cohort. It is funded by the National Institute of Environmental Health Sciences (R01-
ES020836).33
The WHI-EMPC study population is a stratified, random sample of 2 200 WHI CT participants 
who were examined between 1993 and 2001; had available buffy coat, core analytes, 
electrocardiograms, and ambient concentrations of PM; but were not taking anti-arrhythmic 
medications at the time.
As such, WHI-EMPC is representative of the larger, multiethnic WHI CT population from which 
it was sampled: N = 68 132 participants aged 50 - 79 years who were randomized to hormone 
therapy, calcium / vitamin D supplementation, and / or dietary modification in 40 U.S. clinical 
centers at the baseline exam (1993 - 1998) and re-examined in the fasting state one, three, six, 
and nine years later.34
During participant visits, data on age, race/ethnicity, smoking status, depressive symptoms, and 
antidepressant medication use were obtained. Current analyses were in European Americans 
and involved information collected at the first visit with available DNA methylation (DNAm) data. 
DNA Methylation
Genome-wide DNAm at CpG sites was measured using the Illumina 450K Infinium Methylation 
BeadChip, quantitatively represented by beta (the percentage of methylated cytosines over the 
sum of methylated and unmethylated cytosines), and quality controlled using the following 
filters:  detection p values > 0.01 in > 10% of samples, detection p values > 0.01 in > 1% of 
probes, yielding values of beta at 484,220 sites. DNAm data was normalized using BMIQ28, then 
stage- and plate-adjusted using ComBat.10 Modeled epigenome-wide associations also adjusted 
for principal components for ancestral admixture, cell subtype proportions (CD8-T, CD4-T, B cell, 
natural killer, monocyte, and granulocyte)5, and technical covariates including array, row, and 
column.
Depressive symptoms ascertainment
Depressive symptoms were obtained on the day of DNAm collection using a short screening 
instrument developed by Burnman et al.35 that combines six items from the CES-D that highly 
correlate with the full instrument (r = 0.88)36 with two items from the Diagnostic Interview 
Schedule (DIS). This CES-D/DIS screening instrument ranges from 0 to 1 with a higher score 
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Supplementary Figure 2: Quantile-quantile plots for the discovery EWAS. 
Horizontal axis depicts the expected negative logarithm of the association p-value, while the vertical axis 
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Supplementary Figure 4: Quantile-quantile plot of the meta-analysis of discovery and replication 
EWAS (λ = 1.088). 
Horizontal axis depicts the expected negative logarithm of the association p-value, while the vertical axis 
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Supplementary Table 2. Top DNA methylation sites associated with depressive symptoms in the 
discovery EWAS: M2 is model additionally adjusted for antidepressant medication








cg04987734 14 103415873 CDC42BPB ++--+-+++ 4.93×10-8 ++--+-+++ 3.94×10-8
cg07012687 17 80195180 SLC16A3 +++-+++++ 3.47×10-7 +++-+++++ 4.51×10-7
cg08796240 16 70733832 VAC14 +++++++++ 7.43×10-7 ++-++++++ 4.06×10-6
cg06096336 2 231989800 PSMD1;HTR2B ++-++-+++ 8.06×10-7 +++++-+++ 2.11×10-6
cg16745930 10 100220809 HPSE2 --------- 1.34×10-6 --------- 2.19×10-6
cg09849319 5 1494983 LPCATI1 +++-+-+++ 1.81×10-6 +++-+-+++ 6.14×10-6
cg17237086 22 40814966 MKL1 +++++-+++ 3.44×10-6 ++-++-+++ 1.30×10-5
cg03985718 2 105924245 TGFBRAP1 +++-+-+++ 3.61×10-6 +++-+-+++ 1.28×10-5
cg21098005 20 44538605 PLTP +++++++++ 4.36×10-6 +++++++++ 7.86×10-6
cg16466652 19 6271960 MLLT1 +++-+++++ 4.39×10-6 +++-+++++ 7.08×10-6
cg07884764 11 64107517 CCDC88B +++-+++++ 5.03×10-6 +++-+++++ 1.50×10-5
cg01541347 7 4729920 FOXK1 ++++++++- 5.64×10-6 ++++++++- 6.66×10-6
cg02341197 21 34185927 C21or62 +++++-+++ 5.84×10-6 +++++++++ 8.57×10-6
cg01947751 3 196728969 - +++-+++++ 6.23×10-6 +++-+++++ 5.93×10-6
cg13747876 17 80195402 SLC16A3 +++++-+++ 6.32×10-6 +++++++++ 1.31×10-5
cg12764201 1 105101123 CORT;APITD1 +++++-+++ 7.15×10-6 +++++-+++ 1.33×10-5
cg08295111 5 133866097 PHF15 +++-+++++ 7.87×10-6 +++-+++++ 1.73×10-5
cg18030453 3 45506216 LARS2 +++-+-+++ 9.16×10-6 +++-+-+++ 2.44×10-5
cg12325605 3 56810151 ARHGEF3 +++++++++ 9.62×10-6 ++-++++++ 1.82×10-5
cg23282441 10 73533927 C10orf54;CDH23 ++--+++++ 9.69×10-6 ++-++++++ 5.30×10-6
$ Order of cohorts in the direction column: Discovery meta-analysis: CHS, FS, GS, HBCS, KORA, LBC1921, 
LBC1936, RS_BIOS, RS_III; Replication meta-analysis: WHI-EMPC, ARIC; Discovery and replication samples 
meta-analysis: CHS, FS, GS, HBCS, KORA, LBC1921, LBC1936, RS_BIOS, RS_III, WHI-EMPC, and ARIC; + 
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Supplementary Table 3. Top DNA methylation sites associated with depressive symptoms in the 
meta-EWAS (N = 11 256)
MarkerName Weight Zscore P value Direction$ HetPVal CHR MAPINFO UCSC_RefGene
cg12325605 11256 5.839 5.24×10-09 +++++++++++ 0.903 3 56810151 ARHGEF3
cg04987734 11256 5.653 1.57×10-08 ++--+-++++- 0.004874 14 103415873 CDC42BPB
cg14023999 11256 5.419 5.99×10-08 ++++++++-++ 0.1514 15 90543224
cg18030453 11253 5.293 1.20×10-07 +++-+-++++- 0.4738 3 45506216 LARS2
cg10829227 11254 5.1 3.40×10-07 +++++-+++++ 0.5651 19 47200595 PRKD2
cg07175797 11254 5.073 3.92×10-07 +++-+++-+++ 0.389 16 50317656
cg07012687 11251 5.048 4.46×10-07 +++-++++++- 0.2654 17 80195180 SLC16A3
cg12728588 11256 5.011 5.43×10-07 +++++++++++ 0.5798 1 36025489 NCDN
cg22069247 11253 4.93 8.23×10-07 +++-+-+++++ 0.7434 2 232393256 NMUR1
cg12526091 11256 4.912 9.00×10-07 +++-+-+++++ 0.8524 12 58245042
cg14012686 11253 4.89 1.01×10-06 ++-+++++++- 0.6241 2 74785750 C2orf65
cg00153395 11255 4.888 1.02×10-06 +++-+++++++ 0.8356 1 65327523 JAK1
cg04583842 10491 4.836 1.33×10-06 +++-+++?+++ 0.3046 16 88103117 BANP
cg03429645 11255 4.82 1.43×10-06 +++++++-+++ 0.666 3 100053188 NIT2
cg04286697 11256 4.78 1.75×10-06 +++-+++++++ 0.2851 2 232259623 B3GNT7
cg08796240 11256 4.775 1.80×10-06 ++++++++++- 0.2479 16 70733832 VAC14
cg19769147 11255 4.744 2.09×10-06 +++++-++++- 0.1715 14 105860954 PACS2
cg17822325 11253 4.722 2.33×10-06 +++++-+++++ 0.9251 1 31896462 SERINC2
cg06096336 11254 4.707 2.51×10-06 ++-++-+++++ 0.4324 2 231989800 PSMD1;HTR2B
cg10401362 11254 4.691 2.71×10-06 -++-+-+++++ 0.001998 7 157185402 DNAJB6
cg07467649 11256 4.689 2.75×10-06 +++-+-+++++ 0.3612 7 72856462 BAZ1B
cg13747876 11256 4.676 2.93×10-06 +++++-++++- 0.4857 17 80195402 SLC16A3
cg25392060 11256 4.664 3.10×10-06 +++-+++++++ 0.5181 8 142297121
cg22365240 11250 4.659 3.17×10-06 -++++++++++ 0.983 2 105374995
cg08631783 11253 4.62 3.83×10-06 -++-+-+-+++ 0.1325 15 89418456 ACAN
cg19269039 11255 4.62 3.84×10-06 ++++++++-++ 0.5069 1 111743200 DENND2D
cg03720762 11256 4.572 4.82×10-06 +++++++-+++ 0.08729 17 17604184 RAI1
cg21604136 11255 4.568 4.93×10-06 ++-++++++++ 0.1963 1 9910137 CTNNBIP1
cg11931558 11252 4.546 5.46×10-06 +++++++++++ 0.8237 7 11013742 PHF14
cg24550880 11255 4.531 5.88×10-06 +++-+-+++++ 0.4632 17 79420279 BAHCC1
cg07372520 11255 4.526 6.01×10-06 +++-+-+++++ 0.4239 1 180086434
cg05827190 11255 4.524 6.08×10-06 +++++-++-++ 0.2259 4 681440 MFSD7
cg19743103 11253 4.524 6.08×10-06 +++--++++++ 0.1436 1 6304220 HES3
cg17237086 11256 4.523 6.09×10-06 +++++-++++- 0.3516 22 40814966 MKL1
cg16745930 11254 -4.518 6.26×10-06 ----------- 0.1094 10 100220809 HPSE2
cg27305772 11256 4.507 6.57×10-06 +++++-+++++ 0.8274 11 65630355 MUS81
cg02341197 11256 4.5 6.80×10-06 +++++-+++++ 0.8595 21 34185927 C21orf62
cg23606718 11255 4.456 8.37×10-06 +++-+++++++ 0.8073 2 131513927 FAM123C
cg23282441 11254 4.449 8.63×10-06 ++--++++++- 0.4265 10 73533927 C10orf54;CDH23
cg17743381 11256 4.437 9.10×10-06 +++++-+++++ 0.7012 1 39024825
cg05251389 11254 4.424 9.67×10-06 +++-+++-+++ 0.7075 22 43525330 BIK
cg26610247 11255 4.424 9.70E-06 ++---++++++ 0.1656 8 142297175
 
$ Order of cohorts in the direction column: Discovery and replication samples meta-analysis: CHS, FS, GS, 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 7. Differentially expressed probes associated with methylation at cg14023999
probeID Effect SD p value p value FDR Gene Protein_Product Chr Cytoband
ILMN_1743032 -3.1308 0.5973 2.11E-07 0.00448515 CTSS NP_004070.3 1 1q21.2c















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Multiple episodes of late-life 
depression and cognitive decline
Jovanova Olivera, Wolters Frank, Ikram Arfan, Tiemeier Henning, Schmitz Norbert.
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ABSTRACT
Importance: Population-based studies consistently reported a cross-sectional but no prospective 
association between depression and cognitive decline. Clinical studies suggest that the number of 
depressive episodes a patient experienced, may explain the association between depression and 
cognitive decline. To date, no population-based study has investigated the prospective relation 
between single-episode and multiple-episode depression and subsequent cognitive decline.
Objectives: To determine the association between depressive episodes and cognitive change over 
a 12-year period.
Design, Settings and Participants: This study was embedded in the Rotterdam Study, a prospective 
population-based cohort of persons aged ≥ 55 years. 6 221 non-demented participants, with a 
mean (SD) age of 68.6 (8.1) years were enrolled between 1997 and 2001 and were followed for 
cognitive functioning until 2012.
Main outcomes and Measures: Depressive symptoms questionnaire and general practitioner 
records were used to detect 751 (12.1%) persons with single-episode and 350 (5.6%) persons 
with multiple-episode among 6 221 individuals (depression follow-up 1993 - 2004). Cognitive 
decline was determined during three consecutive examination rounds with a test-battery including 
a letter-digit-substitution test, Stroop test, verbal fluency test, and mini-mental state examination 
(cognition follow-up 1997 - 2011). The association between depressive episodes and cognitive 
decline was modelled with a latent growth curve adjusted for sociodemographic and lifestyle 
factors, and comorbidities.
Results: Severity of depressive symptoms at baseline was not related to cognitive decline during on 
average 12 years follow-up. Likewise, participants who experienced a single-episode depression 
had no excess decrease in cognitive functioning during follow-up (beta, -0.088; S.E., 0.12; p = 
0.45). In contrast, participants who experienced multiple-episodes of depression had a stronger 
decrease in the cognitive functioning than persons without depression (beta, -0.656; S.E., 0.16; 
p < 0.001).
Conclusions and relevance: In older adults, multiple-episode but not single-episode depression is 
associated with accelerated cognitive decline. This finding is in line with clinical studies showing 
that chronic psychiatric disease may have impact on brain resilience. Elderly persons suffering 
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INTRODUCTION
Depression and cognitive decline are common chronic and disabling conditions affecting older 
people.1,2 Non-demented elderly diagnosed with depression often report cognitive complaints 
such as concentration loss, memory impairment, word-finding difficulties, or limitations in daily 
activities.2 Depression and cognitive impairment often co-occur1,3-9 and cognitive complaints 
frequently persist even after the remission of the depressive episode.2,7,10,11 Yet, whether 
depression-associated pathology contributes to the subsequent cognitive decline is uncertain.2
While it is often speculated that depression can negatively affect neurocognitive functioning, it 
is unclear whether depression truly contributes to subsequent cognitive decline.12 A substantial 
number of clinical and population-based studies addressed the prospective association between 
depression and cognitive complaints, but findings have been inconsistent.8,9,12-25 Clinical studies 
repeatedly reported greater cognitive decline following depression.12,19,20,22 In contrast, population-
based studies generally found no relation between depressive symptoms assessed at baseline and 
subsequent change in cognitive function.8,15-18,21 This discrepancy between epidemiological and 
clinical findings may relate to the variation in severity of depression between settings.
In order to reconcile these discrepant findings researchers have more recently studied persistent 
depressive symptoms in population-based studies.9,22,26 Persistent depression was defined as 
symptom ratings repeatedly assessed above a certain threshold. These studies showed that the 
persistence of symptoms across a 2 - 5 year follow-up period was paralleled by a decline in 
cognitive functioning.9,22,26 This essentially cross-sectional design of two repeatedly assessed 
measures suggests that multiple episodes23 of depressive symptoms rather than a single episode 
may be associated with cognitive decline. Against this background, a recent review argued that 
the relationship between severity of depression and cognitive disability is poorly understood and 
understudied.12
Longitudinal population-based studies that assess depressive episodes over a long period prior to 
cognitive decline are lacking.12 We aimed to investigate in an ongoing population-based study 
whether the frequency of exposure to depressive episodes in non-demented elderly is associated 
with cognitive decline if followed for many years. We hypothesized that persons with multiple 
episodes of depression have a faster cognitive decline over a 12 years follow-up period than 












































This study was embedded in the Rotterdam Study, a prospective population-based cohort that 
started in 1990 among inhabitants aged ≥ 55 years living in the district Ommoord, Rotterdam, 
the Netherlands.27 The medical ethics committee approved the study according to the Population 
Study Act of the Dutch Ministry of Health (Wet Bevolkingsonderzoek). Written informed consent 
was obtained from all participants.
The first cohort of the Rotterdam Study included 7 983 participants and was expanded with an 
additional 3 011 participants, who had reached age of 55 years or moved into the study area, in 
the year 2000. The details of the objectives and the study design of the Rotterdam Study have 
been previously described elsewhere.27 In brief, all participants underwent home interview and 
an extensive set of examinations in a research centre during follow-up examination rounds that 
were conducted on average every 3 - 4 years.27 The current study included participants assessed 
for depressive episodes and cognitive functioning, during the 1997 - 1999 examination of the 
first cohort, and the 2000 - 2001 examination of the second cohort; this defines the baseline of 
the present study (Supplement 1 and Figure 1).
7 808 persons participated in this baseline examination of this study (Supplement 1). Of these, 
7 533 participants were screened for depressive symptoms (96.5% response rate). We excluded 
1 269 participants, who did not have full cognitive testing (at least two completed cognitive 
tests were required). The subjects with no cognitive assessment were on average older (74.9 
versus 69.0 years), more likely to be female (66.9% versus 56.7%) and had experienced more 
depression (20% versus 18%) than those participants with cognitive assessment. Additionally, we 
excluded 92 persons with prevalent dementia and 8 persons with bipolar disorder. This resulted 
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Age, years 68.4 (8) 70.1 (8.5) 69.6 (7.9)
Sex, female 2757 (53.8) 495 (65.9) 270 (77.1)
Highest education attained
Primary 614 (12.0) 122 (16.2) 57 (16.3)
Lower/intermediate 2203 (43.0) 340 (45.3) 159 (45.4)
Vocational 1566 (30.6) 196 (26.1) 111 (31.7)
Higher 710 (13.9) 86 (11.5) 20 (5.7)
Smoking habits
Never smoker 1642 (32.1) 270 (36) 119 (34)
Current smoker 850 (16.6) 157 (20.9) 82 (23.4)
Past smoker 2628 (51.3) 324 (43.1) 149 (42.6)
Alcohol consumption
No consumption 484 (9.5) 88 (11.7) 51 (14.6)
Current consumers 4345 (84.9) 589 (78.54) 257 (73.4)
Past consumers 291 (5.7) 73 (9.7) 42 (12)
Body mass index, kg/m2 26.9 (3.9) 27.1 (4) 27.5 (4.5)
IADL* 15.6 (7.3) 15.3 (7.5) 15.3 (7.5)
Cardiovascular medication 2088 (40.8) 362 (48.2) 169 (48.3)
Psychotropic medication 631 (12.3) 217 (28.9) 156 (44.6)
Cancer 386 (7.5) 54 (7.2) 38 (10.9)
Diabetes mellitus 252 (4.9) 54 (7.2) 20 (5.2)
Myocardial infarctions 212 (4.1) 34 (4.5) 15 (4.3)
Stroke 152 (3.0) 38 (5.1) 20 (5.7)
Descriptive characteristics of study population were assessed at baseline and present the non-imputed data. 
The values represent counts (percentage) or means (standard deviations).*IADL – instrumental activity of 
daily living.
Assessment of depressive episodes
Participants were monitored for the occurrence of depressive episodes (including: depressive 
symptoms, depressive syndromes, dysthymia and major depressive disorders) during an average 
of 8 years. The time-lines for assessment of depressive episodes are illustrated in detail in Figure 1. 
The occurrence of depressive episodes was assessed continuously four years prior to baseline and 
before the first re-examination of the first cohort (first cohort 1993 - 2004). Likewise, depressive 
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Figure 1. Diagram of the timeline 
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Baseline second 
cohort 
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Baseline first 
cohort 1 










Cognitive assessments; T1 – First 
assessment, T2 – Second assessment, T3 – 
Third assessment  




































In order to enhance case-findings of depressive episodes during the interval between examinations 
and at examination rounds the information was collected with different assessment methods.28 
First, we used information from the screening for depressive symptoms, performed at each 
examination. All participants were screened for depression with the validated Dutch versions of 
the Centre for Epidemiologic Studies Depression (CES-D) scale.29 The 20-item CES-D measure 
self-reported frequency of experienced depressive symptoms. Participants could score from 0 up 
to 60. A cut-off score of ≥ 16 defined participants with clinically relevant depressive symptoms, 
i.e., a depressive episode.29
To identify the depressive episodes that occurred and may have remitted in the intervals between 
follow-up examination rounds, we continuously monitored data on the occurrence of depressive 
episodes from the general practitioners (GP) records. The Netherlands have a primary health 
care system, thus all specialist must report to the GP. The GP records are elaborate and include 
diagnoses obtained from mental-health professionals substantiated by DSM-classification.28 The 
occurrences inferred from the different data sources were consistent.28
With this information, participants were either classified as persons with depressive episodes 
(single-episode (N = 751) and multiple-episode (N = 350) depression) and persons with no 
episodes of depression (N = 5 120). Only depressive episodes occurring before the first re-
assessment of cognitive functioning were included to minimize the overlap between depressive 
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only 60% of the persons suffering recover in the first year, 70 - 80% recover during the second 
year but remission of depression is not always well documented.28 Therefore, to distinguish 
between episodes we assumed that one depressive episode may last for a maximum of two years.
Cognitive functioning
Cognitive function was assessed during three consecutive examination rounds (Figure 1) with a 
battery of cognitive tests that included the Mini Mental State Examination (MMSE), Stroop test, 
a letter-digit substitution task (LDST), and a verbal fluency test (VF). On the MMSE, participants 
could score from 0 to 30 points.30 The 40-items Stroop test31 scored time needed to name the ink 
colour of incongruously printed name of colours. The LDST32 assessed the total number of correct 
digits assigned to letters according to a code key during 60 seconds. VF was assessed with the 
animal naming test.33 The total number of named animals within one minute were scored. Lower 
scores indicated worse performance on all tests, except for the Stroop test.
We used principal component analyses of the four cognitive test scores to derive a more robust 
summary test score (G-factor). The G-factor was calculated at each wave using a multiple 
indicator measurement model. The model was constrained by requiring corresponding loadings 
across waves to be equal in the assumption of measurement invariance (Supplement 3). For each 
participant, z-scores were calculated for the G-factor and each test separately by dividing the 
difference between individual test score and mean test score by the standard deviation.
Table 2. Descriptive of cognitive performance tests measured over time for depression
Depression status          Cognitive test
T1* T2* T3*
(1997-1999) (2002-2004) (2009-2011)
N Mean (SD) N Mean (SD) N Mean (SD)
Letter-digit substitution task
No depression 5036 28 (7.2) 3797 27.4 (7.5) 2480 26.5 (8.2)
Single episode 739 26.2 (7.5) 485 26.1 (7.5) 262 26.5 (9.4)
Multiple episodes 341 26.1 (7) 249 24.4 (7.4) 129 24.4 (9.3)
Verbal fluency test
No depression 5094 21.4 (5.7) 3888 20.7 (5.5) 2560 20.8 (6.3)
Single episode 747 20.8 (6.1) 502 20.5 (5.5) 274 20.9 (7.5)
Multiple episodes 347 20.6 (5.8) 261 19.8 (5.4) 138 19 (5.2)
Stroop test
No depression 4970 58.0 (27.3) 3 523 60.1 (29.9) 2466 61.8 (31.4)
Single episode 730 64.8 (34.9) 455 65.2 (37.8) 265 61.4 (29.4)
Multiple episodes 340 62.9 (29.7) 231 70.6 (38.5) 136 67.9 (40.4)
Mini–mental state examination
No depression 5119 27.8 (1.8) 3998 27.6 (2.2) 2718 27.4 (3)
Single episode 751 27.5 (2.1) 546 27.2 (2.7) 294 27.1 (3.1)
Multiple episodes 350 27.5 (2) 287 26.9 (3.1) 159 26.8 (2.9)
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Covariates
Data on socio-demographic background and life-style factors were assessed at baseline using 
standardized interview questions. Highest level of education was classified in four categories: low, 
intermediate-low, intermediate-high, and high education. Smoking and alcohol consumption 
habits were classifed as current, past and non-consumers. Presence of common chronic 
diseases (stroke, diabetes mellitus, myocardial infarction and cancer) was based on self-report, 
examination, medical record information, and drug utilization. Psychotropic and cardiovascular 
medications were self-reported during interview, and verifed by medication prescriptions. Height 
and weight were measured and body mass index (BMI) was calculated as weight divided by 
height squared (kg/m2). To assess physical self-maintenance, we used the instrumental-Activities 
of daily living scale (IADL).
DATA ANALYSIS
A descriptive analysis provided an overview of the study sample at baseline. Also, we assessed 
crude mean differences in cognitive test scores between persons with no depression, single-
episode, and multiple-episode depression at each of the three examination rounds, by using 
repeated measures analysis of variance.
In order to analyse the temporal relationship between depression and cognitive change we used 
a latent growth curve model (LGCM) approach. This approach models repeated measures into 
latent variables with a random intercept and random slope, allowing individual cases to have 
individual trajectories of change over time. This methodology permitted us to effectively study 
the within-person (intra-individual) and the between-person (inter-individual) change in cognitive 
functioning over time.
In the present study, a trajectory of cognition was modelled from the G-factor of cognitive 
functioning (constructed as described above). The trajectory was estimated by using an intercept 
(the average level of baseline scores) and a slope (linear rate of change over time). The time points 
for the slope growth factor were fixed at 0, 1, and 2 to define a linear growth model and the 
factor loadings were held constant across time to create an LGM process with latent slope and 
intercept.
This study examined the association of depression with the change rates (slope) of the G-factor 
of cognition measured at 3 time points (Figure 1). First, we evaluated the course of cognition 
over time while controlling for sex, age, education and cohort (Supplement 3). Second, we 
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status while controlling for sex, age, education and cohort. Third, we constructed a fully adjusted 
model were we additionally controlled the conditional models for other potential confounders; 
including various comorbidities, life-style, and demographic factors (Table 3).
Parameters were estimated using a maximum likelihood estimation, including estimating a 
random effect and estimator with robust standard errors. The general goodness of fit of each 
model was evaluated using the Comparative Fit Index (CFI) and the Root Mean Square Error of 
Approximation (RMSEA). Conventional rules suggest that a CFI ≥ 0.90 indicates adequate fit 
and CFI ≥ 0.95 indicates excellent fit; a RMSEA ≤ 0.08 indicates adequate fit (≤ 0.05 indicates 
excellent fit).34,35
Multiple imputations were used in to account for missing data on potential confounding 
variables (missing values: alcohol consumption 0.01%, BMI 0.5%, IADL 8.1%, cardiovascular 
and psycotropic medication 4.1%, cancer 0.01%, diabetes mellitus 0.2%, myocardial infarction 
8%, education 0.6%,). All analyses were run in the complete case and ten imputed data sets. In 
this manuscript we present results from the imputed data. Analyses were conducted in M-Plus 
(Version 7.3).
In a sensitivity analyses we conducted the analyses for the initial cohort and the extension cohort 
separately, to account for the slight discrepancy in the assessment of past depression (Supplement 
4).
RESULTS
Table 1 provides the demographics and clinical characteristics of the participants by depression 
status at baseline. Participants with single-episode (70.1 ± 8.5 years) and with multiple-episode 
(69.6 ± 7.9 years) were on average older than participants without depression (68.4 ± 8 years). 
Table 2 presents the mean cognitive status of the three depression groups at each assessment 
wave. The overall decline in all cognitive tests across follow-up in all three groups is shown. 
For example, persons with multiple episodes of depression had a lower MMSE score at all time 
points (27.5 at baseline and 26.8 at the end of follow-up) than those without depression (27.8 at 
baseline and 27.4 at the end of follow-up).
We first tested the association of depressive symptoms at baseline studied continuously with 
decline of cognitive functioning across follow-up (Supplement 2). Although persons with more 
depressive symptoms had worse cognitive function at baseline (see intercept, Supplement 2), we 
found no prospective association between depressive symptoms and cognitive decline (beta [B], 
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Second, we investigated the association between frequency of depressive episodes and cognitive 
functioning (Table 3). All latent growth models had an excellent fit, with no CFI lower than 0.06 
and no RMCEA higher than 0.04. In line with the analysis of continuous depressive symptoms, 
we observed that a single or multiple episodes of depression were related to poor cognitive 
functioning at baseline (Table 3, see intercept). A single episode of depression was not associated 
with subsequent cognitive decline (B, -0.09; S.E., 0.12; p = 0.45; see slope), but persons with 
multiple-episode depression had faster cognitive decline than those without depression (B, -0.66; 
S.E., 0.2; p < 0.001). This finding was not significantly changed after adjustment for various 
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Table 3. Initial level and rate of change of cognitive functioning and single or multiple-episode 
depression using the Latent growth curve modelling (N = 6 221)
Conditional model Intercept Slope
Estimate S.E. p value Estimate S.E. p value
Depressive episodes
No depression reference reference
Single episode -0.911 0.20 <0.001 -0.088 0.12 0.45
Multiple episodes -1.088 0.28 <0.001 -0.645 0.16 <0.001
Sex (female) 0.680 0.13 <0.001 0.198 0.07 0.007
Age -2.945 0.08 <0.001 -1.045 0.05 <0.001
Cohort -1.002 0.15 <0.001 0.075 0.08 0.36
Education 2.043 0.08 <0.001 0.091 0.04 0.034
Model fit indices: RMSEA* (95% CI) = 0.038 (0.036; 0.040); CFI** = 0.967
Fully adjusted model Intercept Slope
Estimate S.E. p value Estimate S.E. p value
Depressive episodes
No depression reference reference
Single episode -0.581 0.20 0.003 -0.088 0.12 0.45
Multiple episodes -0.545 0.28 0.053 -0.656 0.16 <0.001
Sex (female) 1.034 0.14 <0.001 0.153 0.08 0.051
Age -2.678 0.08 <0.001 -1.023 0.05 <0.001
Cohort -0.914 0.15 <0.001 0.094 0.08 0.25
Education 1.958 0.08 <0.001 0.090 0.04 0.036
Body mass index -0.022 0.02 0.18 -0.012 0.01 0.20
Cancer 0.506 0.24 0.033 -0.121 0.14 0.38
Diabetes mellitus -0.855 0.29 0.003 -0.541 0.17 0.002
Stroke -1.611 0.36 <0.001 -0.428 0.26 0.09
Myocardial infarction 0.258 0.33 0.47 -0.003 0.19 0.99
Psychotropic therapy -0.661 0.18 <0.001 0.061 0.11 0.57
Cardiovascular therapy -0.152 0.15 0.30 -0.173 0.08 0.030
IADL*** 1.318 0.12 <0.001 -0.063 0.08 0.44
Smoking habits 0.327 0.08 <0.001 -0.033 0.04 0.42
Alcohol consumption 0.050 0.16 0.75 -0.047 0.10 0.62
Model fit indices: RMSEA* (95% CI) = 0.028 (0.027; 0.030); CFI** = 0.965
* RMSEA: Root Mean Square Error of Approximation **CFI: Comparative Fit Index;***IADL instrumental 
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DISCUSSION
In this population-based cohort of older adults we investigated the impact of late-life depression 
on the change in cognitive functioning. We observed that increased baseline depressive symptoms 
(continuously assessed) did not predict cognitive decline over a 12 year follow-up. However, 
persons who had experienced multiple-episodes of depression were prone to faster cognitive 
decline during follow-up compared to those who experienced only one or no depressive episode. 
These results emphasise that the persistence or recurrence rather than the severity of depression 
at one time point relates to cognitive decline.
Depression and cognitive decline are two conditions consistently co-occurring more often than 
expected. Impaired cognition is an important symptom of depression and it is evident that 
clinical and community-dwelling individuals with depression have impaired cognitive functioning 
compared to non-depressed individuals.13,36,37
In contrast to the cross-sectional associations, the prospective association of depression and 
cognitive decline has been a challenge for both clinical and population based studies. Clinical 
studies mostly report prospective association in patients with depression7,12, while population-
based studies often did not find a prospective association.8,15,17,19 Consistent with previously 
published population-based studies, we also observed that depressive symptoms at baseline did 
not predict cognitive decline.8,14-18,20 The discordance in findings between clinical and population-
based studies is probably not a power problem, since these cohorts were sufficiently large and 
include many individuals with depressive symptoms. Rather, patients with more severe symptoms 
are typically selected in clinical studies due to referral patterns. Thus, in the general population 
studies persons screened positively for depressive symptoms may not have severe or chronic 
enough depressive problems to impact the cognitive functioning.
We continuously monitored persons over longer periods of time for the occurrence of depressive 
episodes and observed that not a single episode of depression but recurrent depression was 
associated with a stronger decline of cognitive functioning over the longer term. A few previously 
published studies support our results and suggest that persistent symptoms of depression are 
related to concurrent cognitive decline.9,21,26 For example, in the EVA study, the authors observed 
that more depressive symptoms at baseline were associated with lower MMSE scores only if the 
depressive symptoms persisted during the entire follow-up of 4 years.26 Also Kohler et al, reported 
a similar association between the co-occurring persistent depressive symptoms and the decline in 
cognition during 6 years follow-up.21 However, in these studies persistent depressive symptoms 
were defined during the same period as the cognitive functioning. In the present study, there is 
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assessments. Hence, the longitudinal association reflects the decline of the cognitive function 
after the assessment of depression.
How does multiple-episode depression affect cognitive functioning?
The neuropsychological consequences of late-life depression are unclear. Various potential 
mechanisms may explain why multiple-episode but not single-episode depression is a risk factor 
for long-term cognitive decline. First, elderly people experience chronic stress due to age-related 
life-style, environmental, and health changes. Exposure to such a chronic stress increases the 
likelihood of developing mental disorders with a more chronic/recurrent course. Chronic stress 
can activate the hypothalamus-pituitary–adrenal (HPA) axis, which responds with cortisol release. 
This depression or stress-related prolonged hypercortisolemia is known to have adverse neurotoxic 
effect such as hippocampal neuronal degeneration and loss.38 Indeed, hyper-activation of the 
HPA axis with consequent hippocampal and hypothalamic atrophy were associated with both 
recurrent depression and cognitive decline.9,22,38-40 Importantly, other biological pathways also link 
depression and cognitive decline such as metabolic changes or inflammation.41,42 Studies have 
shown that severe or repeated depression is related to subsequent increase of interleukin-6 and 
other inflammatory markers.43
Second, depression and cognitive decline might reflect one shared underlying pathophysiological 
mechanism. For example, cerebrovascular disease causes disruption of prefrontal systems that 
can give rise to both mood and executive functions and thereby explain the relationship between 
depression and cognitive decline.44 This could be due to microvascular dysfunction which underlies 
amyloid-β formation, and white-matter changes.23 Indeed, a vascular hypothesis is supported 
by neuroimaging data showing that cerebrovascular lesions were related to both persistent 
depression and increased risk of dementia.45 Importantly, vascular small vessel disease can be 
both a cause and a consequence of depression, thus the two mechanisms above need not be 
exclusive. In this study we carefully adjusted for vascular morbidity at baseline including; stroke, 
diabetes mellitus, and myocardial infarction. Thus confounding by pre-existing vascular diseases 
is not very likely but this does not control for vascular change as a consequence of depression.
Limitations
We continuously monitored participants, both men and women, for depressive episodes for 
almost 12 years. This large population study combines a comprehensive follow-up of depression 
and detailed cognitive functioning assessments. Yet, several limitations need to be addressed. 
First, different aspects of severity of depression such as age of first onset, number and duration 
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meaningful for the subsequent cognitive functioning but are not easily measured in population-
based settings.12 Second, the cognitive battery assessment did not include all cognitive domains 
of interest. However, we constructed G-factor from four cognitive functioning measures which 
yields a good but not ideal proxy of the nominal five items G-factor.46 Third, persons with 
depression may have cognitive impairment prior to the occurrence of depression and a perception 
of cognitive decline can be precipitate depression.3,16 However, we excluded participants with 
prevalent dementia and controlled for baseline cognition function, thus reverse causality cannot 
easily explain our results. Fourth, the first cohort but not the second was assessed for history 
of depression four years prior to baseline (Figure). However, the sensitivity analysis stratified by 
cohort did not change the results (Supplement 4).
In conclusion, our study demonstrates that individuals who experienced multiple episodes of 
depression had accelerated decline in cognitive functioning over an average follow-up of 12 years 
compared to individuals without depression. In contrast, those who experienced a single episode 
of depression followed a similar trajectory of cognitive decline as those without depression. This 
result can help to reconcile the contrasting findings from clinical and population-based studies, 
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ABSTRACT
Background: The association between myocardial infarction (MI) and depression is well described. 
Yet, the underlying mechanisms are unclear and the contribution of psychological factors is 
uncertain. We aimed to determine the risk of recognized (RMI) and unrecognized myocardial 
infarction (UMI) on depression, as both have a similar impact on cardiovascular health but differ 
in psychological epiphenomena.
Methods and results: Participants of the Rotterdam Study, 1 823 men aged ≥ 55, were followed 
for the occurrence of depression. RMI and UMI were ascertained using electrocardiography and 
medical history at baseline. We determined the strength of the association of RMI and UMI 
with mortality, and we studied the relation of RMI and UMI with depressive symptoms and the 
occurrence of major depression.
Results: The risk of mortality was similar in men with RMI (adjusted hazard ratio (HR): 1.71, 
95%CI: 1.45-2.03) and UMI (HR: 1.58, 95%CI: 1.27-1.97). Men with RMI had on average 
(unstandardized regression coefficient (B): 1.14, 95%CI: 0.07-2.21) higher scores for depressive 
symptoms. By contrast, we found no clear association between UMI and depressive symptoms 
(B: 0.55, 95%CI: -0.51-1.62) in men. Analysis including occurrence of major depression as the 
outcome were consistent with the pattern of association.
Conclusion: The discrepant association of RMI and UMI with mortality compared to depression 
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INTRODUCTION
The increased occurrence of depression after myocardial infarction (MI) is well-recognized in 
clinical practice.1-3 In those that experienced MI, the prevalence of depression exceeds 30%.2,4 
Several biological and pathophysiological pathways including inflammation and endothelial 
dysfunction might link MI and depression5,6, but post-MI depression could also occur as a result of 
illness perception. Alterations in mood can be part of the coping process after surviving a cardiac 
event, treatment and recovery.4
MI is traditionally described as a clinical syndrome characterized with precordial discomfort and 
pain. Nevertheless, a substantial proportion of MIs are not clinically recognized by patients or 
treating physicians.7-9 The available epidemiological, clinical and basic science evidence provides 
support for a similar ischemic pathology underlying both recognized (RMI) and unrecognized 
(UMI) myocardial infarctions.10-14 Many studies demonstrated that UMI has a similar long-term 
impact on physical health as RMI. In men, and to a lesser extent in women, both RMI and UMI 
are associated with increased risk of all-cause mortality, heart failure and sudden death.14,15 In 
the Rotterdam Study, men with UMI were also at increased risk for dementia, stroke and cerebral 
small vessel diseases.16-19
Whether there is a common mechanism that engenders RMI and clinically UMI remains 
controversial.12 One theory suggests that the cardiac-pain mechanism is the main reason for the 
difference in the perception of the discomfort.20 A second theory suggests that various humoral 
and neurological factors together determine whether the symptoms arise from myocardial 
ischemia.21 Third, despite similar pathophysiology the size, location or duration of the myocardial 
ischemia could explain the absence of pain in UMI.10,14,21 There is a lack of empirical evidence to 
supporting any of the above theories and the reported long-term impacts of UMI on physical 
health suggests that differences in size and duration of ischemia are unlikely explanations. Finally, 
psychological factors regarding the recognition and willingness of the patient to seek medical 
attention have been discussed.12
To test the impact of RMI and UMI in the present study population, we first compared the 
association of RMI and UMI with mortality in men and women (note, mortality has been studied 
in a slightly different sample of the Rotterdam Study previously15). By definition, the awareness of 
having survived a life-threatening health event is absent in persons with UMI. This characteristic of 
UMI provides us with the opportunity to explore the potential role of psychological mechanisms 
underlying the relation between MI and depression, but only if the long-term impact can be 
established and if depression can be assessed independently of help seeking behavior. In this 
case our approach provides us with the unique opportunity to disentangle the pathophysiological 
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The main aim of our study was to determine the relation of RMI and UMI with depression in older 
persons. If MI would cause depression mainly due to psychological mechanisms, we would expect 
that individuals, who are unaware of having had an MI, are not at risk of developing depression. 
Indeed we hypothesized that RMI but not UMI is associated with an increased risk of depression.
METHODS
The study was part of the Rotterdam Study, a population-based cohort designed to study the 
occurrence and determinants of diseases.22 In 1990, all residents aged ≥ 55 of Ommoord, a 
district in Rotterdam, the Netherlands, were invited to participate. Informed consent to retrieve 
information from treating physicians was obtained from all participants. The medical ethics 
committee approved the study according to the Wet Bevolkingsonderzoek-Population Study Act 
executed by the Ministry of Health, the Netherlands.
In the Rotterdam Study, four examination rounds have taken place. In each round, participants 
underwent home interviews and subsequent physical examinations at the research center. 
During the second examination (1993 - 1995), 4 940 persons were interviewed for depressive 
symptoms. This round constituted the baseline for the current study.23 We excluded 461 persons 
without electrocardiography, due to technical problems, or lack of personnel to operate the 
electrocardiography device. Another 23 persons were excluded because they withdrew the 
informed consent. We excluded persons with a Mini Mental State Exam (MMSE) score of ≤ 26 
at baseline (N = 287)24, no valid information on the MMSE (N = 129), and bipolar disorder (N = 
3). In total, 4 037 participants were eligible with a valid electrocardiography and evaluation of 
depressive symptoms. These participants were followed from baseline to occurrence of major 
depression (MDD), death, loss to follow-up, or the end of the study (January 1st, 2010).
History of myocardial infarction
MI status was assessed as described in detail previously.9 In short, at the research center visit, a 
10-second 12-lead electrocardiogram was recorded using an ACTA Gnosis IV-electrocardiography 
recorder (Esaote Biomedica, Florence, Italy) at a sampling frequency of 500 Hz and sored digitally.
Electrocardiograms were processed by the Modular electrocardiogram Analysis System (MEANS) 
to obtain electrocardiogram measurement and interpretation.25 Two research doctors blinded for 
other clinical information validated the electrocardiograms selected by MEANS. The diagnosis 
of MI using MEANS is mainly driven by pathological Q-waves and auxiliary criteria, such as QR 
ratio and R-wave progression. ST-T changes were not considered as criteria for MI by MEANS, 
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A senior cardiologist, ascertained the final diagnosis of MI. Assessment of clinically RMI was 
done as previously reported.9 A history of RMI was defined by self-reported MI confirmed by 
clinical data (GP records, and Nationwide Medical Registry), and confirmed or not confirmed with 
electrocardiogram characteristics matching MI.9 A history of UMI included all participants without 
documentation or self-reported MI, but with electrocardiogram characteristics matching MI.9 All 
UMIs were therefore Q-wave MIs. Persons without indication of MI on electrocardiography and 
no medical documentation of an earlier MI constituted the reference group.9
Vital status
The information on vital status is collected continuously, on a weekly basis from the Central 
Register of Population of Rotterdam. The follow-up for mortality started from the assessment of 
depression until loss to follow-up or September 5th, 2013 (mean follow-up 13.9 years).9,15
Depression
At baseline, all participants were screened for depression with the validated Dutch versions of 
the Centre for Epidemiologic Studies Depression (CES-D) scale26, or the Hospital Anxiety and 
Depression Scale (HADS-D).27 The reliability of these questionnaires was tested formally: the 
Cronbach alphas were 0.82 and 0.83, respectively. The CES-D consists of 20 items related to 
assess depressive symptoms. All symptoms were self-rated on a 0-3 scale, dependent upon the 
frequency of the experienced symptom.28 Participants could score from 0 up to 60. The HADS-D 
consists of 7 items measuring depressive symptoms. Again, participants rated the symptoms on a 
0 - 3 scale. Standardized Z-score of the CES-D and HADS-D scores at baseline was used to control 
for the severity of depressive symptoms and adjust for pre-existing depressive symptoms.
During first and second follow-up assessments (at the examination rounds in 1997 - 1999 and 
2002-2004) the CES-D scale was used to determine depressive symptoms.
From 1993 till 2010, participants were followed for the occurrence of MDD, which was 
determined from two sources of information as described previously.23 At follow-up examinations 
all participants who scored 16 or above on the CES-D scale, were invited to the research center 
for a semi-structured clinical interview to diagnose depressive disorders. A trained clinician 
diagnosed depression according to the Diagnostic and Statistical Manual of Mental Disorders, 
4th revised edition (DSM-IV) by using the Dutch version of the Schedules for Clinical Assessment 
in Neuropsychiatry (SCAN).29 Second, medical records of general practitioners were continuously 
monitored for occurrence of an episode of MDD from baseline onward (mean follow-up 12.5 
years). Considering the information about possible MDD provided by the psychiatric interviews 
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chronologically occurred in one of the two data sources (note, all record retrievals were blinded 
for prior episodes). The occurrences inferred from the different data sources were consistent.23 
However, one assessment (SCAN) was repeatedly cross-sectional and the other assessment 
reflects continuous monitoring, thus such comparison must be interpreted carefully to account 
for the different assessment methods.
Covariates
Potential confounders were selected on the basis of prior knowledge.1,2 Marital status, education, 
smoking, and alcohol use were assessed at baseline during the home interview. Education was 
classified as low, intermediate, or high. Participants were classified as never married or divorced, 
married, and widowed. Smoking habits were classified as never, past, or current smoker and, 
similarly, alcohol consumption was classified as never, past, or current consumer. The MMSE was 
used to measure cognitive performance.24
Blood pressure was measured twice in the sitting position at the right upper arm with a random-
zero sphygmomanometer. The average of these consecutive measurements was calculated. 
Diabetes was considered present if fasting plasma glucose was 7.0 mmol/l or higher, non-fasting 
glucose or an oral glucose tolerance test result of 11.1 mmol/l or higher, or if the participant 
used blood glucose-lowering medication.30 A history of stroke was defined as a self-reported 
stroke verified by medical records.31 Height and weight were measured without heavy clothing to 
calculate body mass index (BMI).
DATA ANALYSIS
First we determined the relative mortality risk of participants with RMI and UMI using Cox 
proportional hazard regression analyses. These analyses were adjusted for age, level of education, 
smoking status, and alcohol consumption, history of stroke, diabetes, systolic blood pressure, 
and baseline depressive symptoms. Results of previous studies suggested sex difference in the 
prognosis of RMI and UMI.15 Also, the interaction term of history of MI with sex and mortality was 
statistically significant (p < 0.05). Therefore we stratified all analyses by sex.
Second, we studied whether RMI and UMI are associated with depressive symptoms with linear 
regression. The models were adjusted for baseline depressive symptoms in order to correct for 
pre-existing depression. Generalized Estimating Equation (GEE) approach was used to estimate 
the pooled effect of RMI and UMI on repeatedly assessed depressive symptoms. The interaction 
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All analyses related to the association between RMI/UMI and depressive symptoms were tested 
using two models. The first model was adjusted for age and baseline depressive symptoms. The 
second model was additionally adjusted for level of education, marital status, smoking status, 
alcohol consumption, BMI, history of stroke, diabetes mellitus, and systolic blood pressure.
Third, we assessed the association between RMI/UMI and MDD using Cox proportional hazard 
regression analyses. These analyses included two models with the same covariates in those 
testing depressive symptoms described above. The Breslow-Generalized Wilcoxon test was used 
to compare the hazard curves of RMI and UMI.
Multiple imputations were used in order to account for missing data on potential confounding 
variables. Smoking status was missing in 2.9%, marital status in 16.9%, BMI in 3.5%, alcohol 
consumption in 1.4%, systolic blood pressure in 1.5%, and education in 0.3% of the participants. 
All analyses were rerun in the complete case and five imputed data sets. In this paper we present 
results from the imputed data. All analyses were performed using IBM SPSS Statistics, version 21 
(IBM Corp., Somers, NY USA).
RESULTS
Baseline characteristics of 4 037 participants are presented in Table 1. The mean age of men was 
68.1 years (6.9 SD) and women were on average 68.5 years (7.7 SD). Of the men, 12.3% (N = 
220) had a RMI, 6.3% (N = 115) an UMI and 81.4% (N = 1 488) had no evidence of a MI. Of the 
women, 2.4% (N = 53) had had a RMI, 4.7% (N = 104) had had an UMI and 92.9% (N = 2 057) 
were free of MI. In total, 273 persons had a RMI, of these 138 had electrocardiography evidence 
of MI. The remaining 135 RMI cases were identified by clinical records and therefore represent 
non-Q-wave MIs.
First, we assessed the mortality risk of RMI and UMI (Table 2). In men, the average follow-up was 
13.1 years (23 846 person-years) during which 943 men died. RMI and UMI were associated 
with an increased risk of mortality: recognized MI (HR: 1.71, 95%CI: 1.45-2.03); UMI (HR: 1.58, 
95%CI: 1.27-1.97). In women, the average follow-up was 13.9 years (32 438 person-years) 
during which 825 women died. Women with RMI (N = 53) had a higher mortality risk (HR: 1.81, 
95%CI: 1.33-2.46). However, there was no association between UMI (N = 104) and mortality risk 
in women (HR: 0.99, 95%CI: 0.77-1.30).
Next, we studied the association between RMI and UMI and repeated assessments of depressive 
symptoms after a mean of 3.8 and 8.5 years The mean CES-D score at the first and second follow-
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Table 2. Recognized and unrecognized MI and all-cause mortality risk with Cox regression (N = 4 
037)
All-cause mortality
  HR (95% CI) p value
Men (N = 1 823)
Recognized MI (N = 220)
Multivariate adjusted* 1.71 (1.45;2.03) <0.001
Unrecognized MI (N = 115)
Multivariate adjusted* 1.58 (1.27;1.97) <0.001
Women (N = 2 214)
Recognized MI (N = 53)
Multivariate adjusted* 1.90 (1.39;2.61) <0.001
Unrecognized MI (N = 104)
Multivariate adjusted* 0.99 (0.77;1.30) 0.99
1 768 (943 men) of 4 037 person died during 56 284 person-years of follow-up.
* Multivariate adjusted: additionally adjusted for age, level of education, smoking status, Alcohol consumption, 
history of stroke, diabetes mellitus and systolic blood pressure.
In men (Table 3), RMI predicted higher scores of depressive symptoms at the first (B: 1.05, 95%CI: 
0.16-1.95) and second assessment (B: 1.29, 95%CI: 0.07-2.52). UMI was not associated with 
depressive symptoms at the first (B: 0.79, 95%CI: −0.34-1.97), or second assessment (B: 0.54, 
95%CI: −1.14-2.21). In the combined analysis of the two assessments, we observed that RMI (B: 
1.14, 95%CI: 0.07-2.21) but not UMI (B: 0.55, 95%CI: −0.51-1.62) was associated with more 
depressive symptoms. In women (Table 4), RMI was not significantly associated with depressive 
symptoms in the first (B: -1.37, 95%CI: −3.64-0.90) or in the second assessment (B: 1.48, 95%CI: 
−1.94-4.89). Moreover, there were no significant associations in the combined analysis of the two 
depressive symptoms assessments (B: -0.86, 95%CI: −3.13-1.42). UMI was not associated with 
depressive symptoms in any analysis. For this reason we restricted the additional analysis on 
occurrence of MDD in men only.
In an additional sensitivity analysis we explored the relation of RMI and UMI with the occurrence 
of MDD. Men were followed up for 11.8 years ± 4.71 SD (21 664 person years). In total, 52 
men (10 of those with RMI but only 3 of those with UMI) developed MDD during follow-up. We 
calculated occurrence of MDD during follow-up and cannot present point prevalence data. Men 
with a history of RMI were at increased risk to develop MDD (HR: 2.18, 95%CI: 1.04-4.57), but 
not those with an UMI (HR: 0.99, 95%CI: 0.77-1.30). The difference between the risk of RMI and 
UMI was statistically significant (p = 0.024).
We repeated the analyses (see Supplementary material 1) excluding RMI cases that did not meet 
electrocardiography criteria for prior Q-wave MI, to reduce possible misclassification and bias 
by person (over) reporting symptoms. In these analyses, the effect estimates were very similar. 
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DISCUSSION
Men with RMI or UMI had an increased mortality risk in this population-based study, as 
demonstrated previously.15 However, the risks of RMI and UMI for depression did not correspond 
to the mortality risks. Whereas men with RMI had an increased risk to develop depression, men 
with UMI were at similar risk to develop depression compared to persons without MI. In line with 
other studies, we confirmed a much weaker association between unrecognized MI and survival in 
women.8 This has been attributed to the increased likelihood of lead-placement artefacts due to 
breast tissue.32 Therefore, the results of the association between unrecognized MI and depression 
in women are hard to interpret.
A history of UMI conveyed a long-term increased risk of both depressive symptoms and MDD in 
men. Many studies of cardiovascular disease and depression focused on the prognostic value of 
short-term incidence of depression in patients shortly after the diagnosis of MI.2,33,34 One such 
study reported that patients with heart disease have 45% more depressive symptoms compared 
to those without heart disease.35 The long-term risk of psychological distress in post-MI patients as 
well as depression in patients with cardiovascular disease have previously been studied for follow-
up periods of 5-8 years.35,36 The present study addresses a period of 11 years after experiencing 
MI. In men, RMI was associated with an increased risk of MDD that remained elevated even over a 
long period. However, in men UMI was not associated with depressive symptoms or occurrence of 
MDD, although it was a risk factor for mortality. This discrepancy in the risks of UMI for mortality 
and depression, when compared to RMI, can be explained in multiple ways.
First, previous studies have suggested that patients with UMI may have less severe symptoms 
and mostly do not consult physicians.12,37 Others have argued that, the size of myocardial tissue 
damage underlying UMI may also be less severe.38 Yet, our study showed that in men, UMI was 
almost as predictive of mortality as RMI. This suggests that the underlying pathology is of equal 
severity.
Second, it is conceivable that the mortality risk of RMI and UMI are similar only due to the medical 
interventions and behavioral changes occurring after RMI. Successful treatment of RMI certainly 
decreases mortality risk.39 However, it is questionable whether treating MI successfully has a 
strong impact on the risk of depression.40
Third, depression may also be an adverse effect of the treatment of RMI. Patients with RMI are 
more often treated with interventions such as percutaneous coronary intervention to restore the 
coronary blood flow and the tissue perfusion.39 These procedures have been associated with 
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Also, drugs used for blood pressure and heart rate control, such as beta-blockers, may worsen 
depressive symptoms.39 However, we accounted for antihypertensive use and previous cardiac 
interventions at baseline to control for this effect.
Fourth, our results suggest that in men psychological factors contribute to the development 
of depression after MI. Although it remains difficult to disentangle psychological mechanisms 
from the pathophysiological mechanism underlying both MI and depression, we argue that 
psychological mechanisms are key to the different risk patterns of RMI and UMI in men. Due to 
improved clinical management of clinical MI, the survival has improved substantially, yet patients 
with MI often experience the event as life threatening.41 Further, frightening events impact not 
only the survivors health, but also theirs families and working life.42 These resulting lifestyle 
changes contribute to the psychological reaction following the MI experience and often resulting 
in depression.43 Clinical studies of MI patients demonstrated that the psychological distress related 
to health problems makes men particularly vulnerable to depression.36
We did not observe any relation between RMI or UMI with depressive symptoms in women. Only 
53 women but 220 men had RMI at baseline, thus our analysis were underpowered in women. 
Moreover, we found no relation between UMI and mortality in women, suggesting that this 
event does not signal pathophysiological change or that there is possible misclassification of UMI 
in women. Some studies reported a low accuracy of electrocardiography diagnostics in older 
women.32 In this light the association of UMI with both mortality and depression was consistent.
Depression is an established risk factor for coronary heart disease44 and may thus contribute to 
the occurrence of MI. Although we correct for baseline depressive symptoms, reverse causality 
could in theory influence the observed association between RMI and depression.45 The Rotterdam 
Study started with screening for depression during 1993, this assessment constitutes the baseline 
of our study and no prior assessments were conducted.
A limitation of our study is the possible misclassification of UMI. The definition of UMI heavily relies 
on the presence of pathological Q-waves, therefore most non-Q-wave MIs remained undetected. 
Second, electrocardiogram evidence of a previous MI can disappear over time.20 This again could 
lead to misclassification of UMI and thereby lower the effect estimates. Third, the known history 
of RMI might introduce assessment bias towards MDD diagnosis. In contrast, individuals with UMI 
have less specific symptomatology and mostly seek no medical care thus may avoid MDD medical 
diagnosis. However, the systematic approaches we used to ascertain events of MDD minimize the 
possibility of these biases.23 Forth, due to the observational nature of the study design presence 
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Our study has several strengths. It is based on a large well-described population-based cohort with 
a long follow-up. Data were gathered prospectively and without prior knowledge of MI status. 
Participants were monitored continuously during follow-up for the occurrence of depression and 
diagnoses were made by clinical interviews according to the DSM criteria. We used different data 
sources and approaches to collect and validate MDD.23
Furthermore, detailed information on RMI was collected and validated from the medical 
records of the participants.9 Importantly, when we restricted the cases with RMI to those with 
electrocardiography-verified changes (excluding those with clinical symptoms only) results did not 
change. This suggest that possible misclassification cannot explain our findings. Possibly, persons 
(over)reporting more symptoms (without pathology) do not account for the observed association 
and did not bias the effect estimates (see (Macleod et al., 2002) for example).46
In conclusion, RMI and UMI are both associated with a higher mortality risk in men. However, only 
man with RMI had a higher likelihood of depression during follow-up. Although pathophysiological 
differences between UMI and RMI may also explain this discrepancy, our results are consistent 
with the hypothesis that the psychological burden of experiencing MI contributes to the long-
term risk of depression after MI. We can only carefully speculate about clinical implication as 
future studies must confirm this results and the underlying mechanisms but our findings suggest 
that effective long-term prevention of post-MI depression should address the psychological 
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APPENDIX of CHAPTER 5.1

























Figure 1. Flow chart of study population. 
RS = Rotterdam Study, Roman numbers denote cohorts and Arabic numbers examination 
waves, e.g. RS I-3 = third examination round of the first cohort MMSE= Mini Mental State 
Examination 
 N = 7 808                       
Persons participated in the 
baseline examination of this 
study (RS I-3 and RS II-1) 
N = 7 533                       
Persons assessed for 
depression 
 
N = 275 excluded                          
Missing data: not screened for CES-D 
depressive symptoms 
 
N = 8 excluded                         
Prevalent bipolar disorder 
 
 N = 92 excluded                     
Prevalent dementia 
 
N = 7 433                 
Participants free from 
prevalent bipolar disorder and 
dementia 
 
N = 1 212 excluded                
Missing data: cognition assessed 
only with MMSE 
 
N = 6 221                             
Total sample in analysis of 
depressive symptoms with 
cognitive decline 
 RS=Rotterdam Study, Roman numbers denote cohorts and arabic numbers examination waves, e.g. RS I-3 = 








































242  |  Appendix 5.1
Baseline depressive symptoms analysis – Supplement 1.
Initial level and rate of change of cognitive functioning and single or multiple-episode depression 
using the Latent growth curve modelling (N = 6 221)
Conditional model Intercept Slope
Estimate S.E. p value Estimate S.E. p value
Depressive symptoms -0.080 0.01 <0.001 -0.007 0.01 0.18
Sex (female) 0.758 0.14 <0.001 0.180 0.07 0.015
Age -2.909 0.08 <0.001 -1.047 0.05 <0.001
Cohort -0.843 0.15 <0.001 0.098 0.08 0.28
Education 2.031 0.08 <0.001 2.043 0.08 0.028
Model fit indices: RMSEA* (95% CI) = 0.039 (0.037; 0.041); CFI** = 0.967
Fully adjusted model Intercept Slope
Estimate S.E. p value Estimate S.E. p value
Depressive symptoms -0.050 0.01 <0.001 -0.006 0.01 0.28
Sex (female) 1.081 0.14 <0.001 0.139 0.08 0.078
Age -2.665 0.08 <0.001 -1.022 0.05 <0.001
Cohort -0.827 0.15 <0.001 0.120 0.08 0.14
Education 1.954 0.08 <0.001 0.090 0.04 0.037
Body mass index -0.022 0.02 0.17 -0.013 0.01 0.15
Cancer 0.548 0.24 0.021 -0.138 0.14 0.31
Diabetes mellitus -0.858 0.29 0.003 -0.529 0.17 0.002
Stroke -1.523 0.36 <0.001 -0.433 0.26 0.09
Myocardial infarction 0.272 0.33 0.40 -0.04 0.19 0.83
Psychotropic therapy -0.555 0.18 0.002 -0.004 0.11 0.96
Cardiovascular therapy -0.156 0.14 0.27 -0.159 0.08 0.044
IADL 1.289 0.11 <0.001 -0.046 0.08 0.58
Smoking habits 0.327 0.08 <0.001 -0.032 0.04 0.43
Alcohol consumption 0.064 0.16 0.68 -0.050 0.10 0.60
Model fit indices: RMSEA* (95% CI) = 0.029 (0.027; 0.030); CFI** = 0.965
* RMSEA: Root Mean Square Error of Approximation **CFI: Comparative Fit Index;***IADL instrumental 
activity of daily living.
Unconditional Model
Estimate S.E. p value
Factor loadings of latent variable cognition at T1 (baseline)
LDST 1.000
VF 0.571 0.010 <0.001
STROOP -3.629 0.062 <0.001
MMSE 0.215 0.004 <0.001
Intercept and slope of latent variable cognition
Intercept  0.000 0.000 /
Slope -2.812 0.143 0.001
Model fit indices: RMSEA* (95% CI) = 0.041 (0.039; 0.043); CFI** = 0.967
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Stratified analysis in to the respect of cohort
Cohort 1 analysis

























Figure 2. Flow chart of study population within the RS-I 
RS = Rotterdam Study, Roman numbers denote cohorts and Arabic numbers examination 
waves, e.g. RS I-3 = third examination round of the first cohort MMSE = Mini Mental St te
Examination 
N = 4 797 
Persons participated in the 
baseline examination of these 
analyses (RS I-3) 
 
N = 4 601 
Persons assessed for 
depression 
N = 196 
Missing data: Not screened for 
depressive symptoms (CES-D) 
 
N = 2 excluded                         
Prevalent bipolar disorder 
 
 N = 75 excluded                     
Prevalent dementia 
 
N = 4 524                 
Participants free from 
prevalent bipolar disorder and 
dementia 
 
N = 636 excluded                    
Missing data: cognition assessed 
only with MMSE 
 
N = 3 888                             
Total sample in analysis of 
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Age, years, mean (SD) 71.3 (6.8) 72.9 (7) 71.9 (6.4)
Sex*, female, N (%) 1726 (54.9) 326 (65.3) 192 (78)
Highest education attained,
Primary, N (%) 474 (15.2) 90 (18.3) 49 (20.2)
Lower/intermediate, N (%) 1324 (42.5) 219 (44.5) 107 (44)
Vocational, N (%) 970 (31.1) 142 (28.9) 76 (31.1)
Higher, N (%) 348 (11.2) 41 (8.3) 11 (4.5)
IADL**, score, mean (SD) 17.7 (0.6) 17.6 (0.9) 17.5 (0.8)
Smoking habits,
Never smoker, N (%) 1043 (33.2) 186 (37.3) 91 (37)
Current smoker, N (%) 470 (15.2) 98 (19.6) 51 (20.7)
Past smoker, N (%) 1622 (51.6) 215 (43.1) 104 (42.3)
Alcohol consumption,
No consumption, N (%) 316 (10.1) 57 (11.4) 40 (16.3)
Current consumers, N (%) 2642 (84.1) 391 (78.4) 175 (71.1)
Past consumers, N (%) 185 (5.9) 51 (10.2) 31 (12.6)
Body mass index, mean (SD) 26.8 (3.9) 27.1 (4) 27.2 (4.1)
Cardio vascular medication, N (%) 1413 (45) 261 (52.3) 130 (52.8)
Central nervous system medication, N (%) 426 (13.6) 141 (28.3) 107 (43.5)
Cancer, N (%) 167 (5.3) 30 (6) 22 (8.9)
Diabetes mellitus, N (%) 136 (4.3) 24 (4.8) 12 (4.9)
Myocardial infarction, N (%) 106 (3.4) 24 (4.8) 5 (2)
Stroke, N (%) 109 (3.4) 22 (4.4) 14 (5.7)
Descriptive characteristics of study population were assessed at baseline. Values represent percentage (%), or 
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Table 2. Descriptive of cognitive performance tests measured over time for depression
Depressive episodes Cognitive test
Time point T1* T2* T3*
N Mean (SD) N Mean (SD) N Mean (SD)
Letter-digit substitution task
No depression 3088  27.9 (7) 2196 25.6 (6.8) 1127 25.1 (8.3)
Single episode 492 25.1 (7.4) 289 24.5 (7.3) 132 25.1 (11.4)
Multiple episodes 239 25.4 (6.5) 174 23.2 (7.1) 83 23.4 (10.2)
Verbal fluency test
No depression 3125 21 (5.4) 2264 20.4 (5.4) 1323 19.9 (6.4)
Single episode 497 20.1 (6.1) 302 19.8 (5.1) 140 19.3 (7.5)
Multiple episodes 245 20.4 (5.9) 184 19.4 (5.5) 91 18.5 (5.3)
Stroop test
No depression 3048 61.5 (29.1) 2069 64.1 (31.6) 1260 66.9 (35.1)
Single episode 481 68.8 (37.5) 273 69.7 (42.2) 133 69.5 (36.6)
Multiple episodes 239 65.7 (32.8) 165 73.8 (39.2) 88 74 (40.4)
The mini–mental state examination
No depression 3142 27.8 (1.8) 2329 27.5 (2.3) 1434 27 (3.4)
Single episode 499 27.4 (2.2) 336 26.9 (2.8) 154 26.6 (3.6)
Multiple episodes 246 27.5 (2) 200 27 (2.6) 108 26.6 (3)
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Table 3. Initial level (intercept) and rate of change (slope) of cognitive performance and late-life 
depression using the Latent growth curve modelling (N = 3 888)
Unconditional Model
Estimate                     S.E. p value
Factor loadings of latent variable cognition
LDST T1 1.000
VF T1 0.592 0.013 <0.001
STROOP T1 -3.947 0.088 <0.001
MMSE T1 0.235 0.006 <0.001
Intercept and slope of latent variable cognition
Intercept  0.000 0.000
Slope -3.020 0.132 <0.001
Model fit indices: RMSEA* (95% CI) = 0.043 (0.040; 0.046); CFI** = 0.965
Conditional model Intercept Slope
Estimate S.E. p value Estimate S.E. p value
Depressive episodes
No depression reference reference
Single episode -1.017 0.24 <0.001 -0.128 0.16 0.44
Multiple episodes -0.800 0.33 0.016 -0.661 0.21 0.001
Sex (female) 0.296 0.17 0.080 0.170 0.11 0.107
Age -2.608 0.08 <0.001 -0.850 0.06 <0.001
Education 1.988 0.10 <0.001 0.110 0.06 0.072
Model fit indices: RMSEA* (95% CI) = 0.038 (0.036; 0.040); CFI** = 0.965
Fully adjusted Intercept Slope
Estimate S.E. p value Estimate S.E. p value
Depressive episodes
No depression reference reference
Single episode -0.836 0.24 <0.001 -0.155 0.17 0.35
Multiple episodes -0.364 0.33 0.276 -0.718 0.21 0.001
Sex (female) 0.725 0.18 <0.001 0.105 0.11 0.357
Age -2.375 0.09 <0.001 -0.832 0.07 <0.001
Education 1.901 0.10 <0.001 0.116 0.06 0.058
Body mass index -0.011 0.02 0.61 -0.007 0.01 0.62
Cancer 0.571 0.34 0.605 -0.291 0.24 0.21
Diabetes mellitus -0.755 0.39 0.050 -0.533 0.27 0.049
Stroke -1.718 0.43 <0.001 -0.058 0.35 0.87
Myocardial infarction 0.600 0.46 0.19 0.112 0.29 0.70
Psychotropic therapy -0.613 0.22 0.006 0.283 0.15 0.065
Cardiovascular therapy -0.030 0.17 0.861 -0.262 0.11 0.016
iADL 1.258 0.13 <0.001 -0.002 0.10 0.98
Smoking habits 0.291 0.10 0.003 -0.052 0.06 0.38
Alcohol consumption 0.153 0.19 0.43 -0.077 0.14 0.72
Model fit indices: RMSEA* (95% CI) = 0.027 (0.025;0.029); CFI** = 0.964
Model 1: Unconditional model; Model 2: Conditional model; Model 3: Fully adjusted model. * RMSEA: Root 
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Cohort 2 analysis.

























Figure 3. Flow chart of study population within the RS-II 
RS = Rotterdam Study, Roman numbers denote cohorts and Arabic numbers examination 
waves, e.g. RS I-3 = third examination round of the first cohort MMSE = Mini Mental State 
Examination 
N = 3 011 
Persons participated in the 
baseline examination of these 
analyses (RS II-1) 
 
N = 2 932 
Persons assessed for 
depression 
N = 79 
Missing data: Not screened for 
depressive symptoms (CES-D) 
 
N = 3 excluded                         
Prevalent bipolar disorder 
 
 N = 17 excluded                     
Prevalent dementia 
 
N = 2 912                 
Participants free from 
prevalent bipolar disorder and 
dementia 
 
N = 579 excluded                    
Missing data: cognition assessed 
only with MMSE 
 
N = 2 333                             
Total sample in analysis of 
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Age, years, mean (SD) 63.6 (7.6) 64.6 (8.6) 64.1 (8.5)
Sex*, female, N (%) 1031 (52.1) 169 (67.1) 78 (75)
Highest education attained,
Primary, N (%) 140 (7.1) 32 (12.7) 8 (7.7)
Lower/intermediate, N (%) 879 (44.5) 121 (48) 52 (50)
Vocational, N (%) 596 (30.1) 54 (21.4) 35 (33.7)
Higher, N (%) 362 (18.3) 45 (17.9) 9 (8.7)
iADL**, score, mean (SD) 16.3 (6.3) 16.6 (5.3) 14.9(7.9)
Smoking habits,
Never smoker, N (%) 599 (30.3) 84 (33.3) 28 (26.9)
Current smoker, N (%) 372 (18.8) 59 (23.4) 31 (29.8)
Past smoker, N (%) 1006 (50.9) 109 (43.3) 45 (43.3)
Alcohol consumption,
No consumption, N (%) 168 (8.5) 31 (12.4) 11 (10.6)
Current consumers, N (%) 1703 (86.1) 198 (78.9) 82 (78.8)
Past consumers, N (%) 106 (5.4) 22 (8.8) 11 (10.6)
Body mass index, mean (SD) 27.1 (4) 27.1 (4.1) 28.2 (5.3)
Cardio vascular medication, N (%) 675 (34.1) 101 (40.1) 39 (37.5)
Central nervous system medication, N (%) 205 (10.4) 76 (30.2) 49 (47.1)
Cancer, N (%) 219 (11.1) 24 (9.5) 16 (15.4)
Diabetes mellitus, N (%) 116 (5.9) 30 (11.9) 8 (7.7)
Myocardial infarction, N (%) 106 (5.4) 10 (4) 10 (9.6)
Stroke, N (%) 44 (2.2) 16 (6.3) 6 (5.8)
Descriptive characteristics of study population were assessed at baseline. Values represent percentage (%), or 
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Table 2. Descriptive of cognitive performance tests measured over time for depression
Depressive episodes Cognitive test
Time point T1* T2* T3*
N Mean (SD) N Mean (SD) N Mean (SD)
Letter-digit substitution task
No depression 1948 29.9 (7.2) 1601 29.3 (7.9) 1209 28 (7.8)
Single episode 247 28.5 (7.2) 196 28.5  (7.2) 130 27.9 (6.5)
Multiple episodes 102 27.8 (7.8) 75 27.1 (7.2) 46 26.3 (7.3)
Verbal fluency test
No depression 1969 22.2 (5.4) 1624 21.2 (5.6) 1237 21.7 (6.1)
Single episode 250 22.3 (6.1) 200 21.6 (5.8) 134 22.7 (5.7)
Multiple episodes 102 21.3 (5.7) 77 20.7 (5.1) 47 20 (4.8)
Stroop test
No depression 1922 52.6 (23.3) 1454 54.5 (26.3) 1260 56.5 (26)
Single episode 249 57.1 (27.7) 182 58.5 (29.1) 132 53.3 (16.2)
Multiple episodes 101 56.1 (19.4) 66 62.5 (35.7) 48 56.8 (22.9)
The mini–mental state examination
No depression 1977 27.8 (1.8) 1669 27.7 (2.1) 1284 27.7 (2.4)
Single episode 252 27.7 (1.9) 210 26.5 (2.4) 140 27.6 (2.2)
Multiple episodes 104 27.4 (2.1) 87 26.5 (3.9) 51 27.3 (2.5)
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Table 3. Initial level (intercept) and rate of change (slope) of cognitive performance and late-life 
depression using the Latent growth curve modelling (N = 2 333)
Unconditional Model
Estimate                      S.E. p value
Factor loadings of latent variable cognition
LDST T1 1.000
VF T1 0.565 0.018 <0.001
STROOP T1 -3.161 0.093 <0.001
MMSE T1 0.208 0.007 <0.001
Intercept and slope of latent variable cognition
Intercept  0.000 0.000
Slope -2.075 0.131 <0.001
Model fit indices: RMSEA* (95% CI) = 0.040 (0.037; 0.045); CFI** = 0.974
Conditional model Intercept Slope
Estimate S.E. p value Estimate S.E. p value
Depressive episodes
No depression reference reference
Single episode -0.616 0.33 0.061 -0.026 0.15 0.87
Multiple episodes -1.619 0.50 0.001 -0.577 0.24 0.018
Sex (female) 1.330 0.22 <0.001 0.213 0.10 0.029
Age -2.526 0.11 <0.001 -1.057 0.06 <0.001
Education 2.039 0.13 <0.001 0.078 0.06 0.17
Model fit indices: RMSEA* (95% CI) = 0.037 (0.033; 0.041); CFI** = 0.973
Fully adjusted model Intercept Slope
Estimate S.E. p value Estimate S.E. p value
Depressive episodes
No depression reference reference
Single episode -0.106 0.33 0.747 0.039 0.16 0.80
Multiple episodes -0.865 0.50 0.083 -0.451 0.50 0.072
Sex (female) 1.465 0.22 <0.001 0.184 0.10 0.071
Age -2.280 0.11 <0.001 -1.034 0.06 <0.001
Education 1.951 0.13 <0.001 0.060 0.06 0.295
Body mass index -0.031 0.03 0.22 -0.017 0.01 0.16
Cancer 0.368 0.32 0.25 -0.040 0.15 0.79
Diabetes mellitus -1.092 0.41 0.008 -0.512 0.22 0.017
Stroke -1.460 0.63 0.021 -1.052 0.36 0.003
Myocardial infarction -0.080 0.46 0.86 -0.190 0.23 0.41
Psychotropic therapy -0.631 0.30 0.036 -0.304 0.14 0.035
Cardiovascular therapy -0.403 0.23 0.075 -0.045 0.11 0.674
iADL 1.339 0.21 <0.001 -0.112 0.12 0.36
Smoking habits 0.266 0.12 0.025 -0.003 0.05 0.95
Alcohol consumption -0.071 0.26 0.79 -0.003 0.13 0.98
Model fit indices: RMSEA* (95% CI) = 0.026 (0.024;0.029); CFI** = 0.973
Model 1: Unconditional model; Model 2: Conditional model; Model 3: Fully adjusted model. * RMSEA: Root 
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Table 2. Recognized and unrecognized MI and all-cause mortality risk with Cox regression 
(N = 3 940)
All-cause mortality
  HR (95% CI) p value
Men (N = 1 747)
Recognized MI (N = 144)
Multivariate adjusted* 1.99 (1.64;2.42) <0.001
Unrecognized MI (N =115)
Multivariate adjusted* 1.59 (1.27;1.98) <0.001
Women (N = 2 193)
Recognized MI (N = 32)
Multivariate adjusted* 1.97 (1.32;2.94) 0.001
Unrecognized MI (N =104)
Multivariate adjusted* 1.00 (0.77;1.30) 0.97
2 148 (1087 men) of 3 940 persons died during 55,170 person-years of follow-up.
*Multivariate adjusted: additionally adjusted for age, level of education, smoking status, alcohol consumption, 
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In this thesis I present evidence for the possible role of several biological factors and physical 
health problems in the aetiology of depression. The studies described in the previous chapters 
were performed mostly within the frame of the Rotterdam Study (RS), a prospective population-
based data-collection project. One of the studies in this thesis is a consortium based meta-analysis 
comprising eleven cohort studies from the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) consortium and another study comprises data from the Erasmus 
Rucphen Family Study. The details of the conducted research, methods, analysis, and results 
have already been described in detail. In this chapter, I would like to give an overview of the key 
findings and emphasize their possible clinical implications. Studying mental health diseases such 
as depression is a challenge and faces a series of concerns that were already discussed in some 
detail. In this chapter I will also elaborate on the most important methodological issues that I 
encountered conducting this work. Finally, I will conclude and describe some perspectives and 
strategies for future research.
Main findings
Potential biomarkers for depression
Clinically translatable biomarkers in psychiatry are crucial for efficient diagnosis, therapy, and 
prognosis of a psychiatric disease.1 Detection of biomarkers specific for depression is necessary for 
the psychiatric practice. Yet, validated clinically relevant biomarkers specific for depression have 
been very hard to identify.2 In other medical disciplines, such as endocrinology, conditions like 
diabetes mellitus3 are clinically diagnosed, predicted and the severity of the disease is defined by 
a well-established set of biomarkers. Unlike endocrinology, in psychiatry we lack such laboratory 
tools and non-invasive blood tests to diagnose and predict depression. All biological parameters 
that can be repeatedly measured with precision and are related to the occurrence of depression 
are considered potential biomarkers for depression.2 Yet, biomarkers could be factors that are 
causally related to depression or are good predictors of depression (Figure 1). They may also be 
biological markers that just allow a better discrimination between depressed and non-depressed 
patients, and thus constitute diagnostic biomarkers (Figure 1). Therefore, the full definition 
for biomarkers (biological markers) postulated by the World Health Organization includes any 
substances, structures, or processes that can be objectively measured in the body or its products 
and influence or predict the incidence of outcome or disease.4
Epidemiological longitudinal designs have a unique role in refining or rejecting causal hypotheses5 
on the relation of certain biological risk factors with depression. Longitudinal associations may 
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aetiological candidate markers, including blood extracted vitamin D serum levels (neuroendocrine 
factor), or three neuro-inflammatory markers (interleukin (IL)-6, alpha-1-antichymotrypsin (ACT), 
and C reactive protein (CRP)) are risk factors for depression.
In order to re-examine the extensively studied possible causal relation between vitamin D serum 
levels and depression, in Chapter 2.1 we addressed the association between these two factors. 
Both the cross-sectional and the prospective association between vitamin D serum levels and 
subsequent change of depressive symptoms or incident major depressive disorder (MDD) were 
explored. Few studies have tested these associations. Prior longitudinal analyses produced 
inconsistent results that were mostly explained by small sample size, incomplete definition of 
depression, confounding, and short length of follow-up.6-8 We observed no longitudinal association 
between vitamin D and depression after some of the limitations of previous studies, such as poor 
confounder control, were addressed. All authors should be careful when commenting on the 
presence or absences of causality, but our careful analysis sheds doubt on the causal relationship 
between vitamin D and depression. Yet, we observed a negative cross-sectional association 
between vitamin D and depression. Thus, we did speculate about a possible role of vitamin D 
serum levels as a biomarker of depression.
Biological factors need not be causally related to depression in order to be a biomarker for 
depression.2 A marker that differs between those with depression and those without depression 
need not to be involved in the causal pathway of depression to be a diagnostic biomarker (see 
Figure 1). To optimally establish a temporal relationship, the longitudinal design should include 
repeated assessments of the biomarker of interest over a significant period of time.9 Indeed, 
longitudinal designs such as the one we use, with a single measure of the biomarker at baseline 
are not ideal designs and are vulnerable to random measurement error.10 Moreover, the long 
follow-up (almost 12 years follow-up time in the current study) may additionally bias the results 
by introducing regression dilution bias.11 The longitudinal design we used is limited to determine 
the directionality of the association. Yet, I argue that the power of the cross-sectional analysis 
should also not be underestimated to capture two correlates. Vitamin D deficiency and depression 
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measurement error.10 Moreover, the long follow-up (almost 12 years follow-up time in the current study) may additionally bias the results by introducing regression dilution bias.11 The longitudinal design we used is limited to determine the directionality of the association. Yet, I argue that the power of the cross-sectional analysis should also not be underestimated to capture two correlates. Vitamin D deficiency and depression are unquestionably correlated but vitamin D does not have the role of a long-term risk factor for depression.  
             Pre-diagnostic and treatment period                                 Post-diagnostic and treatment period 
 
   
 
 











Biomarkers can be defined as biomarkers used before diagnostics and treatment initiation, and are classified 
as diagnostic, predictive, or moderators. Diagnostic biomarkers classify an patient with depressive disorder, 
predictive biomarkers determine overall likelihood of response/remission, and moderators determine 
likelihood of response/remission with a particular treatment. Mediators are biomarkers collected soon after 
tre tment initiation an  help predict over ll likelihood of response/remission. Long-term treatment resp nse 
biomarkers are factors that may also be indicative of ultimate outcome.
I doubt that vitamin D can be classified as a biomarker with clinical relevance for depression. 
Nowadays, depression is being diagnosed by self-reported depressive symptoms diagnosed by 
clinician’s criteria such as the DSM criterion.12 This nosologic method of depression diagnosis is an 
obstacle in further clinical validation of vitamin D as a predicting biomarker. Venkatasubramanian 
G. commented on biological factors with discriminating power but low or no predicting power: 
“If in heart research we look for characteristics that would help classify chest pain patients into 
those with and without coughing, we will get nowhere”.1 “On the other hand, testing specific 
enzymes elevations in persons with specific ECG changes compared to persons with no ECG 
changes is more informative and might bring more meaningful clinical discrimination”.1 In this 
notation, I rather see vitamin D deficiency as a biomarker of conditions such as skeletomuscular 
diseases, osteoporosis, increased risk of falls with subsequent fractures in patients with chronic 
psychiatric disease such as depression, than as a biomarker specific for depression.13
Biomarker research has focused and worked on identifying potential peripheral proteins of 
interest such as inflammatory markers.14 Tumor necrosis factor alpha (TNF-alfa), interleukin-6 
(IL-6), interleukin-1Beta (IL-1Beta), and C-reactive protein (CRP) are just some of the proteomic 
markers that have been associated with depression.14 In Chapter 2.2 we investigated both the 
cross-sectional and the longitudinal association between IL-6, alpha-1-antichymotrypsin (ACT), 
and CRP and depressive symptoms. As previously observed in other studies2,14, this study provides 
evidence for IL-6 and CRP as potential predictive biomarkers for depression. More specifically, we 
found that higher levels of IL-6 and CRP are longitudinally associated with incident depressive 
symptoms over five years follow-up. Even though many large epidemiologic studies reported 
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observed no cross-sectional association in our study. This may be attributed to the small-sample 
size of the current study. The absence of the cross-sectional association in this study suggests that 
IL-6 and CRP are measures of a process or a product of key pathophysiological stages that lead to 
depression (Predictive biomarkers see Figure 1).2
The fact that we observed a longitudinal but no cross-sectional associations between these 
inflammatory proteins and depressive symptoms may also indicate that the brain-response with 
subsequent depression precipitated by inflammatory proteins occurs only if this inflammatory 
stimulus is chronic/persistent; and does not occur in an acute and transitional response of 
the inflammatory system.18 Indeed, ACT is a known acute phase plasma protein. If depressive 
symptoms occurred as a response to the present acute inflammation, we would expect that 
elevated levels are associated with more depressive symptoms. However, we observed neither 
a cross-sectional or a longitudinal association between elevated levels of ACT and depressive 
symptoms. Earlier clinical studies reported elevated ACT in depression, for example among 21 
male depressed patients compared to healthy control subjects.19 However, this study was based 
on clinical samples of severe cases of depression (often with other comorbidities). Alternatively, 
ACT could be a less sensitive inflammation marker in the general population and signal early 
inflammation.
To conclude, the results of this study confirm the hypothesis of depression occurring rather in 
response to chronic/persistent and not to acute inflammatory processes. It could have been 
interesting to investigate whether persistently elevated inflammatory markers contribute 
the occurrence of depressive symptoms. However, the data to explore this question were not 
available. Yet, previously published reports show that persistent elevation of inflammatory markers 
contribute to the development of subsequent common mental disease such as depression.20
Depression is a syndrome with a high recurrence rate21, more than a well-defined disease. Also, 
depression describes a heterogeneous population including those that experience depressive 
symptoms once and those that suffer depressive symptoms persistently. The association between 
inflammatory markers and specific subgroups of depression such as those with persistent 
depressive symptoms has not been established yet. Therefore, we also tested whether IL-6, 
CRP, and ACT may also have the power to predict the persistence of depressive symptoms. We 
found that IL-6 and CRP are not only predictive of the occurrence of depressive symptoms but 
are also independent predictors of the persistence of depressive symptoms. Therefore, these 
inflammatory biomarkers may be not only meaningful predictive biomarkers of depression but it 
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Epigenetic findings
Peripherally measured proteins and vitamin D were not the only candidate biomarker of 
depression I investigated. Variations in a gene, set of genes, and other molecular factors are 
other potential diagnostic and prognostic biomarkers of depression.1 Depression is a complex 
multifactorial disorder substantially affected by both environmental and genetic factors.22 The 
genetic contribution to the development of depression has been estimated to be almost 40% and 
environmental and other factors contribute the additional 60%.22 However, the knowledge of the 
interacting processes between the genetic and environmental factors is incomplete. A few studies 
suggest that epigenetic mechanisms might play an important role in the pathophysiology of 
depression and capture the genetic environment interection.22-25 DNA methylation is an epigenetic 
mechanism in which methyl groups are added to the DNA as a response to an environmental 
or genetic influence. DNA epigenetic markers may play important role in the pathophysiology 
of psychiatric diseases but are also interesting targets for clinically translatable biomarker of 
depression (see Figure 2).1 Yet, the epigenetic method is a novel genomic tool and whether the 
epigenetic alterations can be used as a biomarker is not yet clear and must be carefully studied. 
In an intense collaborative effort, we studied possible epigenetic markers of depressive symptoms 
in a population-based setting.2
The aim of Chapter 4 was to study and map gene-environment interaction in depression by 
identifying epigenetic alterations associated with depressive symptoms. We performed the first 
and largest (N = 11 256) epigenome-wide association population-based study of depressive 
symptoms to date. We found three epigenetic markers associated with depressive symptoms 
(hypermethylation of cg04987734 annotated on the CDC42BPB gene; cg12325605 annotated 
on the ARHGEF3 gene; and cg14023999 an intergenic epigenetic marker. The genes on which 
these epigenetic marks are located, are known to be involved in the regulation of serotonin and 
dopamine levels in the brain26, sphingolipid metabolism27, and immune response22. Moreover, 
the gene pathway analyses of our findings have shown that these genes are involved in synaptic 
plasticity, inflammatory mechanisms, regulation of monoamine levels in the brain, axon guidance, 
and growth factor signalling. These are all mechanisms previously associated with psychiatric 
disorders including depression.22,28-30 Certain expression mechanisms of these genes, RNA 
transcription, protein function and structures, could also be involved in the pathophysiological 
mechanisms underlying depression.22 Indeed, RNA expression analysis within the frame of our 
study have shown that differentially expressed genes reveal one significant pathway; the immune 
system (more specifically, expression of these genes was involved in the adaptive immune system).
This study was performed within a multi-ethnic population based sample of approximately 11 000 
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discussed in Chapter 4. Here I would like to emphasize few considerations. Most importantly, 
the cross-sectional design of the study limits the interpretation of the associations. I speculate 
that that there are few possible ways to interpret these findings (Illustrated in Figure 2). First 
(Figure 2.(a)), blood DNA hypermethylation of cg04987734, cg12325605, and cg14023999 
may occur due to environmental influences, stress events, or early childhood trauma preceding 
the occurrence of depressive symptomes.22 Second (Figure 2.(b)), the epigenetic alterations 
may also be mediators of genetic risk for depressive symptoms. In this scenario, the epigenetic 
mark mediates the causal pathway from genes to depression. Many DNA methylation differences 
can be partially traced back to genetic variations, suggesting that differentially methylated CpG 
sites serve as evolutionarily established mediators between the genetic code and phenotypic 
variability.31 These epigenetic DNA imprinting’s may reflect genetic mechanisms such as silencing 
of the gene or gene expression22,32, that lead to depression. Third (Figure 2.(d)), depression itself 
could be the cause of the epigenetic changes. Via endocrinological, immune or other metabolic 
changes secondary to depression, methylation or demethylation of the DNA may occur.
These proposed pathophysiological mechanisms, however, could not be confirmed by the study 
presented in this thesis and describing both causality and the direction of causality should be a 
focus of future research. Finally, these epigenetic marks may not involve in the pathophysiological 
mechanism underlying or arising from depression and thus present “only” biomarkers of 
depression. The cross-sectional association between the epigenetic markers and depressive 
symptoms may also be confounded by large number of environmental factors (Figure 2.(c)). 
The analyses presented in this study were controlled for the effect of factors such as age, sex, 
smoking habits, and antidepressant medication. Yet, confounding by unmeasured environmental 
factors is possible. Therefore, if the association between the blood DNA methylation markers 
and depressive symptoms were explained by these unmeasured environmental factors, then such 
markers would present biomarker of exposure only.
Since we can only speculate about the directionality, this study is certainly only an indicator that 
blood methylation of the three identified CpG sites are a potential tool to discriminate individuals 
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Figure 2. Possible interpretations of the epigenetic epidemiologic findings. 
Genetic findings
Depression is a complex, heterogeneous, and common disease with modest heritability.22 A 
number of common single nucleotide polymorphisms were found to be associated with depression 
by DNA microarray-based whole genome-wide association studies (GWAS).33 However, it has 
been suggested that common variants have small effects and do not completely account for the 
heritability. Moreover, GWAS studies are non-informative of rare variants that outnumber the 
common variants.34 The next generation sequencing is a new method for identifying rare novel 
variants that might fulfil the genomic heritability gap.34 Rare variants in exonic or coding regions 
that affect protein function, are probably important for depression.34 Therefore, identifying rare 
variants opens new hopes for genetic research of depression and psychiatric research in general. 
In Chapter 3 we have performed exome sequencing studies to identify rare unknown variants 
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In Chapter 3.1 we performed the first large-scale population-based high-coverage exome 
sequencing study. We found a significant association of depressive symptoms with a rare variant 
(rs77960347-G; MAF = 1%, N (carriers) = 60; β = 7.2; p value = 5.2 × 10-08) on chromosome 18. 
The large estimated effect of this variant on depressive symptoms suggesting that each allele yields 
an increase of depressive symptoms by 7.2 points. Rs77960347 is a highly conserved missense 
variant in the LIPG gene (Asn396Ser). Moreover, it is predicted to be damaging (polyPhen = 
1) for the LIPG gene. LIPG is a gene predicted to be involved in enzymatic function in steroid 
biosynthesis, cholesterol biosynthesis and thyroid hormone metabolic processes.35 These results 
were replicated in three independent samples. Also, within the Rotterdam Study, we observed 
that carriers of such missense non-synonymous variant have a higher risk of Alzheimer’s disease 
and more white matter lesions.
The heterogeneity and the complexity of depression is a challenge that genetic research constantly 
faces.36 To overcome heterogeneity of depression, enlarging the studied sample sizes is widely 
used as a methodological strategy.36 Indeed, the number of common variants with small effects 
identified by GWAS associated with depression increases by expanding the sample size.37 To 
identify rare variants associated with complex trait such as depression large sample sizes are 
required, like in studies of common variants.34 Using isolated cohorts with less genetic variance, 
and similar environmental, and cultural characteristics is another strategy to overcome the 
limited power inherent to this approach.38 Rare variants accumulated in isolated populations can 
counterbalance problems of studying heterogeneity. Therefore, in Chapter 3.2 we performed 
exome-sequencing and exome-chip genotyping in a genetically isolated European population to 
identify rare variants associated with depressive symptoms. We found an association of a rare 
non-synonymous variant in the NKPD1 gene with depressive symptoms (the missense variant that 
showed the strongest association within the NKPD1 gene was rs75291769/exm1479956, p value 
= 2.5 x 10-04 with a frequency of 4.6% in the discovery sample). These variants explained 0.9% 
of the age- and sex-adjusted variance and 3.8% of heritability of depressive symptoms in the 
isolated population. Importantly, these results were replicated in the Rotterdam Study. The NKPD1 
gene is involved in the biosynthesis of sphingolipids that was earlier proposed as a therapeutic 
target for depression.39
These two studies are among the first studies to use exome-sequencing on a large scale with a 
specific aim to discover novel risk genes for depressive symptoms and therefore uncover pathways 
that lead to the development of depression. The strengths of this approach have already been 
discussed in the previous chapters. However, the interpretation of the achieved results has to 
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First, a question that arises when looking in to the results of these studies is whether the observed 
depression-associated rare variants are really depression specific. Psychiatric disorders have a 
great overlap in their genetic architecture and it is known that many of the genetic associations 
are common to all schizophrenia, bipolar disorder and depression.37,40,41 The studies performed 
in Chapter 3 were performed in a population-based setting where the prevalence of diseases 
such as bipolar disorder and schizophrenia are low (< 2%).42,43 Thus, we were not able to test 
the independence of the reported associations from other mental disorders. Yet, in Chapter 3.1 
we tested the statistical difference between carriers of the Asn396Ser variant and non-carriers 
and their risk of suffering Alzheimer’s disease. We observed carriers of the Asn396Ser variant 
to be more likely to suffer from Alzheimer’s disease compared to non-carriers. Adjusting the 
association between this rare variant and depressive symptoms for prevalent Alzheimer disease 
did not change the results. Therefore, we speculate that depressive symptoms could mediate 
the pathway between this Asn396Ser variant and Alzheimer’s disease but we cannot reject the 
possibility that this variant contributes to the development of Alzheimer’s as well, i.e. it has 
pleotropic effects.
Second, the rare variants may be population specific.34 Rare variants identified in isolated 
populations such as the one we study in Chapter 3.2, could be extremely rare in other populations 
or absent.44 We replicated the results of our studies in one population-based sample; however, 
the samples we used for replication have a similar ancestry. Thus, replication in a more distinct 
population sample than the discovery sample might be more appropriate.34 This issue challenges 
the generalizability of the results to other populations. Yet, we argue that rare variants need not 
be population specific since rare variants associated with other phenotypes such as Alzheimer’s 
disease were replicated across populations successfully.45
Third, even though we used high coverage sequencing in the study presented in Chapter 3.2 
Exome-chip sequencing is not capable in detecting rare variants with a minor allele frequency 
lower than 0,004%.46 Exome-sequencing captures only the exomes (~1% of the entire genome) 
and hence does not capture all rare variation in the genome and that can be achieved using 
whole genome sequencing. Further other kinds of variants e.g. structural variants cannot be 
reliably detected using exome-sequencing. Thus, we cannot exclude the possibility that other rare 
coding variants contribute to depression as well.
Taking all the limitations in to consideration, the results of these two studies present strong 
evidence that the identified rare variants in the LIPG and the NKPD1 genes are involved in the 
occurrence of depressive symptoms. Although the variants are rare among populations, the 
estimated effect on the risk of depression was meaningful. This suggests that we discovered new 
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Physical Health factors for depression
Living with chronic disability and disease such as cardiovascular disease or dementia is difficult, 
challenging, and decreases the quality of life significantly.47 These diseases develop slow, they 
are chronic, require constant treatment, and are perceived by the individual as life threatening.47 
In both, clinical and epidemiological settings high co-occurrence of such chronic diseases with 
depression was observed.48,49 Depression also often has a recurrent character and can take a 
chronic course. The relation between physical health problems and psychiatric disease is complex 
and the underlying biology is poorly understood. Whether depression is a cause or a consequence 
of other chronic conditions often remains questionable. Addressing the question of “the chicken 
or the egg” may help understand why depressed individuals have a substantial increased burden 
of diseases, physical disability, and mortality. An answer may improve BETTER management and 
therapy for depression.50 Moreover, studying the longitudinal relations between depression and 
diseases such as myocardial infarction and dementia may also elucidate the pathophysiology and 
provide clues to aetiological mechanisms. The Rotterdam Study setting allowed us to construct 
advanced longitudinal designs and address some of these questions. Therefore, In Chapter 5 we 
took the opportunity to study the impact of depression on neurodegenerative processes such as 
cognitive decline as well as the impact of chronic diseases such as myocardial infarction on the 
occurrence of depression.
In Chapter 5.1 we studied the longitudinal association between depression and cognitive decline. 
This subject was widely studied and produced contradictory results.49 Characteristics of depression 
like the age of first onset, chronicity, duration, number of episodes in the past may predict the 
longitudinal association between depression and subsequent cognitive decline. Therefore, we 
followed participants who experienced a single, multiple or no depressive episodes for their 
cognitive decline over, on average, 12 years to evaluate whether repeated episodes of depression 
predicted cognitive decline. The simple descriptive analysis showed that most persons experience 
cognitive decline over time in all the cognitive tasks irrespective of prior depression (See Table 2, 
Chapter 5.1 Mini-mental state examination). These results only confirmed the cognitive decline 
with aging. Moreover, we also observed that at baseline cognitive performance is worse among 
participants, who had had depression, compared to those with no past episodes of depression 
(See Table 2., Chapter 5.1). Next, we used three repeated measures of four different cognitive 
domains to construct a latent growth curve of cognitive change. With this advanced approach of 
modeling repeated measures we evaluated the course of cognitive decline. This approach accounts 
for the within-person and the between-person change in cognitive functioning over time and was 
additionally controlled for an extensive list of potential confounders such as age, sex, education 
and other life-style, demographic factors, and comorbidities that may affect the relation between 
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and cognitive decline are co-occurring conditions. However, our longitudinal analysis showed that 
depression contributes significantly to worse long-term cognitive performance only if experienced 
multiple times. Persons with single or those with no experience episodes of depression had similar 
cognitive decline.
This study provides evidence that only depression with a recurrent course contributes to a faster 
cognitive decline than the cognitive decline we normally experience due to aging. This is in line 
with studies that showed prominent neurological vulnerability among patients suffering recurrent 
depression.51,52 A previous study showed that persons with recurrent depressive symptoms 
have a higher risk of dementia and Alzheimer’s disease, reduce hippocampal volume, and are 
characterized by a cognitive deficit prodrome.53 We can only speculate that recurrent depression 
precedes cognitive deficits that eventually evolve into dementia or Alzheimer’s disease. Participants 
with prevalent dementia did not take part in this study. However, I argue that reversed causality 
could still explain our results. Dementia and Alzheimer’s disease are extremes that arise with 
minor cognitive deficits prior to the occurrence of depression. The baseline cognitive performance 
was lower among participants with multiple-episode depression compared to those with single-
episode or no depression across all cognitive domains. Indeed, there is a limited evidence that 
milder cognitive performance may precede the occurrence of consequent depression.54 However, 
such a scenario should be less likely since the tested models were corrected for baseline general 
cognitive performance. On the other hand, we were unable to explore whether trajectories with 
a steeper cognitive decline contributed to the occurrence of or the recurrence of depression. 
Overall, we conclude that depression and cognitive decline are comorbid conditions. Depression 
predicts a higher risk of worse long-term cognitive performance only if the experienced depression 
occurs multiple times.
In Chapter 5.2 we explored the long-term impact of experiencing health condition such as 
myocardial infarction (MI) on the occurrence of depression. We have contrasted the impact 
of a clinically recognized MI to that of a clinically unrecognized MI (without experience of any 
symptoms and absence of knowledge for the disease) on depression and compared both to the 
depression risk of persons with no MI experience. Comparing these three groups was an exclusive 
opportunity to distinguish the biological pathophysiological mechanisms behind the association of 
MI and depression from the psychological mechanism. The occurrence of depression in someone 
with an MI with a clear clinical presentation is the result of both psychological/reactive and 
biological/pathophysiological mechanism. In contrast, those having had a clinically unrecognized 
MI should develop depression only due to presence of a biological mechanisms linking MI to 
depression. We observed a discrepancy in the risk for depression among those with clinically 
recognized MI and those with unrecognized MI if compared to those without MI. We found that 
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contrast, men with unrecognized MI had similar risk to develop depression as those without MI. 
This suggests that in men the awareness of experiencing a life-threatening condition increased 
the risk of developing depression and not only the pathology related to MI. Interestingly, we 
did observe a similar impact of recognized and unrecognized MI on the mortality risk in this 
population. This confirms the serious pathophysiological impact both conditions had on the 
general health and life expectancy. Yet, clinically recognized and unrecognized MI seem to affect 
the mental health rather differently. We have to emphasize that due to low statistical power and 
possible measurement error we could not draw any conclusions from our data with regard to 
women. Thus, the evidence we provide should be interpreted carefully and is restricted to men.
In conclusion, Chapter 5 presents studies in which we see whether physical diseases are risk 
factors for the occurrence of depression and vice versa, how depression is a risk factor for the 
occurrence of physical diseases. More specifically, we provide evidence how MI contributes to 
the development of depression and how multiple-episode depression contributes to poor long-
term cognitive performance. The complexity of the interrelations between depression and its 
comorbidities requires well-designed epidemiological studies including repeated exposure and 
outcome measures to unravel bi-directional associations and the effect of chronic exposure. 
We have made an attempt to advance the epidemiological knowledge using epidemiological 
tools appropriate for the available data. Yet our results can only hint at the possible pathological 
mechanisms and factors that can help screen specific groups, or target to better manage or treat 
depressed individuals.
Methodological considerations
Analysing repeated measures in recurrent phenotypes
Traditionally, epidemiologists and statisticians advise that longitudinal population-based studies, 
even if observational, should be cautiously interpreted when referring to causality. Yet, recently 
advanced methodological tools have opened the possibility of a deeper and more complex 
understanding of disease initiation, course and progress. These methods were developed jointly 
by statisticians, social scientists, and epidemiologists to allow the possibility to disentangle the 
causal relationship between exposures and disease.5 As a result, we now have new and more 
diverse types of approaches to consider when analysing data beyond the traditional epidemiologic 
analyses.
The Rotterdam Study has a unique way of assessing depression, previously described in detail 
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rounds (on average every 4 to 5 years). In addition, to learn about the course of the disease 
and capture events that might have happened between examination rounds, we performed 
continuous monitoring for depression during 12 years of follow-up. This assessment strategy 
allows individuals to be followed for the course of the disease, the index occurrence of the 
observed events; but it also allows individuals to be assessed for the severity of the depressive 
events. The severity of the experienced depression (from depressive symptoms to MDD) was 
defined by well-specified and sensitive questionnaires, interviews, and information collected from 
general practitioners (GP) medical records. This approach is an attempt to assess mental disorders 
such as depression; disorder with a remitting course across time, and characterized duration and 
severity, in more detail. The Rotterdam Study depression data allows to conceptualize depression 
as both episodic (counting episodes of the disorder that occur over time), and persisting (to define 
whether the disorder persists across time or not), and finally to distinguish between different 
degrees of severity within a population-based sample. Most longitudinal designs on depression 
have limited validity37 due to the fact they conceptualize depression either by severity or by 
persistence only, but never combine or compare the two aspects. Our complex data avoids such 
limitation, yet collecting such a rich data is challenging and may introduce a number of limitations 
and obstacles that should be discussed.
In Chapters 2.1 and 5.2 two studies with almost identical study design are presented. We test the 
longitudinal association between an exposure of interest measured at baseline and depression as 
an outcome. In order to test the change of the depressive symptoms over time I used repeated 
measures of the outcome at a regular time points (two re-assessments). Such repeated measures 
of the outcome are correlated with each other and such correlation need to be treated cautiously. 
I used Generalized Estimating Equations (GEE) model.55 This model is more advanced than a 
traditional linear regression model and estimates a marginal population averaged effect that 
takes into account the within-subject correlation by using a covariance matrix.55 Our depressive 
symptoms data are balanced data and therefore such a method is appropriate. However, GEE is 
a marginal model and no conclusions about individual patterns can be drawn, especially patterns 
that occur across time such as trajectories.55 Indeed, depressive symptoms are not a normally 
distributed outcome variable and this may bias the within-subject correlation. To estimate the 
individual change of depressive symptoms across time we could have better used conditional 
model such as the generalized linear mixed model (GLMM).56 Conditional models are a more 
fundamental approach and estimate a random effect while holding other covariates constant. 
Also, from the estimated random effect we can easily draw conclusions about the population 
effect, which is estimated by the GEE models; but from the GEE model we cannot estimate the 
individual effect.56 Moreover, linear mixed models treat loss to follow-up more flexible than GEE 
models. GLMM are evidently better approach to analyse our data. However, the marginal GEE 
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Longitudinal analyses are considered biased if they do not take into account the duration of 
follow-up. Thus, in addition to the GEE analyses we estimated the survival risk using a Cox 
regression model.57 When compared to the GEE model, the Cox survival model takes into account 
time but does not fully address the course of the depressive disorder. Moreover, the survival 
model was used to estimate the effect of a one-time measure of the exposure at the baseline of 
the study. Such an approach is an important limitation given the type of exposure that changes 
over time such as vitamin D (Chapter 2.1).58,59 Therefore, I argue that longitudinal associations 
between exposure and outcome, both changeable across time, and with complex interrelations; 
should be tested by advanced models that would address this issue. Joint models where the 
exposure using GLMM and the outcome using Cox model with time varying exposure are possible 
solutions.60
In Chapter 2.2 we estimated the 5 year risk of increased depressive symptoms in persons with 
inflammatory measures such as CRP. Traditional linear and logistic models were used to analyse the 
longitudinal association between an exposure assessed at baseline and an outcome assessed at a 
fixed follow-up time. In order to test whether persistence of depressive symptoms can explain this 
longitudinal association we combined the baseline measure of the outcome depressive symptoms 
and defined persistence, as clinically relevant depressive symptoms at baseline and at follow-up. 
We tested both whether inflammatory factors were related to worsening depressive symptoms 
and persistent depressive symptoms. However, such model is incomplete and does not answer 
the question whether more depressive symptoms also increase the risk of increased inflammatory 
markers at follow-up. Prior depression and reverse causality may bias the reported results. Ideally, 
if data of two inflammatory markers assessments and depressive symptoms were available, we 
could have used cross-lagged structural equation modelling and address the directionality of the 
association and reduced the potential bias of reverse causality.61
Chapter 5.1 of this thesis uses a contemporary statistical method to estimate the contribution 
of depression to the long-term course of cognitive functioning using the latent growth curve 
modeling.62 First, in order to conceptualize depression as episodic disorder, the exposure of 
interest, we used repeated measures of depression. Second, in order to estimate individual curves 
of cognitive decline over 12 years’ time (the outcome of interest) we used repeated measures 
of four tests of cognitive functioning. Finally, to estimate the risk of a faster cognitive decline 
among persons with multiple episodes, a single episode compared to no episodes of depression, 
we regressed the exposure on the estimated latent growth curve of cognitive decline. This design 
appears ideal, however it was limited by a small overlap of the depression and the cognitive 
functioning assessments (see Figure 1, Chapter 5.1). Thus, our results only partially explain how 
the course of depression could predict the course of cognitive functioning. Most of the studies 
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(i.e. the periods of depressive symptoms and cognitive decline assessment overlap). The limitation 
of such a design increases the likelihood of reverse causality. Mixed modelling with depression 
assessment prior to the cognitive curve would be a possible solution to avoid this limitation of our 
design. One study assessed a trajectory of persistent depressive symptoms prior to the cognitive 
functioning assessments to avoid this limitation.63 However, such a design also has limitations as 
it might introduce bias by immortal time.64
The above-mentioned more advanced statistical methods would ideally fill the gaps and 
limitations of the traditional analysis we performed in this thesis. However, such analyses require 
data that were not yet available within the Rotterdam Study. Longitudinal cohort studies are 
time consuming and expensive designs. Financial and other methodological obstacles (such as 
data cleaning) sometimes result in incomplete measurements in a particular examination round. 
My decisions in terms of statistical designs were mostly based on the available data. Finally, we 
should also consider that advanced methodologies have difficult computations (require certain 
fits, are dependent on number of assumptions), require big sample sizes, and are mostly difficult 
to interpret. They are also a formidable challenge for PhD students; however, mastering these 
techniques certainly improves academic career prospects.
Time varying confounding
Population-based studies use observational data to study associations while trying to address 
causal questions. One of the fundamental problems of these studies is confounding bias. 
Confounding bias is a bias introduced by all factors considered to be common causes of both 
the exposure and the outcome of the study.65 Defining which are the factors that may bias 
the association between the exposure and outcome, to be addressed as potential confounders, 
requires prior knowledge on the causal assumption. In this thesis we control for confounding by 
using baseline adjustment. Based on prior knowledge we typically included all factors that may 
be related to both exposure and outcome in the tested model. This approach constitutes the most 
basic statistical method for treating confounding and it is called analysis of covariance.66
The Rotterdam Study has extensive measures of demographic, life-style and health factors 
across time. Therefore, this prospective cohort design allows us to adjust for numerous potential 
confounders and minimize the risk of residual confounding by unknown or unmeasured 
confounding. Yet, what remains a serious concern in using this methodology is omitting the 
effect that time-varying factors have on the observed association. For example, in the tested 
vitamin D depression association in Chapter 2.1 vitamin D is an exposure that is time varying and 
change of the exposure over time may have been caused by confounder factors. In the case that 
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the outcome the association may be biased. Due to limited data (repeated measures of vitamin D 
were not available in the Rotterdam Study) we could not account for time-varying exposure and 
confounding.
Ideally, we could have avoided time-varying confounding by using the methodology of inverse 
probability weighting and the Marginal Mixed models.66 As previously suggested, using Joint 
models are another strategy to treat both repeated measures of time-varying exposure and 
outcome under one model.60 These methodologies are more advanced and allow to test the 
interrelation and interaction between exposure and time. Such methods are also appropriate for 
recurrent outcomes and may answer potential causal relations better than traditional designs. 
However, as already discussed it is not always possible to implement such methods. Moreover, 
using such methods may also produce biased results. For example, similarly to traditional models 
they do not account for unmeasured confounding.
Broad phenotype of depression
Depression is a heterogeneous disease, and no established mechanism, risk factor, or features of 
the disease can explain all the aspects of this disorder. In my opinion, the biggest challenge of 
the work presented in this thesis and in psychiatric research in general is the definition and the 
characterization of the depressive phenotype. The question whether depression should be studied 
as a broad continuous phenotype (depressive symptoms) or as the narrow DSM-classification 
based phenotype of depression is what I have been asking myself most often. Indeed, the 
scientific world knows an endless discussion over the most appropriate depression phenotype 
to be used in research. This dilemma has not been solved yet and the decision to use one or the 
other depression phenotype brings advantages and disadvantages that should be discussed.
In epidemiologic research, both depressive symptoms phenotype but also DSM-categorizations 
phenotypes are widely used. The Rotterdam Study, as already discussed, performs assessment 
of both phenotypes; screening for depressive symptoms and establishment of DSM-criterion 
based depression diagnosis among those with clinically relevant depressive symptoms. Using the 
broad phenotype of depressive symptoms has helped identify numerous associations. Depressive 
symptoms were found to be associated with number of demographic factors67, comorbidities68, 
life style factors69, biological markers70, increased risk of disabilities71, chronic diseases72, and 
mortality73. Moreover, the recently developed neuroimaging technology has enabled us to 
relate depressive symptoms to various structural and functional brain measures.74-76 Obviously, 
epidemiologic research profited from using such a broad phenotype. Depressive symptoms are 
meaningful on the population-based level and for public health purposes in general. However, 
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Therefore, many population-based studies have attempted to study DSM-categorized diagnosis 
as their depression phenotype of interest. This work showed success as well and replicated 
almost all associations reported with depressive symptoms.77 For example, structural brain 
changes associated with MDD were also found to be associated with even mild depressive 
symptomes.75,77 In two of the studies we also observed consistent results regardless of the used 
depression phenotype (Chapter 2.1 and 5.2). However, we have to emphasize that assessment 
of DSM-categorized depression phenotypes within population-based studies is challenging. It 
requires more complicated semi-structured psychiatric interviews or/and retrieval of GP records 
data. Compared to this approach, screening questionnaires are easily assessable, cheap and more 
simple. Moreover, the prevalence of cases with depressive symptoms is much higher (around 
10 - 29%) than the low prevalence of MDD cases (around 6%) in population-based studies.77,78 
Therefore, the likelihood of detecting associations with low effect decreases when using DSM-
categorizes depression phenotypes and requires larger sample sizes although this may be partly 
counterbalanced by smaller effects if clinically relevant depressive symptoms are used as a 
categorical outcome.
In genetic-epidemiology research, however, we are not so successful in identifying associations 
and we are certainly far from replicating results using different phenotypes of depression as 
in non-genetic epidemiologic research. Early Genome wide association study (GWAS) failed to 
identify single nucleotide polymorphisms in association with MDD in almost 9 000 participants.79 
It was suggested, that the potential for discoveries in genetics is likely to increase if we use 
more broad and heterogeneous samples of depressive phenotypes without exclusions based on 
the DSM-diagnostic criteria and without constraining their measurement to consensus based 
categorize.37 Therefore, following GWAS investigated the depressive symptoms phenotype in 
30 000 individuals.80 However, this study also failed to identify genome-wide significant genetic 
associations. Genetic studies are based on the assumption that studying heterogenic, polygenic, 
complex, and common phenotypes such as depression requires studying bigger sample sizes or 
lowering the heterogeneity in order to find significant genetic associations.33,77 Indeed, restricting 
the definition of depression to a more severe type of recurrent disorder helped in identifying 
two genetic loci.33 Also, combining the phenotypes MDD and depressive symptoms to increase 
power at the expense of heterogeneity to detect loci associated with depressive symptoms.81 
However, such an approach may not unravel the effects of SNPs associated only with one 
phenotype, and therefore produce biased results towards the genetics of a broad phenotype.33 
Finally, the most successful published GWAS so far, by 23 and Me, identified 15 loci by using mild 
MDD phenotyping from a self-report of diagnosis.82 Although this phenotype strategy brought 
success in identifying depression associated SNPs, the possibility of misclassification bias is likely.33 
Therefore, using the most appropriate phenotype of depression in genetic research is crucial and 
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It is sometimes assumed that a smaller number of genes will be involved in the causality of 
more severe depressive illnesses than in depressive symptoms. Also, some genotype variations 
should be related to a specific subtype of depressive illness only.37 Thus, we may expect that the 
identified genetic loci of studying depressive symptoms and MDD will differ but a considerable 
overlap. Indeed, such overlap is likely and a recent GWAS has proven that by replicating genetic 
association between depressive symptoms and the FHIT gene in an independent sample of MDD 
cases.83 Yet, the rare variants located on the LIPG and NKPD1 gene (Chapter 3) we identify 
as associated with depressive symptoms may not be relevant to MDD or other more specific 
depression phenotypes. But that does not mean our results are biased or wrong.
In conclusion, epidemiology benefited from using broad depression phenotypes but these findings 
typically replicate when DSM-criterion based phenotypes were used. Whether we choose to use 
one or the other phenotype should mainly depend on the research question. Genetic research 
on the other hand, still attempts to learn which phenotype choice will bring success and, even 
more important, accurate results. So far it seems that combining phenotypes and using more 
flexible measures allows identifying more genetic associations. However, whether such findings 
have important theoretical meaning for an in-depth understanding of depression is questionable.
The depression phenotype issue was probably a good motivation for The National Institute of 
Mental Health (NIMH) to develop new criteria for research; the research domain criteria (RDoC).84 
The RDoC is a matrix based approach structured by specified functional constructs characterized 
by genes, molecules, cells, circuits, physiology, self-report, and paradigms. The constructs are 
finally grouped into five higher-level domains of functioning (negative valence systems, positive 
valence systems, cognitive systems, systems for social processes, and arousal/regulatory systems). 
The main aim of the RDoC is to provide an attempt for a deeper understanding of the biological 
and psychosocial basis of psychiatric disorders but also to help to improve current classification 
systems.77 Such an approach opens new possibilities for psychiatric research in general and may 
solve the current phenotyping issues.
Future perspectives and implications
Most of the suggestions for future research perspectives for and clinical implications of the studies 
included in this thesis were already discussed in the earlier sections of this discussion. However, 
here I would like to summarize and emphasize some of the most important points and draw a 
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The projects included in Chapter 2, Chapter 3, and Chapter 4 all provide evidence on biological 
factors related to depression. Vitamin D, inflammatory markers, blood DNA epigenetic markers, 
and the rare variants of the LIPG and NKPD1 gene are biological factors that may be used as 
biomarkers for depression. The reported studies suggest these biological factors as potential 
diagnostic markers of depression that might help differentiation between depressed and non-
depressed persons. However, future epidemiologic studies should prove their clinical validity and 
translate results to clinical practice. Moreover, some of these factors (for example the studied 
inflammatory markers IL-6 and CRP) could be used to identify specific subgroups of depressed 
individuals, for example individuals with persistent depression. They may therefore provide better 
screening of depressed individuals for specific subtypes and help to target more successful 
treatment for depression.
The studies presented in Chapter 2.1 and 5.2 have limited clinical implications. Both vitamin 
D serum levels and unrecognized MI are not related to the occurrence of depression. They may 
help targeting specific groups of individuals suffering from chronic diseases and conditions; 
for example, detecting depressed patients with lower vitamin D serum levels for osteoporosis 
preventing strategies. However, I doubt their clinical meaning as depression specific biomarkers.
The presented evidence is population-based; therefore, it is more relevant to populations than 
clinical samples. Policy makers can use these reports as direction for making future public 
health policies and strategies to improve people’s general health and quality of life. Yet, these 
studies also provide evidence for biological associations (for example between certain genes and 
depression) that have theoretical importance and may guide future basic research, which will 
hopefully confirm their clinical relevance and practical use.
In terms of future research perspectives, the literature lacks prospective studies with repeated 
measures of both depression and its determinants. Such designs will allow studying interrelations 
between depression and exposures of interest as well as address direction of the relations. Also, 
repeated assessment data will allow using more advance statistical methodology and thus yield 
more valid results.
Moreover, future psychiatric research should certainly address poly-causation by considering 
multiple genetic and environmental measures. Depression is a common disease, often with an 
adolescent first onset, and with a high prevalence through the entire life span. Elderly cohorts 
studying aging such as the Rotterdam Study are limited in studying first onset, childhood 
exposures, and life-course of depression. Exploring such a retrospective hypothesis within 
these setting is inaccurate and would produce biased results. Therefore, future epidemiological 
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Genetics is a field that has evolved and developed rapidly in the last years and scientists had high 
hopes that genetics will disentangle many mysteries. However, psychiatric genetics faced several 
challenges when studying depression: the definition of depressive phenotypes appeared to be the 
greatest obstacle for the scientists. In the future we will have to agree on concepts and definitions 
of the depressive phenotype and be open for implementing new concepts in psychiatric research 
such as RDoC.84 I believe overcoming the issue of defining depression will help genetic research 
but also the scientific knowledge of depression in general.
Finally, depression is a multifactorial disorder and in order to deeply understand the aetiology 
we need to address gene-environment interactions. Analyses of poly-causation including gene-
environment and environment-environment interactions can help in learning more about causal 
types and mechanisms that are also likely to generate new methods of prevention and therapy.37 
Yet, current studies of gene-environment interactions are flawed due to the lack of power and 
biological understanding.
In conclusion, this thesis uses epidemiologic and genetic tools to explore the associations between 
potential aetiological factors and depression. We have managed to partly fill a few of the many 
gaps in the knowledge of the pathophysiological mechanisms underlying depression and the 
biological markers for depression. Further, I have discussed the clinical importance of the findings 
in this thesis, as well as the methodological challenges I have faced during this work. Most of 
the evidence presented in this thesis will not directly influence clinical practice and the life of 
those suffering depression. However, I believe that this body of research will definitely be a good 
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SUMMARY
Depression is a complex multifactorial disease, it is the result of an interaction and accumulation of 
various different psychosocial, biological and environmental risk factors. Evidence on the aetiology 
of depression is mixed and important elements are still missing. In this thesis, we attempted to 
fill some of these knowledge gaps by studying the association of several biomarkers, genetic, 
epigenetic, and physical health factors with depression. Here we summarize the main findings 
that have been described in detail in chapters 2 to 5.
Chapter 2 presents two studies exploring the relation between serum extracted biomarkers and 
depression. In Chapter 2.1, we studied the cross-sectional and longitudinal relation between 
vitamin D serum levels and depression. All analyses were controlled for life-style factors, including 
sunlight exposure, socio-demographic factors, and general health factors. Although vitamin D 
deficiency co-occurred with depression, we found no evidence for an effect of vitamin D serum 
on the change in depressive symptoms or the long-term (12 year) occurrence of depression. In 
Chapter 2.2, we explored serum levels of inflammatory biomarkers in relation to depressive 
symptoms with a specific focus on the effect of inflammation on the persistence of depressive 
symptoms. Markers of inflammation, such as higher levels of interleukin-6 and C reactive protein, 
predicted both increase and persistence of depressive symptoms over 5 years. In contrast, markers 
of inflammation were not associated with depressive symptoms cross-sectionally. These results 
suggest that depression does not occur as an acute response to inflammation but rather as a 
reaction to chronic inflammation.
Chapter 3 employed exome-sequencing and exome-chip genotyping methodology to explore 
rare genetic variants that potentially had large effects on the risk of depression. In Chapter 3.1 
we demonstrated that depressive symptoms were associated with missense Asn396Ser mutation 
(rs77960347) located in the endothelial lipase (LIPG) gene in a general population setting. 
Chapter 3.2 identified rare non-synonymous variants located in the NKPD1 gene associated 
with more depressive symptoms in a genetically isolated European population. The LIPG and 
the NKPD1 genes are candidate genes for depression that require further genetic and functional 
investigation.
Chapter 4 presents the largest (N = 11,256) cross-ethnic epigenome-wide association study 
(EWAS) of depressive symptoms. Hypermethylation of cg04987734 (annotated to the CDC42BPB 
gene), cg12325605 (annotated to the ARHGEF3 gene), and cg14023999 (having an intergenic 
position) were all associated with depressive symptoms. The identified genes are involved in 
mechanisms such as axon guidance, nerve growth factor, regulation of serotonin and dopamine 
levels in the brain, and inflammation, yielding new insights into the molecular mechanisms 
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In Chapter 5 we explored the relation between depression and comorbid physical conditions 
such as cognitive decline and myocardial infarction. In Chapter 5.1 we tested whether cognitive 
function declines faster in older adults who had single or multiple depressive episodes than in 
older adults with no depression. We found that persons with multiple episodes of depression 
had a faster cognitive decline over a 12 years’ period than persons with a single or no depressive 
episode. This study suggests that the recurrence of depression, opposed to a single episode, 
contributes to subsequent cognitive decline. Chapter 5.2 aimed to distinguish the physiological 
and psychological impacts from myocardial infarction on depression. Therefore, we explored the 
risk of recognized (RMI) and unrecognized myocardial infarction (UMI) pose for depression. The 
results demonstrated that men with RMI had an increased risk to develop depression, while 
men with UMI were at similar risk to develop depression as persons without MI. However, RMI 
and UMI increased mortality risk similarly compared to those with no MI. We thus concluded 
that both RMI and UMI have evident physiological effects but that the psychological burden of 
experiencing MI contributes to the long-term risk of depression.
Finally, Chapter 6 of this thesis discusses the main findings and elaborates on the main 
methodological limitations of the presented work. In addition, this chapter gives an overview of 
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SAMENVATTING
Depressie is een complexe, multifactoriële ziekte die ontstaat door interactie tussen, diverse 
psychosociale, biologische en omgevingsfactoren. Hoewel er meer en meer bekend is over 
depressie, is de etiologie van depressie nog altijd onduidelijk. In dit proefschrift probeer ik 
enkele lacunes in kennis over de etiologie van depressie in te vullen door het bestuderen van 
de relatie van depressie met verschillende biomarkers, genetische, epigenetische en fysieke 
gezondheidsfactoren. De belangrijkste onderzoeksbevindingen van dit proefschrift zullen hier 
worden samengevat, een gedetailleerde beschrijving kan gevonden worden in de hoofdstukken 
2 tot en met 5.
Hoofdstuk 2 omvat twee studies die de relatie tussen depressie en serum biomarkers 
beschrijven. In hoofdstuk 2.1 bestudeerden we de cross-sectionele en longitudinale relatie 
tussen de concentratie van vitamin D in serum en depressie. We corrigeerden daarbij voor een 
uitgebreid aantal lifestyle factoren (waaronder blootstelling aan zonlicht), socio-economische en 
demografische factoren, en algemene gezondheidsfactoren. Alhoewel vitamine D deficiëntie 
vaak samen gaat met depressie, vonden we geen bewijs dat de vitamine D concentratie de 
verandering in depressieve symptomen beïnvloedt, noch dat vitamine D de ontwikkeling van 
depressieve episoden op de lange termijn (12 jaar) beïnvloedt. In hoofdstuk 2.2 onderzochten 
we de relatie van verschillende biomarkers voor inflammatie met depressieve symptomen, we 
richtten ons daarbij specifiek op de persistentie van de depressieve symptomen. Biomarkers van 
inflammatie, zoals verhoogde interleukine-6 en C reactieve proteïne waarden, voorspellen zowel 
de toename als de persistentie van depressieve symptomen over een periode van 5 jaar. De 
toename van inflammatoire markers was echter niet gerelateerd aan depressieve symptomen in 
cross-sectionele analyses, wat suggereert dat depressie waarschijnlijk niet een acute reactie is op 
inflammatie, maar een reactie op chronische inflammatie.
In hoofdstuk 3 kijken we met exome sequencing en exoom-chip genotypering naar zeldzame 
genetische variaties, waarvan bekend is dat ze samenhangen met een verhoogd risico op 
depressie. In hoofdstuk 3.1 demonstreerden we dat depressieve symptomen gerelateerd zijn aan 
een missense Asn396Ser mutatie (rs77960347), gelegen in het endothelial lipase (LIPG) gen in 
de algemene bevolking. In hoofdstuk 3.2 identificeren we zeldzame ‘niet-synonieme’ varianten, 
gelegen in het NKPD1 gen. Het NKPD1 gen was geassocieerd met verhoogde depressieve 
symptomen in een genetisch geïsoleerde Europese populatie. Onze resultaten geven aan dat 
zowel het LIPG als het NKPD1 gen mogelijk belangrijke kandidaat genen zijn voor depressie. 
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In hoofdstuk 4 presenteren we de grootste, multiculturele, epigenoom associatiestudie 
(‘EWAS’) van depressieve symptomen (N = 11,256). We identificeerden dat hypermethylatie van 
cg04987734, behorend bij het CDC42BPB gen, cg12325605, behorend bij het ARHGEF3 gen, en 
cg14023999, in een intergenic positie, allen gerelateerd zijn aan depressieve symptomen. Deze 
genen zijn betrokken bij mechanismen zoals axongeleiding, groeifactoren voor zenuwcellen, 
regulatie van serotonine en dopamine in het brein, en ontsteking. Mogelijk duiden deze 
bevindingen op moleculaire mechanismen die de ontwikkeling van depressie onderliggen.
In hoofdstuk 5 onderzochten we de complexe relatie tussen depressie en comorbide fysieke 
factoren zoals cognitie en hartfalen. In hoofdstuk 5.1 bestudeerden we of de cognitie van 
ouderen met één of meerdere depressieve episode sneller achteruit gaat dan ouderen zonder 
een historie van depressieve episoden. Ouderen met meerdere depressieve episoden hadden 
inderdaad een snellere cognitieve achteruitgang over een periode van 12 jaar dan ouderen met 
een historie zonder depressieve episoden of een enkele depressie episode. Dit suggereert dat niet 
een enkele episode, maar de terugkeer van depressieve episoden, een rol speelt in de cognitieve 
achteruitgang in ouderen. Hoofdstuk 5.2 probeert te achterhalen in hoeverre de fysiologische 
dan wel de psychologische gevolgen van een hartinfarct van belang zijn voor het ontwikkelen 
van depressie. Hiervoor onderzochten wij depressie in relatie tot gediagnosticeerde hartinfarcten, 
bekend bij de deelnemer, en zogenaamde ‘stille’ hartinfarcten, onbekend bij de deelnemer. 
Mannen met een gediagnosticeerd hartinfarct hadden een verhoogd risico op het ontwikkelen 
van depressie in vergelijking met mannen zonder hartinfarct. In contrast, mannen met ‘stille’ 
hartinfarcten hadden een vergelijkbaar risico op depressie als mannen zonder hartinfarct. Ter 
vergelijking, het risico op overlijden is verhoogd voor zowel mannen met gediagnosticeerde als 
‘stille’ hartinfarcten ten opzichte van mannen zonder hartinfarct. Zowel gediagnosticeerde als 
‘stille’ hartinfarcten hebben dus nadelige gevolgen voor de fysieke gezondheid, maar alleen de 
psychologische ervaring van een gediagnosticeerd hartinfarct draagt bij aan het ontwikkelen van 
een depressie.
Als laatste worden in hoofdstuk 6 de belangrijkste bevindingen en conclusie van dit proefschrift 
besproken. Daarnaast wordt verder ingegaan op de methodologische beperkingen, de betekenis 
van dit proefschrift voor de klinische praktijk en suggesties voor toekomstig onderzoek op het 
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Summary of PhD training and teaching activity
Name PhD student: Olivera Story-Jovanova
Erasmus Medical Center department: Epidemiology
PhD period: August 2012 – August 2017
Research School: NIHES
Promotor: Prof.dr. H. Tiemeier
Copromotor: Dr. N. Amin
PhD Training Year Workload
(ECTS)
General courses
Research integrity 2014 2.0
Biomedical writing 2015 4.0
Specific courses (Research School)
Master of science in Health Sciences, Epidemiology 2012-2013 75
Study Design 2012 4.3
Biostatistical Methods I: Basic Principles 2012 5.7
Clinical Epidemiology 2012 5.7
Methodologic Topics in Epidemiologic Research 2012 1.4
Biostatistical Methods II: Classical Regression Models 2012 4.3
Principles of Research in Medicine 2012 0.7
Methods of Public Health Research 2012 0.7
Cohort Studies 2012 0.7
Introduction to Global Public Health 2012 0.7
Primary and Secondary Prevention Research 2012 0.7
Social Epidemiology 2012 0.7
Courses for the Quantitative Researcher 2012 1.4
English Language 2012 1.1
Introduction to Medical Writing 2013 1.4
Causal Inference 2013 0.7
History of Epidemiologic Ideas 2013 0.7
Markers and Prognostic Research 2013 0.7
Advances in Epidemiologic Analysis 2013 0.4
Logistic Regression 2013 1.4
Psychiatric Epidemiology 2013 1.1
Women’s Health 2013 0.9
Planning and Evaluation of Screening 2013 1.4
Chronic Disease Epidemiology, Institute of Public Health, 
University of Cambridge, United Kingdom
2013 1.1
Maternal and Child Health 2013 0.9
International conferences
29th European College of Neuropsychopharmacology Congress 
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18th meeting of the Section of Epidemiology and Social Psychiatry of 
the European Psychiatric Association EPA Gothenburg, Sweden (Oral 
presentation)
2016 1.0
Workshops, Meetings and symposia
Research meetings, Psychiatric Rotterdam Study Group 2012-2017 1.0
Epidemiology research seminars 2012-2017 2.0
Epigenetic CHARGE research meetings 2015-2017 2.0
Teaching and Supervision
Teaching Assistant,
Erasmus Summer Program – Principles of Research in Medicine 2014 0.4
Supervision of medical students,
- Supervising Cienne Poolmans, medical student, Department 
of Psychiatry, Erasmus MC. 
Project title: A sad heart : depression and cardiovascular disease a 
virtuous cycle. 
2014 2.0
- Supervising Amin Achari, medical student, Department of 
Psychiatry, Erasmus MC.
Project title: A sad heart : depression and cardiovascular disease a 
virtuous cycle.
2014 2.0
Supervision of master students,
- Supervising Mayara Auler, master student, Department of 
Epidemiology, Erasmus MC. Project title: Cardiovascular, 
metabolic and renal biomarkers and their association with 
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Oh what a journey this was ! I am awaiting the birth of my son Aaron (who was supposed 
to arrive in this world 4 days ago) and completing this thesis by writing probably the most read 
section: the words of thanks. All of you who know me good enough, you know how important 
family and friends are to me. Private life is and it will be number one on my priority list. Without 
the love and support of the people I am surrounded with, I would have never achieved any of 
what I did today. You can imagine that the list of those who I have to thank will be a very long 
one; but I have to start somewhere. I will do it in an unconventional chronological way not to 
miss someone .
Taking risks and grabbing what life brings was somehow my expertise since I know myself. 
Coming in Rotterdam and doing my PhD training was more of an adventure to me rather than 
living my dreams. To be honest, I have never even dreamt that I will get a Master’s or a PhD 
Degree. Academic career was always a plan B for the old days. Yet, during my clinical work at 
Heliomedika, I realized I might need a change and I might have to try doing something new. I 
needed more knowledge, I simply wanted to study more. Thanks to my dear colleagues Dr. Vani, 
nurse Lile, Natka, and my ex-director and biggest motivator till this day Dr. Slavica; I decided 
to look for opportunities and challenged myself. I applied for Master’s study at the University 
of Erasmus in Rotterdam supported by the ERAWEB grant. Thank you Heliomedika ladies, the 
working experience I had with you and the support you gave me through the whole application 
procedure means a lot to me. You all have a big part in all the decisions I have made then and 
without you, I am not sure I would have discovered myself and what my needs were with such 
an ease.
My application was accepted and I got admitted not only to a Master’s program, but also got an 
opportunity to continue with PhD training. In August 2012, I was here in front of the Erasmus 
MC building yearning for all what this adventure would bring. The start was very difficult but I 
somehow managed it. For that, I would first like to thank the Ullmann Family. Mor, if it was not 
for you, I would have never came to the Netherlands at first. Thank you for that!! You were my 
start here, helping me integrate with the speed of light, supporting me during my beginner’s 
troubles and whenever it was needed. You are the best ex-boyfriend someone can have. Bella 
what can I say, your Dutch Integration expertise helped me go through the last years smoothly. 
Thanks to you, I make the best soup in the world and not even one word of this book would have 
been written if it was not for the laptop I got from you. In short family Ullmann; you are the kick 
off to this PhD adventure, I own one to you.
Prof. Henning Tiemeier was one of the first people I met at Erasmus MC. The first things I learnt 
from him was not to shake in front of people who have a title professor. Therefore, Henning I 
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and a great teacher but for the most you are so human. Always down to earth, with a beautiful 
harsh German humor, it was a pleasure to have you as a leader in the working environment. I 
really appreciate that you always took in to account my personal circumstances when leading me 
through this PhD trajectory. You had that deep understanding and compassion for both work and 
private life and for that I give you all my credits. We are very different characters but somehow 
we managed working well together. Thank you for everything! I am happy to know you and 
even more happy to say that I have finish my PhD under your supervision. This thesis is a mutual 
product of both; your enthusiasm and stubbornness, and my patience and dedication.
Then, my co-promoter and mentor Najaf Amin. Dear Najaf, you are a role model to me. What 
Henning and I were missing to complete this project, was you. You were our balance and our 
tornado at the same time. Why tornado? I remember when you proposed to work together I 
thought: “Genetics, nooooo way I cannot do this.” So yes your ideas came to me as a tornado. 
But you also had another skill, the skill of reading my mind all the time and you motivated 
me by saying “Don’t worry genetics is not that difficult.” You brought the balance in this PhD 
project. Learning and working with genetic data was not easy at all but with your systematic, 
organized, efficient and friendly way of working, everything became possible. Thank you, you are 
an example of a strong women and we women scientists should all follow your example.
I will never forget the first course I took that first summer with prof. Albert Hofman. Prof. Hofman 
you approved my application and I have learned the basics of epidemiology from you. Thank you 
for that. But Oh g-d during your course, everything was so new to me that I did not understood a 
word of what you were teaching. However, with joint efforts with my ERAWEB-NIHES friends, we 
managed to learn all and pass the Master’s courses easily. Bibi, Dina, Kate, can you remember our 
long hours in the library? It was worth it. We have all managed to accomplish what we came here 
for and even better we have built friendships that will last forever. Thank you girls I am happy that 
these five years brought a lot of professional success but also extended family which you certainly 
are. Ana Maksimovic, Olja, Nasos, Gustavo, Ana Vitezova, and Janko you were my partners in 
crime from the very beginning. Owing to your presence, I did not forgot to smile, party and have 
fun during the first year of this PhD trajectory. Hope to meet you all once more and revive the 
memories we have built together.
During this PhD story, I was part of a great group: the PSYCH-EPI group. I had an opportunity to 
work with great colleagues, some of which I still work with even today and some will be marked 
as great friends whom I meet on regular basis. Annemarie you are such a friend! I have no words 
to explain it, but I can say you crashed my stereotype for Dutch friendship . I love to talk with 
you and even more to gossip with you. I am even more glad that you are coming back to the NL 
so we can continue seeing each other again regularly. Also, I have to mention that thanks to you 
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Lisette, even though I have lost you somewhere on the road of motherhood,  I can never forget 
our lunch moments in the park and the way you stress out every time I kiss you and hug you. Nese, 
my soulmate sister, you are the mini older me. Miss you a lot curly. Деси, сепак да останеме 
достоинствени на мајичниот Македонски јазик . Ти и Кате сте ми моја Македонска 
банда.  кога на балканот ќе кажеме крвта не  вода, не  за џабе кажано. Вие ми 
бевте најголема подршка и луѓе од доверба, другарки за се и сешто. Маките не споиа 
засекогаш . Ве обожавам секоја на свој начин најискрено, и ви благодарам за се.
Ayesha my paranymph, what are you “women”? Are you my group colleague, my office-mate, 
my soulmate, my pregnancy/motherhood trouble partner, my friend, my shrink? I would say you 
are all of that. Henning was testing if a Jew and a Muslim can share an office, but he did not 
know he matched the only two strong crazy women in this world that can actually adore and love 
each other for real. Thank you Henning you have connected me with someone I know I will have 
near me for a life-time! Dear Ayesha two years ago, I was supporting you during this moment of 
glory and now there you are supporting me in the same. But that is what we do for each other. 
No matter what or where we are, we will always be there one for another. Thank you my princess 
Jasmine, you know how much I love you and appreciate you and sorry that I am so useless at the 
moment because of living so far from you.
The colleagues’ circle is not small and there are some more people I have to thank. Saira, Heidi, 
Jelena, Marina, Akhghar, Mayara, Tom, Andrea, Else, Raluca, Nina, Ank, Rosanne, Jolien S, 
Irene, Dragan, Gogo, Ryan, Alex, Laura, Maartje B, Chantal, Roza, and Ingrid some of you I 
have worked with, some of you were my office-mates, some of you are just friends. What we 
have shared was Henning as a mentor, and thanks to all of you for making this period easier for 
me, since we have also shared our struggles that we faced during our scientific journeys. Fadila 
pa šta smo to nas dve preživele ? Kafa sa tobom mi je najdrža. Gde si sad našla da ideš tako 
daleko?! Nedostaješ jako jako. Frank, Vincent, Hieab, Hazel, Marileen, Rens, Renee, Natalie T., 
Trudy, Taulant, Olta, Jelena P., Clodian, Rene Sch., Emina, Jana N, Kozeta, Maarten B, Fjorda, and 
Sigi, sharing the elevator and the space with you which was a pleasure. Even better were all the 
chit-chat moments and all the taarten we shared these years.
This thesis is a product of joint work of many amazing people I have worked with. Prof. Oscar 
Franco, prof. Arfan Ikram, prof. Albert Hofman, prof. Cornelia van Duijn, prof. Wite Hoogendijk, 
prof. Norbert Schmitz, prof Miriam Fornage and the epigenetic group within CHARGE Consortium, 
Abbas, Maarten Leening, Wolters Frank, Carvalho Livia, Argita Zallili, Raymond Noordam, Nikkie 
Aarts, thank you for collaborating with me, I have learned a lot from all of you. Finally, I would 
like to thank Ivana Nedeljkovic. Ivana with joint forces we have finished my biggest and dearest 
project of this thesis. Thank you very much Ivana. I really appreciate your work, and want to let 
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All these years, a large number of people helped me grow in this process in a different way. Most 
of them were coming in my life and going out of my life; a real dynamic cohort. However, there is 
a cluster of people that were always by my side and I know they will stay that way. In last part of 
this word of thanks, I would like to especially thank THEM; my family and my friends.
Ana Tasevska, Dafina, Marija, Ive, Rushka, you are certainly the footprint of my Skopje life. But, 
even though we are separated physically (viva la Viber) you are still a big part of my daily life. 
I miss you always. Chris bedankt for de cover and the funny discussions that we have. Helena, 
Marlies, Rachel you are my only friends in Alphen thank you for all the nice coffee/tea moments.
My Jewish friends: Lela, Dina, Mina, Dunja, Mavro, Sale, Urosh, Vase, Jana Nichota, Ruben, Liza, 
Andrea Steiner, Beca, Gabor, Pidja, Bojana, Sandra, Poli, Deborah, and Martin Levi; writing your 
names reminds me that I am the richest person on this world. Some of you I know since I am 10, 
that is long . We all live in different parts of the world. Yet, our Jewish life connected us and 
made us who we all are today. You have shaped a big part of me and I am who I am also because 
of all of you. 
Лелка ти си ми другарица par-excellence! Толку сме исти, но спак толку различни, 
фала ти за сите долгочасовни разговори и што си дел од мојот живот. Дина и Мина 
другарице најдраже, па ви сте самном данас . Нама је заједно увек тако добро. Нема 
тих речи које могу описати колко сам захвална да сте данас самном и што сте тако 
добре праве другарице. Јако сам поносна што вас имам.
A special word in English for my second paranymph, Dina. In 1996 I met you in Szarvas, Hungary, 
during a camp. You were from Serbia, me from Macedonia, both from freshly separated 
Yugoslavia. I am sure our parents did not have a clue what a big favor they did to us by sending us 
to that camp. Here we are now, in 2018 and still together, sharing the best and the worst in our 
lives. Living the past, the present and the future. Dina dear, I don’t need you to be my paranymph 
to give you special place in my life, because you are so special to me. No one else in this world can 
be proud of such a friendship. Nothing can separate us because our lives are deeply connected. 
Thank you so much for being my paranymph and supporting me in this time of my life as you 
supported me in everything else so far (we should send JDC a copy of this book as a proof that 
their projects are not failures : Lela I will send you a second copy highlighting these sentences 
and so that you can present it to the board of directors LoL). Дики љубим те!
Ana Tasevska, Dafina, Marija, Ive, Rushka, you a  certainly the footpri t of my Skopje life. But, even though we are separated physically (viva la Viber) you are still a big part of my daily life. I miss you always. Chris bedankt for de cover and the funny discussions that we have. Helena, Marlies, Rachel you re my only friends n Alphen thank you for al  the nice coffee/tea moments. My Jewish friends: Lela, Dina, Mina, Dunja, Mavro, Sale, Urosh, Vase, Jana Nichota, Ruben, Liza, Andrea Steiner, Beca, Gabor, Pidja, Bojana, Sandra, Poli, Deborah, and Martin Levi; writing your names reminds me that I am th  richest person on this world. Some of you I know since I am 10, that is long . We all live in different parts of the world. Yet, our Jewish life connected us and made us who we all are today. You have shaped a big part of me and I am who I am also because of all of y !הבר הדות 
Лелка ти си ми другарица par-excellence! Толку сме исти, но спак толку различни, 
фала ти за сите долгочасовни разговори и што си дел од мојот живот. Дина и Мина 
другарице најдраже, па ви сте самном данас . Нама је заједно увек тако добро. 
Нема тих речи које могу описати колк  сам захвална да сте дан с самном и што сте 
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My family Dedo Pero, Baba Vera, Dedo Ljupcho, Baba Tinche, Teta Lide, Tetin, Tea, Martin, Family 
Stojanovi, Family Shumkovski, Family Gligorovi, you are my roots and I am grateful that I have 
the opportunity to grow with so much love and as part of such a huge family. Дедо Перо 
биди горд на Оличка и сите твои внуци, ние сме твојата иднина и таа е светла. Баба 
Тинче ми фалиш најмногу и нема ден да не помислам на тебе. Хуморот и желбата за 
патувања ги наследив од тебе а тие нешта го чинат животот пресладок. Дедо Љупчо 
ти си непреболен, ама ете ја имам таа чест да те гледам повторно секој ден во очите 
на Арон. Баба Вера, фала ти на се а највеќе на тврдоглавоста што ја наследив од 
тебе. Да не беше таа немаше да постигнам волку многу. Тети, ти благодарам на сите 
моменти поминати со мене, знам дека ми се радуваш многу и ми е зал што не можеш 
да присуствуваш на одбраната на оваа теза. Бибе ти си ми единствена во Холандија и 
многу сум благодарна што те имам.
Mijn schoonfamilie: Opa Gerard, Oma Riek, Michael, Mariska, Sam, Nick en Jill Story. Ik ben trots 
dat ik een Story ben en dat ik deel mag uitmaken van jullie familie. Jullie zijn een grote steun in 
mijn dagelijks leven. Dank je wel voor alles. Opa, dank voor je onnavolgbare humor, dank je dat 
je zoveel van ons houdt. Oma dank je wel voor alle zorgen voor Ruth en alle hulp die je ons hebt 
geboden.
*
My Sister Eli. The biggest pain is that I am so far from you. Whatever I am busy with, I am 
constantly thinking: wish Eli would have been here. As I write this, I have tears in my eyes. Sorry 
if I was bothering you with my 100 daily calls. It is simply because I miss you so much. Thank you 
for being my sister, thank you for believing in me and always supporting me. Kufi thank you for 
taking care for my sister so much. Taking care for her means the same as if you have taken care 
for me. I am so sorry you are both not here for this day but it is for a good cause, awaiting another 
member of the Jovanov family.
Mama and Tato, I can write a whole book for you and it would still not be enough. You should 
be proud. Henning told me that he performed a research once, in which he was studying the 
offspring of couples that married in early age. The results of this research work were that no one 
that married at the age of 17 stayed happily married 33 years after with children that became 
doctors, master’s in science and certainly not PhD. Conclusion, you are an exception. Thank you 
for all that you have done and you still do for me. Thank you for teaching me to be human, 
to be a good friend, wife, doctor, and most importantly a good mother! I am a mirror of your 
wishes, expectations, and ambitions. И малку на македонски; ви се извинувам што сум 
неподнослива кога ми е тешко. Ве сакам најмногу и сигурна сум дека не постојат 
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And who shell I be grateful the most for all? My husband Egbert, of course.  No matter how 
much I think, I just do not get to the right words to thank you my love. You are the biggest 
surprise in my life. I know that If someone could have told me before I met you, that I will be so 
loved by a man I would not have believed it. Our story deserves another book, and this thesis is 
just a small chapter of it. Schat, if it was not you there would have certainly not be a PhD either. 
That unconditional love we share makes us both so strong that we can take every challenge and 
solve every problem. That small paradise we live in, our home, is reason enough for me to move 
mountains. We have mastered depression for sure. Ik hou van je! I believe in karma and I am sure 
I must have done something very good in my life previously to get the opportunity to share the 
rest of my life with you. Dank je wel!
Finally, this is the end of my PhD fairytale. I must admit it took me 4 months to write these 
words of thanks . It started when I was still pregnant with Aaron and here I am today 6th 
February,2018, and still writing it. It’s time to finish it for good!
My life is an adventure that I am super proud of and happy to be writing about it. On 4th April I 
will become a PhD most probably but to be honest the title I am the most happy with is being a 
MOTHER. During this period, I was pregnant two times and I have become a mother of two kids. I 
got Ruth in the second year of my PhD and Aaron 4 months ago. They have marked this period by 
large. Therefore, I must write a few words to my children: Dear Ruth and Aaron, you are now so 
little and you can’t read yet (Ruth knows the letter Н in Macedoninan only), but in a few years you 
can find these words and be even more proud of your mother. You are the best thing I have ever 
created. I am so proud of both of you. You are beautiful, sweet, funny, adorable and the biggest 
source of inspiration for me. You suck my energy out every day. I must admit that taking care of 
you is not easy. But those smiles and kisses gives me tremendous power to go further every day. 
Thank you for making my live meaningful and so happy. Ве сака мама!
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